Therapeutic adeno-associated viruses for treatment of pompe disease with long-term stop of GAA enzyme replacement therapy
By using AAV vector to deliver GAA polypeptides to the liver, the problem of limited therapeutic effect of aracosidase alpha is solved, and the interruption or cessation of long-term GAA enzyme replacement therapy is achieved, reducing antibody response and infusion frequency, and improving the quality of life of patients .
Patent Information
- Application Number
- CN202380036185.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-12
- Filing Date
- 2023-02-23
- Publication Date
- 2024-12-06
AI Technical Summary
The existing aracosidase alpha enzyme replacement therapy has limited effect on patients with Pompeii disease, especially in infant and late-onset patients, with insufficient antibody response, high demand for frequent infusions, long-term dependence and poor treatment effect. question.
Adeno-associated virus (AAV) vector is used to deliver heterologous nucleic acid encoding α-glucosidase (GAA) polypeptides to the liver, secrete GAA polypeptides through hepatocytes, reduce or eliminate the clinical need for long-term GAA enzyme replacement therapy, and provide sustained enzymes Activity and reduce antibody response.
The need for long-term GAA enzyme replacement therapy is achieved over an extended period of time, providing flexible treatment options, reducing antibody side effects, improving patients' quality of life and lifestyle, and avoiding the geographical limitations of frequent infusions.
Smart Images

Figure CN119095612A_ABST
Abstract
Description
Related Applications
[0001] Pursuant to 35 U.S.C. §119(e), this application claims priority to U.S. Provisional Application Serial No. 63 / 314,093, filed on February 25, 2022, and U.S. Provisional Application Serial No. 63 / 319,034, filed on March 11, 2022, and U.S. Provisional Application Serial No. 63 / 340,972, filed on May 12, 2022, the contents of each of which are incorporated herein by reference in their entirety. Technical Field
[0002] The present invention relates to methods of treating Pompe disease by administering adeno-associated viral (AAV) particles, virions and vectors for expressing alpha-glucosidase (GAA) polypeptides, wherein the methods can reduce or eliminate the clinical need for long-term GAA enzyme replacement therapy (ERT) administered for an extended period of time. Background Art
[0003] Pompe disease (glycogen storage disease type II; acid maltase deficiency; MIM 232300) is caused by recessive mutations in the GAA gene, resulting in complete or partial deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). Loss of GAA results in progressive accumulation of glycogen in lysosomes of many tissues, particularly skeletal muscle and cardiomyocytes. Impaired energy metabolism subsequently leads to severe disruption of muscle architecture, marked fat replacement of skeletal muscle cells (in adults), dysfunction, and autophagy.
[0004] Clinically, the range of the disease ranges from fulminant infantile onset Pompe disease (IOPD), which usually causes death before 12 months of age, to late-onset Pompe disease (LOPD), which progresses slowly, causes myopathy, leads to loss of mobility, and usually causes death due to respiratory failure 5-15 years after diagnosis. Infantile-onset patients have cardiomyopathy, which is usually found even at birth or even before birth, with elevated creatine kinase (CK), and then develop severe hypotonia, respiratory insufficiency requiring ventilator support, and severe cardiomegaly within weeks to the first few months of life. Death is most commonly attributed to cardiopulmonary failure, aspiration pneumonia, or ventricular arrhythmias. Late-onset Pompe disease (LOPD) patients (mostly adults, some teenagers) experience slowly progressive muscle weakness (which usually leads to delayed diagnosis), massive fat replacement of trunk and proximal limb muscles, and develop to respiratory failure, which is the main cause of death (Carlier et al., 2011). Basilar artery aneurysms occur and can be life-threatening if ruptured (El-Gharbawy et al., 2011; Hobson-Webb et al., 2012). As an alternative or adjunct to enzyme therapy, the feasibility of gene therapy for treating GSD-II has been studied (Amalfitano, A., et al., (1999) Proc. Natl. Acad. Sci. USA 96:8861-8866; Ding, E., et al., (2002) Mol. Ther. 5:436-446; Fraites, TJ, et al., (2002) Mol. Ther. 5:571-578; Tsujino, S., et al., (1998) Hum. Gene Ther. 9:1609-1616).
[0005] (alglucosidase alfa) was the first product approved in the United States for the treatment of Pompe disease (2006); (alglucosidase alfa) was approved in 2010 and is currently the standard of care (SOC) for patients with infantile-onset and late-onset Pompe disease. Alglucosidase alfa is given intravenously at a dose of 20 mg / Kg every 2 weeks as an infusion (LUMIZYME prescribing information 2014). Alglucosidase alfa provides an exogenous source of GAA. It has been shown that binding to the mannose-6-phosphate receptor on the cell surface occurs through carbohydrate groups on the GAA molecule, after which it is internalized and transported to the lysosome, where it undergoes proteolytic cleavage that causes increased enzyme activity. It then exerts enzymatic activity that cuts glycogen. Although this enzyme replacement therapy (ERT) prolongs the survival of most patients with infantile Pompe disease, a portion of patients, despite compliance with SOC ERT, die, suffer from persistent muscle weakness or still severe hypotonia and require mechanical ventilator support. For patients with late-onset disease, ERT initially modestly improves muscle function and lung function parameters, followed by functional stabilization or decline, which is still far from ideal therapy (Schoser et al., 2017).
[0006] For infantile-onset patients, especially those with severe or null mutations (cross-reactive immune material [CRIM] negative), high and persistent anti-rhGAA immunoglobulin G (IgG)-mediated immunity to the GAA enzyme is the primary cause of the impaired or inadequate response to ERT. That is, ERT is known to elicit antibody responses in the form of both IgG and IgE, and may also cause infusion-related reactions (Kishnani et al., 2007; Kishnani et al., 2010). Current practice is to use ERT to induce immune modulation in LOPD patients who are at risk for antibody development.
[0007] In addition, alglucosidase alfa Enzyme replacement therapy (ERT) is delivered as cumbersome every-other-week or weekly infusions and is the only treatment currently available. For people with infantile-onset Pompe disease (IOPD), GAA is absent (CRIM-negative) or very low (~1% of normal), and if untreated, it leads to rapidly progressive cardiopulmonary failure and death by age 2 years (Parini et al., 2018). Subjects with a significant deficiency of GAA present as adolescents or adults (late-onset Pompe disease [LOPD]) with less severe symptoms and slower progression. In addition, missing biweekly treatment can cause severe set backs, requiring months of ERT to return to the same level.
[0008] Therefore, despite the temporary treatment success, there is still a significant unmet medical need for alglucosidase alfa ERT in both IOPD and LOPD. Longitudinal data in subjects confirm that ERT does not induce complete correction or normalization in patients with Pompe disease. Ultimately, subjects generally still decline, albeit at a slower rate, delaying the inevitable progression to death (Kuperus et al., 2017; Parini et al., 2018). Although alglucosidase alfa prolongs survival in subjects with both IOPD and LOPD (LUMIZYME Prescribing Information, 2014), the reduced antibody response and efficacy to GAA presents some disadvantages.
[0009] Therefore, from a clinical point of view, the long-term treatment of Pompe disease patients with ERT has limited success. In the IOPD subgroup of patients, many patients experience high and persistent anti-rhGAA antibody titers (HSAT). Pompe disease patients without any residual GAA protein are considered CRIM negative. CRIM negative patients develop HSAT, and a subgroup of CRIM positive patients who also develop high or persistent intermediate titers suffer a significantly increased mortality rate (Banugaria et al., 2011). In addition, the use of immunosuppressants to prevent antibody formation in patients at risk of HSAT significantly prolongs survival and confirms the clinical relevance of HSAT (Mendelsohn et al., 2009; Banugaria et al., 2011). In addition, the literature indicates that only about ~ 1% of ERT has pharmacological activity.
[0010] Therefore, although enzyme therapy has demonstrated reasonable efficacy for severe infantile GSD II, the benefits of GAA enzyme therapy are limited due to the need for frequent infusions and the development of inhibitors or neutralizing antibodies against recombinant hGAA protein by subjects (Amalfitano, A., et al., (2001) Genet. In Med. 3: 132-138), and improved methods and alternative therapies are needed to treat patients with Pompe disease. Adeno-associated virus (AAV) vector-mediated gene transfer provides a suitable and feasible alternative. Summary of the invention
[0011] The technology described herein generally relates to gene therapy constructs, methods and compositions for the treatment of Pompe disease. More specifically, the technology relates to methods using adeno-associated (AAV) virions configured to deliver heterologous nucleic acids encoding GAA polypeptides to a subject, more specifically, to deliver heterologous nucleic acids encoding GAA polypeptides to the liver of a subject, where the GAA polypeptides are secreted from hepatocytes.
[0012] In particular, the technology described herein is based on findings from human clinical trials demonstrating that the clinical need for chronic hGAA ERT administration over extended periods of time can be reduced or eliminated when AAV expressing GAA polypeptides are administered to subjects.
[0013] Without wishing to be bound by theory, the only current treatment for Pompe disease is long-term administration of recombinant human GAA (rhGAA) ERT, which is typically administered on an every-other-week schedule. Herein, the inventors have demonstrated that if a subject with Pompe disease is administered a specific dose of an AAV vector expressing a GAA polypeptide disclosed herein, the subject can interrupt a normal ERT treatment regimen for an extended period of time (e.g., an extended ERT cessation period) without clinical regression. In some embodiments, withdrawal of long-term ERT administration begins at about the time (e.g., the day before, the day after) the AAV vector is administered to the subject, or in some embodiments, withdrawal of long-term ERT administration can occur at any time within about 24 weeks or about 24 to about 26 weeks after administration of the AAV vector.
[0014] In some embodiments, a subject administered an AAV vector expressing GAA disclosed herein may be administered supplemental ERT after an initial phase of discontinuation of long-term ERT administration for an extended period of time, wherein the supplemental ERT is administered about 6 months, or about 1 year, or longer than 1 year after cessation of long-term ERT. In other words, without wishing to be bound by theory, the technology disclosed herein relates to a method by which a subject with Pompe disease administered an AAV vector expressing GAA disclosed herein can take a break or "vacation" from normal long-term ERT administration. That is, according to the methods disclosed herein, a subject administered an AAV vector expressing GAA disclosed herein can have an extended period of time without long-term ERT administration. In some embodiments, the methods disclosed herein allow flexibility in normal ERT regimens because extended discontinuation or discontinuation of long-term ERT administration does not cause clinical decline - that is, the subject remains clinically stable despite the lack of continued long-term ERT.
[0015] In some embodiments, the methods disclosed herein include re-administering ERT after ERT administration has ceased for an extended period of time (referred to herein as "supplemental ERT"), and allow flexibility in the normal ERT regimen because the continued production of AAV-expressed GAA allows ERT flexibility. In some embodiments, as disclosed herein, supplemental ERT is a pulsed administration of ERT. In some embodiments, supplemental ERT is administered less frequently, or at a lower dose, or at irregular doses, or at irregular intervals, compared to the previous long-term ERT administration.
[0016] Thus, the methods disclosed herein provide significant advantages for subjects with Pompe disease, including, but not limited to, reducing or eliminating the rigorous and laborious weekly or every other week infusions of long-term rhGAA ERT therapy, which are significantly time-consuming and geographically limited, and prevent Pompe disease patients from traveling away from the area where their ERT infusions are given for extended periods of time. In addition, as disclosed herein, not administering ERT also reduces any side effects attributed to anti-rhGAA antibodies to ERT, and for certain doses, also avoids the need to administer immunosuppressants that are typically co-administered with ERT. Thus, the methods disclosed herein for treating Pompe disease allow for greater flexibility in the treatment of Pompe disease and improve the quality of life and lifestyle of subjects with Pompe disease.
[0017] Thus, in one embodiment, the technology relates to a method for treating Pompe disease in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a recombinant adeno-associated virus (AAV) vector comprising in its genome a heterologous nucleic acid sequence encoding an alpha-glucosidase (GAA) polypeptide in an expressible form, wherein the heterologous nucleic acid is operably linked to a liver-specific promoter, without long-term GAA enzyme replacement therapy (ERT) administration for an extended period of time (e.g., ERT administration can be withdrawn or discontinued at about 24 weeks, or about 26 weeks, or earlier than 24 weeks or 26 weeks, such as at any time between one day and 26 weeks after administration of the recombinant AAV). In some embodiments, the dose of the recombinant AAV comprising a nucleic acid encoding GAA does not exceed 4.0E 12 vg / kg, and in some embodiments, GAA is expressed to a level such that, for at least two weeks of administration, the subject achieves a serum level of GAA expressed by AAV that is in the following ranges of pharmaceutical activity: 160 to ≤2,260 nmol / mL / hr, 165 to ≤2,260 nmol / mL / hr, 175 to ≤2,260, 180 to ≤2,260, 185 to ≤2,260, 189 to ≤2,260. In some embodiments, the dose of AAV expressing GAA is no greater than 4.0E 12 vg / kg, and in some embodiments, GAA is expressed to a level such that, for at least two weeks of administration, the subject achieves a serum level of GAA expressed by the AAV in the range of 189 to ≤2,260 nmol / mL / hr of pharmaceutical activity. In some embodiments, the dose of the AAV expressing GAA is no greater than 4.0E 12vg / kg, and in some embodiments, GAA is expressed to a level such that, for at least two weeks of administration, the subject achieves a serum level of GAA expressed by AAV in the pharmaceutically active range of 189 to ≤2,260 nmol / mL / hr. In some embodiments, serum levels of GAA are achieved for at least about 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days. In some embodiments, serum levels of GAA are achieved within about 3 weeks, about 4 weeks, about 5 weeks, or later. In some embodiments, the dose of AAV-GAA is between 5e 10 vg / kg to 1.6e 13 vg / kg, so that the specified serum level is achieved within this time window. In some embodiments, the subject suffers from IOPD. In some embodiments, the subject suffers from LOPD.
[0018] In some embodiments, the dose of the recombinant AAV comprising nucleic acid encoding GAA is between about 1.6E12 and about 1.6E13 vg / kg; and GAA is expressed to a level such that, at least within two weeks of administration or within less than two weeks after administration, the subject achieves a pharmaceutically active range of 160 to ≤2,260 nmol / mL / hr, 165 to ≤2,260 nmol / mL / hr, 175 to ≤2,260, 180 to ≤2,260, 185 to ≤2,260, 189 to ≤2,260 GAA serum levels expressed by AAV. In some embodiments of the invention, after rAAV administration, glycogen content in tissue is reduced from baseline by about 10% to about 40%, about 10% to about 30%, or about 15% to about 25%. In some embodiments, after rAAV administration, clinically stable motor function is observed, as determined by a decrease of ≤12% from baseline in the 6MWT, or a decrease of less than 43 meters in two consecutive assessments separated by no less than 3 months. In other words, the clinically stable level of motor function determined by the 6MWT position is within a decrease of 0-12% from baseline in two consecutive assessments separated by no less than 3 months. In some embodiments, after rAAV administration, clinically stable FVC% is observed, as predicted by a decrease of ≤15% from baseline in the upright position in two consecutive assessments separated by no less than 3 months. In other words, the clinically stable level of lung function determined by the predicted %FVC in the upright position is between 1%-14% from baseline in two consecutive assessments separated by no less than 3 months.
[0019] In some aspects of the invention described herein, an immunomodulator is co-administered with AAV on the day of AAV administration or on any day between 1 day and 15 days before AAV administration. In some embodiments, the immunomodulator is steroidal and / or non-steroidal; and / or a combination thereof. In some embodiments, the immunomodulator is prednisone. In some embodiments, the immunomodulator is methotrexate. In some embodiments, the immunomodulator is a combination of methotrexate and prednisone. In some embodiments, methotrexate is administered at an initial dose of between about 2.5 mg / day to about 30 mg / day. In some embodiments, prednisone is administered at an initial dose of 60 mg / day, followed by a gradual reduction to a lower dose.
[0020] In some embodiments of the invention, the dose of recombinant AAV (rAAV) comprising a nucleic acid encoding GAA is between about 1.6E10 and about 1.6E12 vg / kg, wherein the subject receiving the AAV dose has received prior ERT, and wherein ERT is withdrawn on the day of, the day after, the day before, or any time between day 1 and week 26 after rAAV administration, and rAAV is administered on the day of, the day after, the day before, or any time between days after ERT withdrawal; and GAA is expressed to a level such that the subject achieves a serum level of GAA expressed by AAV in the pharmaceutically active range of 160 to ≤2,260 nmol / mL / hr, 165 to ≤2,260 nmol / mL / hr, 175 to ≤2,260, 180 to ≤2,260, 185 to ≤2,260, 189 to ≤2,260, at least within two weeks of administration or within less than two weeks after administration. In some embodiments, ERT is withdrawn after a longer time point, for example, after more than about 26 weeks. In some aspects of the invention described herein, the immunomodulator is co-administered with AAV on the day of AAV administration or on any day between 1-15 days before AAV administration. In some embodiments, the immunomodulator is steroidal and / or non-steroidal; and / or a combination thereof. In some embodiments, the immunomodulator is prednisone. In some embodiments, the immunomodulator is methotrexate. In some embodiments, the immunomodulator is a combination of methotrexate and prednisone. In some embodiments, methotrexate is administered at an initial dose of between about 2.5 mg / day to about 30 mg / day. In some embodiments, prednisone is administered at an initial dose of 60 mg / day, followed by tapering to a lower dose.
[0021] In some aspects of the invention, there is no substantial overlap between rAAV administration and ERT. In some aspects of the invention, there is only one day of overlap between rAAV administration and ERT. In some embodiments, the subject receives a single rAAV infusion and the prior ERT is withdrawn before or on the same day as the rAAV infusion. In some embodiments, the subject receives at least about 24 weeks, at least about 26 weeks, at least about 30 weeks, at least about 50 weeks, about 52 weeks or longer than the prior ERT of rAAV administration. After withdrawal of ERT, a single rAAV administration of at least 1.6E12 vg / kg can produce one or more clinically stable results, such as measured by GAA levels within the normal range in circulation and tissues, glycogen levels within the normal range in tissues, clinically stable FVC%, and clinically stable 6MWT.
[0022] In particular, the technology described herein relates to the following discovery: a single infusion of a rAAV vector expressing human acid alpha-glucosidase (GAA) can be used as an independent alternative to repeated infusions of enzyme replacement therapy (ERT) using recombinant human GAA protein (rhGAA). The inventors have demonstrated that a one-time administration of an AAV expressing GAA causes long-term transduction of the normal GAA gene into hepatocytes and continuous constitutive expression of GAA in the systemic circulation. Therefore, the inventors have demonstrated herein that the administration of a composition comprising an AAV expressing hGAA can replace the biweekly exogenous administration of ERT that subjects with Pompe disease typically receive. That is, the inventors have demonstrated herein that subjects with Pompe disease who have been administered an AAV expressing hGAA disclosed herein can stop ERT for a long time.
[0023] In particular, described herein are methods of treating Pompe disease in a subject in need thereof by administering to the subject a composition comprising an AAV vector expressing an alpha-glucosidase (GAA) protein, wherein the subject is not concurrently administered GAA enzyme replacement therapy. In some embodiments, the technology relates to methods of administering an AAV expressing GAA, wherein the subject can be weaned from GAA enzyme replacement therapy (ERT) for an extended period of time, such as at least 3 months, at least 4 months, at least 5 months, at least 1 year, at least 1 year, at least 2 months, at least 3 months, at least 4 months, at least 5 months ... 1 / 2 In some embodiments, the subject is off ERT at a time point between 1-2 days before or after administration of the AAV expressing GAA and about 6 months after administration, and is clinically stable with respect to at least one or more symptoms of Pompe disease, as disclosed herein. In some embodiments, the subject is off ERT at any time between 1-2 days before or after administration of the AAV expressing GAA and about 6 months after administration, and is clinically stable with respect to at least one or more symptoms of Pompe disease for at least 6 months, as disclosed herein.
[0024] In addition, the inventors have also found that Pompe disease patients who were administered AAV expressing GAA according to the methods and dosage ranges disclosed herein had minimal immune response to the GAA protein expressed by the AAV. Thus, in some embodiments, minimal or no need for immunomodulation or administration of immunosuppressants is required at, before, or after administration of the AAV to the subject, and thus no normal immunosuppressant regimen is required, which is typically administered when a subject is administered a viral vector or undergoes gene therapy.
[0025] Thus, in all embodiments herein, the method of treating Pompe disease comprises, consists essentially of, or consists of administering an AAV vector expressing GAA disclosed herein in the absence of ERT for Pompe disease and without immunomodulation. In some embodiments, the subject suffers from late-onset Pompe disease (LOPD) or infantile-onset Pompe disease (IOPD).
[0026] In all aspects disclosed herein, the AAV comprises a nucleotide sequence containing an inverted terminal repeat (ITR), a promoter, a heterologous gene, a poly-A tail, and potentially other regulatory elements for treating Pompe disease, such as late-onset Pompe disease (LOPD), wherein the heterologous gene is GAA, and wherein the vector (e.g., rAAV) can be administered to a patient in a therapeutically effective dose that is delivered to appropriate tissues and / or organs to express the heterologous GAA gene and treat the disease, such as Pompe disease.
[0027] Aspects of the present invention teach certain benefits in construction and use, which produce the exemplary advantages described below. Other features and advantages of aspects of the present invention will become apparent from the following more detailed description in conjunction with the accompanying drawings, which illustrate the principles of aspects of the present invention by way of example.
[0028] Aspects of the invention described herein also relate to methods of treating Pompe disease in a subject, the methods comprising administering to the subject being treated for Pompe disease by long-term GAA enzyme replacement therapy (ERT), a pharmaceutical composition comprising about 1.6 e 12 vg / kg to about 1.6e 13vg / kg dose of a recombinant adeno-associated virus (AAV) vector, the vector comprising in its genome a heterologous nucleic acid sequence encoding a polypeptide, the polypeptide comprising an alpha-glucosidase (GAA) polypeptide in an expressible form, wherein the heterologous nucleic acid is operably linked to a liver-specific promoter, and wherein the administration of long-term GAA enzyme replacement therapy (ERT) is withdrawn on the same day (d1), the day after, or at least the day before the administration of the recombinant AAV, and wherein, at least within two weeks of administration, the subject obtains a serum level of pharmacologically active GAA expressed by AAV of at least 165nmol / mL / hr. In some embodiments of the methods disclosed herein, methotrexate and prednisone are administered to the subject for immunomodulation. In some embodiments of the methods disclosed herein, methotrexate is administered at an initial dose of less than 30 mg / week, between about 5 mg / week and 30 mg / week, or between 5 mg / week and 7.5 mg / week. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] The file of this application contains at least one drawing in color. Copies of this patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee. The drawings illustrate various aspects of the invention. In such drawings:
[0030] Figure 1 is a representation of a plasmid map of the pAAV-LSPhGAA plasmid, used to generate AAV8-hGAA (ACTUS-101) for use in methods for treating Pompe disease according to at least one embodiment. Also shown are the nucleotide sequences of the ITRs (single underline), the promoter (double underline), the coding sequence of hGAA (uppercase letters), and polyA (bold and italic). The entire sequence shown is SEQ ID NO: 606. The 5' ITR sequence is SEQ ID NO: 601, the 3' ITR sequence is SEQ ID NO: 602, the promoter sequence is SEQ ID NO: 603, the coding sequence of hGAA is SEQ ID NO: 604, and the polyA sequence is SEQ ID NO: 605.
[0031] Figure 2A and Figure 2B Tables (A) and (B) show the initial demographic and baseline characteristics of the cohort, respectively.
[0032] Figure 3 contains two tables, the upper table showing adverse events and the lower table showing reported adverse events and resolution reports for the corresponding subjects in the cohort through Week 52.
[0033] Figure 4 is a series of graphical representations of safety and efficacy data collected for each subject (101001, 101002, and 101003) over a specified period of time. ELIspot activity was collected using three polypeptides representing the AAV8 capsid protein, AAV8_A, AAV8_B, and AAV8_C. The levels of serum GAA and alanine aminotransferase (ALT) are also shown.
[0034] Figure 5A- Figure 5D is a series of graphical representations of bioactive markers. From left to right, Figure 5A) serum GAA, Figure 5B) muscle GAA, Figure 5C) muscle glycogen, and Figure 5D) glucose tetrasaccharide (Glc4).
[0035] FIG6 is a set of graphical representations of data from muscle function measurements.
[0036] FIG. 7 is a set of graphical representations of data from muscle fatigue measurements.
[0037] Figure 8 It is Appendix 1.
[0038] Fig. 9 It is Appendix 2.
[0039] Figure 10A- Figure 10F is a series of graphical representations of data showing the 52-week safety profile of liver transaminases, CK, anti-rhGAA Ab and AAV8-A ELISPOT. Figure 10A: Aspartate aminotransferase; Figure 10B: Alanine aminotransferase; Figure 10C: γ-glutamyltransferase; Figure 10D: Creatine kinase; Figure 10E: Anti-human recombinant acid α-glucosidase antibody (counter titer); Figure 10F: T cell response (AAV8-A).
[0040] FIG. 11 is a graphical representation of serum acid alpha-glucosidase activity for each patient over 52 weeks.
[0041] Figure 12A-12B Long-term follow-up results for each subject (001, 002, and 003) 104 weeks after administration of AAV8-LSPhGAA (ACTUS101) are shown. Fig. 12A Results from the 6MWT (6-minute walk test) are shown, while Fig. 12B Results from FVC (forced vital capacity) are shown. Subjects 001 and 002 remained ERT-free throughout the period of 24 weeks - 104 weeks, while subject 003 was weaned off ERT at 24 weeks but resumed ERT after 97 weeks.
[0042] Figures 13A-13B are graphical representations of T cell reactivity (SFU / million PBMC) to AAV8 vectors as well as transaminitis (ALT levels) and serum GAA levels for subjects in Cohort 2. Figure 13A is data for subject 006, and Figure 13B is data for subject 004.
[0043] FIG. 14 is a graphical representation of the methotrexate and prednisone treatment regimen for subjects in Cohort 3.
[0044] Fig.15 is a table showing biopsy results for subjects in Cohort 3 at 24 and 52 weeks.
[0045] Figure 16 is a graphical representation of the results of cohort 3, showing T cell reactivity to vector capsid and GAA, as shown by SFU / 1e6 PBMC (bars), and transaminase elevation, as shown by AST / ALT (IU / L) levels (solid line). The dotted lines represent the normal range of ALT (top line) and the normal range of AST (bottom line).
[0046] FIG. 17 is a graphical representation of Cohort 3 serum GAA levels over time.
[0047] Fig.18 is a schematic diagram showing the study design. Supplies are prepared for treatment A (active and indistinguishable placebo) and treatment B (active and indistinguishable placebo), and subjects then receive two treatments; A (active) and B (placebo), or A (placebo) and B (active).
[0048] The above-mentioned accompanying drawings illustrate aspects of the present invention in at least one exemplary embodiment, and aspects of the present invention are further defined in detail in the following description. According to one or more embodiments, the features, elements and aspects of the present invention referred to by the same numbers in different drawings represent the same, equivalent or similar features, elements or aspects. DETAILED DESCRIPTION
[0049] The technology described herein relates to the following discovery: administration of rAAV vectors expressing human GAA can be used as a stand-alone alternative to repeated infusions of GAA enzyme replacement therapy (ERT). The examples herein demonstrate that a single administration of the AAV expressing GAA disclosed herein at an appropriate dose causes permanent transduction of the normal GAA gene into hepatocytes and continuous constitutive expression of systemic GAA, thereby eliminating the need for weekly or every other week exogenous administration of ERT that subjects with Pompe disease typically receive. That is, the inventors have demonstrated herein that subjects with Pompe disease who have been administered the AAV expressing hGAA disclosed herein can stop ERT for a long time.
[0050] Thus, the disclosure described herein generally relates to methods and compositions for treating Pompe disease in a subject, the methods comprising, consisting essentially of, or consisting of administering an AAV vector expressing GAA disclosed herein in the absence of co-administration of enzyme replacement therapy (ERT) through GAA or other small molecule treatments for Pompe disease. In some embodiments, the methods further comprise, consisting essentially of, or consisting of administering an AAV vector expressing GAA with minimal, or no, immunomodulation.
[0051] In some embodiments, the methods disclosed herein for treating Pompe disease include administering to a subject a pharmaceutical composition comprising, consisting essentially of, or consisting of an AAV vector expressing GAA disclosed herein, wherein the administration is performed without concurrent treatment or administration of other therapies or treatments for Pompe disease, including but not limited to enzyme replacement therapy (ERT) by GAA or other small molecule treatments for Pompe disease. That is, the methods disclosed herein involve treating Pompe disease by administering to a subject an AAV expressing GAA, wherein there is no co-administration, co-treatment, or concurrent treatment with GAA ERT.
[0052] In some embodiments, the subject has late-onset Pompe disease (LOPD) or infantile-onset Pompe disease.
[0053] The disclosure herein generally relates to methods of treating a subject having Pompe disease, the methods comprising, consisting essentially of, or consisting of administering to the subject a pharmaceutical composition comprising a recombinant adenovirus-associated (AAV) vector comprising in its genome a heterologous nucleic acid sequence encoding a polypeptide comprising an alpha-glucosidase (GAA) polypeptide, wherein the heterologous nucleic acid is operably linked to a liver-specific promoter, and wherein GAA enzyme replacement therapy (ERT) is not administered to the subject.
[0054] In all aspects disclosed herein, recombinant AAV (rAAV) vectors and rAAV constructs for delivering nucleic acids encoding GAA polypeptides to subjects for treating Pompe disease are disclosed in international patent applications WO 2020 / 102645 and WO2021102107A1, both of which are incorporated herein by reference in their entireties.
[0055] The inventors demonstrate herein that rAAV vectors (e.g., comprising an AAV8 capsid, a liver-specific promoter (LSP), and a transgene for hGAA (referred to herein as AAV8-LSPhGAA)) selectively express and secrete GAA from transduced hepatocytes when administered as a one-time single IV administration. The inventors demonstrate that the primary mechanism of action of rAAV8-LSPhGAA is the secretion of sustained low levels of GAA from the liver into the systemic circulation to provide therapeutic exposure levels of GAA to tissues (e.g., but not limited to muscle), resulting in glycogen removal and restoration of cellular structure and function. In addition, the inventors demonstrate that rAAV8-LSP-hGAA also mediates the host's regulatory T cell response, resulting in immune tolerance to the secreted GAA. Thus, the data presented in the Examples herein demonstrate that rAAV8-LSP-hGAA expresses GAA at levels that induce immune tolerance and antagonize ERT (e.g., alglucosidase ) and thereby suppress the inhibition of receptor-mediated GAA uptake by neutralizing antibodies.
[0056] In some embodiments, the recipient subject has substantially low T cell reactivity to the vector capsid. In some embodiments, the T cell reactivity is below a threshold range of >40 to <120 SFU / million PBMCs, as measured, for example, by ELISpot reactivity. In some embodiments, the subject exhibits these levels at least about 250 days after AAV-LSP-hGAA administration and / or at least about 80 days after ERT withdrawal.
[0057] In some embodiments, the expressed GAA comprises at least a signal peptide that promotes secretion of the GAA polypeptide from the liver. In some embodiments, the GAA polypeptide or modified GAA is expressed as a fusion protein comprising at least a signal peptide that promotes secretion of the GAA polypeptide from the liver. In some embodiments, GAA can be optionally fused to a targeting sequence that allows for effective targeting to lysosomes in mammalian cells, such as muscle cells, such as human cardiac and skeletal muscle cells.
[0058] In all aspects of all embodiments of the technology described herein, the liver-specific promoter preferentially expresses the hGAA polypeptide in the liver. In all aspects of all embodiments of the technology described herein, the liver-specific promoter preferentially expresses the hGAA polypeptide in the liver. In all aspects of all embodiments of the technology described herein, in some embodiments, the AAV vector comprises at least one capsid protein targeted to the liver. I. Method of Administration
[0059] The disclosure herein generally relates to methods of treating a subject with Pompe disease, the methods comprising administering to a subject with Pompe disease a pharmaceutical composition comprising or consisting essentially of a recombinant adenovirus-associated (AAV) vector comprising in its genome a heterologous nucleic acid sequence encoding a polypeptide comprising an alpha-glucosidase (GAA) polypeptide, wherein the heterologous nucleic acid is operably linked to a liver-specific promoter, and wherein the patient is not given GAA enzyme replacement therapy (ERT) for an extended period of time, or is given an extended break from ERT. In one embodiment, ERT is continued, but at least one of the dose or frequency is reduced.
[0060] Disclosed herein in the Examples are results of a human clinical trial of AAV-mediated gene transfer of GAA for Pompe disease. In particular, the Examples disclosed herein disclose results of a clinical development program established to evaluate the therapeutic effects of administering an AAV8-LSPhGAA viral vector, which is an AAV8 expressing GAA under the control of a liver-specific promoter (LSP) (see, e.g., herein). Figure 1 ), and the ability to treat Pompe disease in the absence of concomitant ERT and / or after withdrawal of ERT.
[0061] In all aspects disclosed herein, recombinant AAV (rAAV) vectors for delivering GAA polypeptides to subjects in the methods for treating Pompe disease disclosed herein and constructs for rAAV are disclosed in international patent applications WO 2020 / 102645 and WO2021102107, both of which are incorporated herein by reference in their entirety.
[0062] Without wishing to be bound by theory, the inventors have discovered a method for treating Pompe disease by AAV-mediated delivery of GAA to a subject, wherein the rAAV expresses GAA to a steady state shortly after administration, so that the subject can withdraw ERT as early as the time of rAAV administration, or at the time of rAAV administration, or approximately at the time of rAAV administration, for example, the ERT can be withdrawn one day before administration, on the day of administration, or one day after administration, within one week of administration, or within two weeks of administration. As disclosed herein, the steady state of GAA expression by the rAAV disclosed herein is a GAA serum level within the pharmacologically active range of about 160 to ≤2260nmolmlhr or about 189 to ≤2,260nmol / mL / hr. In some embodiments, ERT is withdrawn when the subject shows biochemical evidence of transgenic GAA secretion. In some embodiments, the subject also shows no clinically significant decline in motor function (6MWT) or function (FVC upright). In some embodiments, ERT is withdrawn at any time between about 24 weeks to about 104 weeks.
[0063] In some embodiments, the methods disclosed herein for treating Pompe disease by rAAV expressing GAA comprise administering a therapeutically effective amount of rAAV such that the serum level of expressed hGAA is within the pharmacologically active range of 189 nmol / mL / hr to 410 nmol / mL / hr or 410 nmol / mL / hr to ≤2,260 nmol / mL / hr.
[0064] In some embodiments, the method disclosed herein for treating Pompe disease by rAAV expressing GAA comprises administering rAAV so that the serum level of hGAA expressed is within the range of 189 nmol / mL / hr to ≤2,260 nmol / mL / hr, and wherein the subject achieves clinical stability of one or more symptoms of Pompe disease. Clinical stability includes a stable state of one or more of the following parameters: 6MWT (6-minute walk test), FVC (forced vital capacity). In some embodiments, clinical stability refers to a stable level of motor function (as determined by 6MWT) and / or lung function (as determined by FVC) in two consecutive assessments separated by no less than 3 months. In some embodiments, the clinically stable level of motor function determined by 6MWT is a decrease of ≤12% from baseline in two consecutive assessments separated by no less than 3 months, or a decrease of less than 43 meters. In other words, the clinically stable level of motor function determined by the 6MWT position is within a decrease of 0-12% from the baseline level in two consecutive assessments separated by no less than 3 months.
[0065] In some embodiments, the clinically stable level of lung function as determined by the %FVC predicted in the upright position is a decrease of ≤15% from baseline in two consecutive assessments separated by no less than 3 months. In other words, the clinically stable level of lung function as determined by the %FVC predicted in the upright position is between 1%-14% from baseline in two consecutive assessments separated by no less than 3 months.
[0066] In some embodiments, the baseline level of 6MWT or FVC is the level measured at or before the time of administering rAAV expressing GAA. In some embodiments, the baseline level of 6MWT or FVC is the level measured at or before the time of administering rAAV expressing GAA when the subject is administered GAA ERT at the same time. In some embodiments, the baseline level of 6MWT or FVC is the level measured at or before the time of administering rAAV expressing GAA when the subject withdraws GAA ERT. In some embodiments, the baseline level of 6MWT or FVC is the level measured before the withdrawal of GAA ERT, for example, at about 24 to about 26 weeks. In some embodiments, clinical stability is maintained between before and after the withdrawal of ERT in Pompe disease patients, wherein the patient receives a single administration of AAV when, before or after ERT is administered, and the AAV comprises nucleic acid encoding GAA. Maintaining clinical stability indicates that 6MWT and / or FVC are within the range of baseline described herein.
[0067] In some embodiments, the methods disclosed herein for treating Pompe disease by rAAV expressing GAA include administering an amount of rAAV to reduce glycogen levels in one or more tissues to within a normal range, wherein the normal range is the glycogen levels in a control tissue of a subject not suffering from Pompe disease. In some embodiments of the invention, the glycogen content in the tissue is reduced from a baseline (e.g., a measurement taken on or before day 1 of AAV-GAA administration) by about 10% to about 40%, about 10% to about 30%, or about 15% to about 25%. A. AAV-hGAA Dosage
[0068] As disclosed in the Examples herein, human subjects were administered a dose of 1.6E12 vg / kg of rAAV expressing GAA (Cohort 1), wherein ERT withdrawal occurred at approximately 24 or 26 weeks after recombinant AAV administration—that is, the last dose of ERT for subjects in Cohort 1 was administered approximately 24 weeks after rAAV administration, and thus ERT withdrawal occurred at or approximately at the beginning of week 26 after administration. In Cohort 1, disease pathophysiology was therapeutically corrected even in the absence of ERT, and there was protection against immune responses to expressed hGAA (e.g., as measured by antibodies to expressed hGAA), thus demonstrating that subjects with Pompe disease who were administered the hGAA-expressing AAV disclosed herein can discontinue ERT long-term.
[0069] In some embodiments, the dose of the rAAV vector or rAAV genome to be administered to a subject according to the methods for treating Pompe disease disclosed herein depends on the mode of administration, the severity of Pompe disease or other condition to be treated and / or prevented, the condition of the individual subject, the particular viral vector or capsid used, the liver-specific promoter used, and the nucleic acid to be delivered (including but not limited to a nucleic acid encoding a signal peptide attached to the 5' of a nucleic acid encoding a GAA polypeptide that can express), etc., and can be determined in a routine manner.
[0070] In some embodiments, a therapeutically effective amount of a rAAV vector expressing GAA is an amount that produces a steady-state serum GAA concentration that is similar to the GAA pharmacological activity achieved by long-term GAA ERT (e.g., within 5%, 10%, 20% of such levels). For example, a steady-state target GAA serum concentration ranging from about 160 nmol / mL / hr to ≤2,260 nmol / mL / hr, about 189 nmol / mL / hr to ≤2,260 nmol / mL / hr, or ranging from 410 nmol / mL / hr to ≤2,260 nmol / mL / hr. In some embodiments, a dose of a rAAV vector expressing GAA is a therapeutically effective amount to achieve a steady-state target serum GAA concentration that confers a pharmacological activity ranging from 189 nmol / mL / hr to ≤2,260 nmol / mL / hr. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to increase the tissue GAA level of the subject to >0.30 μmol 4MU / min / gram of tissue, wherein the normal range of tissue GAA content in a subject without Pompe disease is 0.36±0.13 μmol 4MU / min / gram of tissue. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to increase the tissue GAA level of the subject to between 0.25 and 0.4 μmol 4MU / min / gram of tissue. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to produce a normal tissue GAA content of about 0.36 μmol 4MU / min / gram of tissue (e.g., about 0.25, or about 0.26, or about 0.27, or about 0.28, or about 0.29, or about 0.30, or about 0.31, or about 0.32, or about 0.33, or about 0.34, or about 0.35, or about 0.36, or about 0.37, or about 0.38, or about 0.39, or about 0.40 μmol 4MU / min / gram of tissue).
[0071] In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to increase the tissue GAA level of the subject to between 0.1-0.5 μmol 4MU / min / gram of tissue. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to produce a normal tissue GAA content of about greater than 0.36 μmol 4MU / min / gram of tissue. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to increase the tissue GAA content or level of the subject within the range of 0.2-0.4 μmol 4MU / min / gram of tissue. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to increase the tissue GAA content of the subject to within 40%, or within 30%, or within 20%, or within 10%, or within 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the normal muscle tissue GAA content of 0.36±0.13 (μmol4MU / min / gram of tissue), wherein the normal muscle tissue GAA content is a reference level of GAA for subjects without Pompe disease. In some embodiments, the dose of the rAAV vector expressing GAA is to increase the tissue GAA content of the subject to greater than 0.1 mol 4MU / min / gram of tissue, wherein the normal range of GAA content in subjects with Pompe disease is 0.05±0.04 (μmol4MU / min / gram of tissue). In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to increase the tissue GAA content of the subject by more than 2-fold, or 3-fold, or 4-fold, or 5-fold, or 6-fold, or 7-fold, or 8-fold, or 9-fold, or 10-fold or more than 10-fold of the GAA tissue content level of a subject with Pompe disease. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to increase the tissue GAA content of the subject to about 50%, or about 40%, or about 30%, or about 20%, or about 10%, or about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, or about 1% of the GAA tissue content level of a subject with Pompe disease. In some embodiments, GAA activity in muscle is at least 1.5-fold, at least 2-fold, at least 3-fold, at least 5-fold, at least 8-fold, or at least 10-fold compared to the level before AAV administration. In some embodiments, GAA activity in muscle is at least 1.5-fold, at least 2-fold, at least 3-fold, at least 5-fold, at least 8-fold, or at least 10-fold compared to the level after withdrawal of long-term ERT for at least about 24 weeks.
[0072] In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to reduce the subject's tissue glycogen level within the range of 0.25% tissue wet weight to about 1.5% tissue wet weight. In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to reduce the subject's muscle tissue glycogen level to within 40%, or within 30%, or within 20%, or within 10%, or within 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the normal muscle tissue glycogen content of 0.99% ± 0.74 (% tissue wet weight), the normal muscle tissue glycogen content is the normal muscle tissue glycogen content (measured as % tissue wet weight) of a subject who does not have Pompe disease.
[0073] In some embodiments, the dosage of the rAAV vector expressing GAA is a therapeutically effective amount of GAA to exhibit a 3-fold to 5-fold improvement in the therapeutic index.
[0074] In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount, which is used to stabilize one or more symptoms of Pompe disease, such as determined by the clinical stability parameters disclosed herein. Such parameters include the stable state of 6MWT (6-minute walk test) and / or FVC (forced vital capacity) in two consecutive assessments separated by no less than 3 months disclosed herein. In some embodiments, the clinically stable level of motor function determined by 6MWT is a decrease of ≤12% from baseline in two consecutive assessments separated by no less than 3 months, or a decrease of less than 43 meters. In some embodiments, the clinically stable level of pulmonary function determined by the predicted FVC% in an upright position is a decrease of ≤15% from baseline in two consecutive assessments separated by no less than 3 months.
[0075] In some embodiments, the dose of the rAAV vector expressing GAA is a therapeutically effective amount to provide a subject with clinically stable levels of hGAA 10 weeks, or at least 20 weeks or 30 weeks after AAV administration.
[0076] In embodiments, as used herein but without limitation, the term "effective amount" is synonymous with "therapeutically effective amount," "effective dose," or "therapeutically effective dose." In embodiments, the effectiveness of a therapeutic compound disclosed herein for treating Pompe disease can be determined, without limitation, by observing improvements in an individual based on one or more clinical symptoms and / or physiological indicators associated with Pompe disease. In embodiments, improvements in symptoms associated with Pompe disease can be indicated by a reduced need for concurrent therapy.
[0077] In some embodiments, when the rAAV vector expressing hGAA is AAV8-LSPhGAA disclosed herein, exemplary doses for achieving a therapeutic effect are titers of at least about 1.0E11 vg / kg, 1.1E11 vg / kg, 1.2E11 vg / kg, 1.3E11 vg / kg, 1.4E11 vg / kg, 1.5E11 vg / kg, 1.6E11 vg / kg, 1.7E11 vg / kg, 1.8E11 vg / kg, 1.9E11 vg / kg, about 1.0E12 vg / kg, about 1.1E12 vg / kg, about 1.2E12 vg / kg, about 1.3E12 vg / kg, about 1.4E12 vg / kg, about 1.5E12 vg / kg, about 1.6E12 vg / kg, about 1.7E12 vg / kg vg / kg, about 1.8E12 vg / kg, about 1.9E12 vg / kg, about 2.0E12 vg / kg, about 3.0E12 vg / kg, about 4.0E12 vg / kg, about 5.0E12 vg / kg, about 6.0E12 vg / kg, about 7.0E12 vg / kg, about 8.0E12 vg / kg, about 9.0E12 vg / kg, about 1.0E13 vg / kg, about 1.2E13 vg / kg, about 1.2E13 vg / kg, about 1.3E13 vg / kg, about 1.4E13 vg / kg, about 1.5E13 vg / kg, about 1.6E13 vg / kg, about 1.7E13 vg / kg, about 1.8E13 vg / kg, about 1.9E13 vg / kg, about 2.0E13 vg / kg, about 3.0E13 vg / kg, about 4.0E13 vg / kg, about 5.0E13 vg / kg.
[0078] In preferred embodiments, exemplary dosages for achieving a therapeutic effect according to the methods disclosed herein are titers between 1.2E11 and 4.0E11 vg / kg, for example, at least about 1.0E11 vg / kg, 1.1E11 vg / kg, 1.2E11 vg / kg, 1.3E11 vg / kg, 1.4E11 vg / kg, 1.5E11 vg / kg, 1.6E11 vg / kg, 1.7E11 vg / kg, 1.8E11 vg / kg, 1.9E11 vg / kg. In other preferred embodiments, exemplary doses are titers between 1.2E12 and 4.0E12 vg / kg, such as at least about 1.0E12 vg / kg, about 1.1E12 vg / kg, about 1.2E12 vg / kg, about 1.3E12 vg / kg, about 1.4E12 vg / kg, about 1.5E12 vg / kg, about 1.6E12 vg / kg, about 1.7E12 vg / kg, about 1.8E12 vg / kg, about 1.9E12 vg / kg, about 2.0E12 vg / kg, about 2.1E12 vg / kg, about 2.2E12 vg / kg, about 2.3E12 vg / kg, about 2.4E12 vg / kg, about 2.5E12 vg / kg, about 2.6E12 vg / kg, about 2.7E12 vg / kg, about 2.8E12 vg / kg, about 2.9E12 vg / kg, about 3.0E12 vg / kg, about 3.1E12 vg / kg, about 3.2E12 vg / kg, about 3.3E12 vg / kg, about 3.4E12 vg / kg, about 3.5E12 vg / kg, about 3.6E12 vg / kg, about 3.7E12 vg / kg, about 3.8E12 vg / kg, about 3.9E12 vg / kg, about 4.0E12 vg / kg.
[0079] In some embodiments, when the rAAV vector expressing hGAA is AAV8-LSPhGAA as disclosed herein, exemplary doses for achieving a therapeutic effect are titers of at least about 1.0E11 to 4.0E11 vg / kg, or about 1.0E12 to 4.0E12 vg / kg, or about 1.2E12 to 3.0E12 vg / kg, or about 1.2E12 to 2.5E12 vg / kg, or about 2.5E12 to 4.0E12 vg / kg, or about 2.0E12 vg / kg to about 5E12 vg / kg, or about 4.E12 vg / kg to about 2E13 vg / kg.
[0081] In some embodiments, the dosage can be modified by one of ordinary skill in the art, for example, when a stronger promoter than the LSP used in the AAV8-LSPhGAA vector disclosed herein is operably linked to the nucleic acid encoding GAA, the dose administered can be less than 1.0E12 vg / kg, or less than about 1.6E12 vg / kg. Conversely, in alternative embodiments, the dosage can be modified by one of ordinary skill in the art, for example, when a weaker liver-specific promoter than the LSP used in the AAV8-LSPhGAA vector disclosed herein is operably linked to the nucleic acid encoding GAA, the dose of the rAAV vector administered can be greater than about 1.6E12 vg / kg, or greater than about 5.0E12 vg / kg. Exemplary dosages for achieving a therapeutic effect are titers of at least about 1.0E 5 , 1.0E 6 , 1.0E 7 , 1.0E 8 , 1.0E 9 , 1.0E 10 , 1.0E 11 , 1.0E 12 vg / kg, optionally about 1.0E 10 to about 1.0E 12 Transduction units (vg / kg), and optionally no more than about 4.0E 12 vg / kg or optionally about 3.0E 12 Transducible units (vg / kg).
[0082] Similarly, in some embodiments, the dosage can be modified by one of ordinary skill in the art, for example, when a stronger signal sequence than the endogenous GAA signal sequence used in the AAV8-LSPhGAA vector disclosed herein is linked to the 5' of the expressed GAA polypeptide, the administered dose can be less than 1.0E12 vg / kg, or less than about 1.6E12 vg / kg. Conversely, in alternative embodiments, the dosage can be modified by one of ordinary skill in the art, for example, when an immunomodulator is used, the administered dose of the rAAV vector can be greater than about 1.6E12 vg / kg, or greater than about 1.6E13 vg / kg.
[0083] In further embodiments, administration of a rAAV vector or rAAV genome according to the methods disclosed herein to treat a subject with Pompe disease can result in production of a GAA protein with a circulating half-life of 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, one month, two months, three months, four months or more.
[0084] In some embodiments, the methods of treating Pompe disease disclosed herein involve a single dose of rAAV expressing hGAA for treating a subject in a single administration. However, in some embodiments, the dose of rAAV to be administered can be administered to a subject in multiple administrations, for example, the dose of rAAV can be divided into subdoses and administered in multiple administrations.
[0085] In embodiments, according to the methods for treating Pompe disease disclosed herein, the time period between administration of sub-doses of the rAAV vector is selected from any one of: 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or longer.
[0086] In some embodiments, it is contemplated that the methods of treating Pompe disease disclosed herein may include multiple administrations of a single dose of rAAV expressing hGAA, that is, the subject may be treated with a booster administration (i.e., a second, third, fourth, etc.) of rAAV expressing hGAA after a defined period of time following the initial or first administration. The dose of the booster administration (i.e., the second, third, fourth, or fifth, etc.) may be the same as the dose (amount) of rAAV-hGAA administered in the first administration, or may be a higher dose or a lower dose, depending on the factors described above, including, but not limited to, a therapeutically effective dose to achieve one or more of the following: (i) serum GAA levels indicating a steady state of GAA expression, (ii) a decrease in muscle glycogen levels and / or maintenance of glycogen levels within a normal range, and (iii) one or more symptoms of Pompe disease (including muscle function and / or lung function) within a clinically stable level. As disclosed herein, the stable state of GAA expressed by rAAV disclosed herein is a serum GAA level in the pharmacologically active range of 165 to ≤2260nmol / mL / hr or 189 to ≤2,260nmol / mL / hr. The stability of one or more symptoms of Pompe disease can be determined by the clinical stability parameters disclosed herein, and includes the stable state of 6MWT (6-minute walk test) and / or FVC (forced vital capacity) in two consecutive assessments separated by no less than 3 months disclosed herein. In some embodiments, the clinical stable level of motor function determined by 6MWT is a decrease of ≤12% from baseline in two consecutive assessments separated by no less than 3 months, or a decrease of less than 43 meters. In some embodiments, the clinical stable level of pulmonary function determined by the predicted FVC% in an upright position is a decrease of ≤15% from baseline in two consecutive assessments separated by no less than 3 months.
[0087] In embodiments, the time period between the first dose and subsequent doses (i.e., booster doses) of the rAAV vector administered according to the methods for treating Pompe disease disclosed herein is selected from any of the following: about 4 months, about 6 months, about 7 months, about 8 months, about 9 months, about 12 months, about 18 months, about 24 months, or about 3 years, about 4 years, about 5 years, or more than 5 years.
[0088] In another embodiment, administration of a rAAV vector or rAAV genome as disclosed herein for treating Pompe disease results in weight gain, e.g., at least 0.5 pounds, at least 1 pound, at least 1.5 pounds, at least 2 pounds, at least 2.5 pounds, at least 3 pounds, at least 3.5 pounds, at least 4 pounds, at least 4.5 pounds, at least 5 pounds, at least 5.5 pounds, at least 6 pounds, at least 6.5 pounds, at least 7 pounds, at least 7.5 pounds, at least 8 pounds, at least 8.5 pounds, at least 9 pounds, at least 9.5 pounds, at least 10 pounds, at least 10.5 pounds, at least 11 pounds, at least 11.5 pounds, at least 12 pounds, at least 12.5 pounds, at least 13 pounds, at least 13.5 pounds, at least 14 pounds, at least 14.5 pounds, at least 15 pounds, at least 20 pounds, at least 25 pounds, at least 30 pounds, at least 50 pounds.
[0089] In another embodiment, AAVGAA of any serotype as disclosed herein for use in treating Pompe disease causes weight gain, e.g., 0.5 lbs to 50 lbs, 0.5 lbs to 30 lbs, from 0.5 lbs to 25 lbs, 0.5 lbs to 20 lbs, 0.5 lbs to 15 lbs, 0.5 lbs to 10 lbs, 0.5 lbs to 7.5 lbs, 0.5 lbs to 5 lbs, 1 lb to 15 lbs, 1 lb to 10 lbs, 1 lb to 7.5 lbs, 1 lb to 5 lbs, 2 lbs to 10 lbs, 2 lbs to 7.5 lbs. B. Withdrawal of long-term ERT
[0090] Treatment of Pompe disease is usually performed by long-term enzyme replacement therapy (ERT) by administering recombinant human acid α-glucosidase (rhGAA), and it has been previously reported to prolong the survival of both LOPD and IOPD patients by improving lung function and muscle function. However, Schoser et al. reported that after a period of stability, both parameters continued to decline over time (see Schoser et al., 2017 Neurol, 264: 621-30). In addition, ERT performed by recombinant GAA protein has many disadvantages, including, but not limited to, the short half-life of the administered recombinant GAA in the blood, the lack of effective skeletal muscle uptake, the possibility of high titer antibody response, and even some patients do not respond to ERT, and strict administration of recombinant GAA infusion every 2 weeks, which may take between 5-8 hours. Furthermore, although disease progression is slowed compared to untreated subjects, the benefits of ERT may not be long-lasting, and many patients die or remain frail despite compliance with treatment (Tarnopolsky et al., 2016 Can J Neurol Sci, 43:472-85).
[0091] The reduced efficacy of subjects receiving recombinant GAA protein ERT is partially explained by the immune response to ERT, in which high and persistent anti-GAA antibody titers (HSAT) are formed. Compared with patients who do not form or only form low-titer antibodies, subjects with HSAT show a greatly increased mortality rate (Banugaria et al., 2011). In addition, the ability to prevent antibody formation in subjects at risk of HSAT by immunosuppression (which significantly prolongs survival) confirms the clinical relevance of HSAT (Mendelsohn et al., 2009; Banugaria et al., 2013; Kazi et al., 2017).
[0092] If a subject with Pompe disease has residual GAA enzyme activity, it is considered to be cross-reactive immune substance (CRIM) positive, and if no residual GAA activity is detected, it is considered to be CRIM negative. According to the aggregated clinical research data, 28% of Pompe disease cases are infantile-onset, of which about 85% are classic infantile-onset, and three-quarters of these are CRIM positive (Kemper, Comeau and Green 2013). It is important to determine the CRIM status in newly diagnosed IOPD patients because it allows preventive immunomodulatory measures to be taken before starting ERT, thereby offsetting the worst damaging effects of HSAT. CRIM-negative Pompe disease subjects produce HSAT and show a significant reduction in the efficacy of ERT with rhGAA (Amalfitano et al., 2001). In the first pilot study of ERT for Pompe disease using rhGAA derived from Chinese hamster ovary cells, two subjects with CRIM negative produced higher anti-GAA antibody titers than the third subject with CRIM positive. This corresponds to a significant reduction in the efficacy of ERT in CRIM-negative subjects. The relevance of antibody formation to the efficacy of therapy in Pompe disease has been highlighted by the poor response to ERT in CRIM-negative subjects, which has been associated with the onset of HSAT (Kishnani et al., 2010).
[0093] Although no LOPD subjects were CRIM negative, some subjects developed high antibody responses to rhGAA that could interfere with optimal efficacy of ERT (Patel et al., 2012; de Vries et al., 2017; "LUMIZYME Prescribing Information" 2014). In addition, all Pompe disease patients develop some level of anti-GAA antibody response, which has an unknown impact on ERT efficacy.
[0094] As described herein, the inventors have demonstrated herein that subjects with Pompe disease who were administered an AAV expressing hGAA disclosed herein can have prolonged periods of cessation of long-term ERT administration. In particular, the Examples present data demonstrating that subjects with Pompe disease who were administered an AAV expressing a GAA polypeptide were able to reduce or eliminate the clinical need for long-term hGAA ERT administration for prolonged periods of time.
[0095] Thus, the disclosed methods enable subjects with Pompe disease to withdraw or stop long-term administration of recombinant human GAA (rhGAA) ERT, which is typically administered on a weekly or every other week schedule. In some embodiments, if a subject is administered a specific dose of an AAV vector expressing a GAA polypeptide disclosed herein, the methods disclosed herein enable subjects with Pompe disease to interrupt a normal ERT regimen for an extended period of time (e.g., an extended ERT cessation period). In some embodiments, withdrawal of long-term ERT administration begins approximately when the AAV vector is administered to the subject (e.g., the day before, the day after, or the day after), or in some embodiments, withdrawal of long-term ERT administration may occur at about 24 weeks after administration of the AAV vector, or at any time within about 24 weeks to about 26 weeks. In some embodiments, withdrawal of ERT begins at any time within a defined time period after administration of AAV-GAA (e.g., between the first day and 26 weeks or the first day and 6 months). In some embodiments, withdrawal of ERT is initiated after the subject demonstrates biochemical evidence that transgenic GAA secretion is within a specified pharmacologically active range (eg, as described herein).
[0096] As disclosed herein, "long-term ERT" refers to the standard of care (SOC) treatment for subjects with Pompe disease (including IOPD and LOPD), and is generally a regimen of regular and frequent (e.g., weekly or every 2 weeks) intravenous administration of recombinant human alglucosidase alpha protein (rhGAA) to the subject without any breaks in the regimen, and wherein the administered rhGAA protein provides an exogenous source of GAA. The first U.S. approved product for the treatment of Pompe disease (2006) (alglucosidase alfa) and approved in 2010 (alglucosidase alfa) is the current exemplary standard of care (SOC) treatment for patients with infantile-onset and late-onset Pompe disease. The normal long-term ERT administration regimen is intravenous administration of alglucosidase alfa at a dose of 20 mg / Kg as an infusion every 2 weeks (LUMIZYME Prescribing Information 2014).
[0097] As disclosed herein, the methods disclosed herein enable withdrawal or cessation of administration of long-term ERT over an extended period of time. In some embodiments, the extended period of time is at least about 3 months, or at least about 6 months, or at least about 1 year, or longer than 1 year.
[0098] As disclosed herein, an "extended" "period" of time as referred to in reference to a period of time during which long-term ERT administration is discontinued refers to a period of time longer than 1 month, and in some embodiments, longer than that if up to 5 ERT administrations are missed.
[0099] Thus, in some embodiments, the method for treating a subject with Pompe disease as disclosed herein comprises administering to the subject a pharmaceutical composition comprising an AAV expressing GAA, and wherein the subject is not administered long-term GAA enzyme replacement therapy (ERT) for an extended period of time. In some embodiments, stopping or withdrawing the administration of long-term ERT occurs at any time between 1-2 days of administration and at least 24 weeks after administration of the AAV-GAA vector. That is, in some embodiments, the subject receiving treatment may stop administering ERT on the day of administration of AAV-GAA, or the day before or the day after. In some embodiments, the subject treated according to the methods disclosed herein may stop ERT about 1 week, or about 2 weeks, or about 3 weeks, or about 1 month, or about 2 months, or about 3 months, or about 4 months, or about 5 months, or about 6 months after administration of AAV-GAA.
[0100] The exact time window for discontinuation of ERT or cessation of ERT for each subject according to the methods disclosed herein can be determined by an ordinary technician, but without wishing to be bound by theory, methods are included herein, wherein ERT is discontinued at a time point when serum GAA levels achieved by AAV-hGAA expression are close to or about serum levels within the pharmacologically active range of at least 165 nmol / mL / hr or at least 189 nmol / mL / hr (e.g., between 189 to ≤2,260 nmol / mL / hr). In some embodiments, methods are included herein, wherein ERT is discontinued at a time point when serum GAA levels achieved by AAV-hGAA expression are within 50%, or within 60%, or within 70%, or within 80% of serum levels within the pharmacologically active range of 189 nmol / mL / hr. In some embodiments, the present invention includes methods wherein ERT is discontinued at a time point when AAV-hGAA expression achieves serum GAA levels within 50%, within 60%, within 70%, or within 80% of serum levels within the pharmacologically active range of 165 nmol / mL / hr to about 2000 nmol / mL / hr.
[0101] In some embodiments, the present invention includes methods in which ERT is discontinued at a time point when serum GAA levels achieved by a normal ERT regimen are replaced by serum GAA levels achieved by AAV-hGAA expression. For example, as serum GAA levels produced by recombinant hGAA from the last ERT administration decrease, serum GAA levels achieved by AAV-hGAA expression increase simultaneously, such that withdrawal or cessation of ERT does not cause a decrease in clinical stability of one or more symptoms of Pompe disease in the subject, as measured by 6MWT or FVC according to the methods disclosed herein. For purposes of illustration only, in some embodiments, ERT withdrawal or cessation occurs when the AAV-hGAA administered is such that the expressed GAA achieves a serum GAA level that clinically stabilizes one or more symptoms of Pompe disease in the subject, e.g., a clinically stable level of motor function as determined by the 6MWT of a decrease of ≤12% from baseline, or a decrease of less than 43 meters, on two consecutive assessments no less than 3 months apart, or a clinically stable level of pulmonary function as determined by FVC% in the upright position of a decrease of ≤15% from baseline on two consecutive assessments no less than 3 months apart, thereby rendering recombinant hGAA from the last ERT administration superfluous.
[0102] In some embodiments, the methods disclosed herein enable long-term cessation of ERT for a period of about 1 year, about 15 months, about 18 months, about 24 months, about 30 months, or more than 30 months (e.g., 3 years, 4 years, 5 years, or more) while maintaining clinical stability of one or more symptoms of Pompe disease, such as measured by 6MWT and / or %FVC, GAA levels in tissue or serum within the normal range, tissue glycogen levels within the normal range, or other symptoms disclosed herein. For example, at least 73 weeks, at least 75 weeks, at least 80 weeks, at least 100 weeks, at least 150 weeks, at least 200 weeks, and all time points therebetween.
[0103] Thus, the methods disclosed herein provide significant advantages for subjects with Pompe disease, including, but not limited to, reducing or eliminating the rigorous and laborious weekly or every other week infusions of long-term rhGAA ERT therapy, which are significantly time-consuming and geographically limited, and prevent Pompe disease patients from traveling away from the area where their ERT infusions are given for extended periods of time. In addition, as disclosed herein, not administering ERT also reduces any side effects attributed to anti-rhGAA antibodies to ERT, and also avoids the need to administer immunosuppressants that are typically co-administered with ERT. Thus, the methods disclosed herein for treating Pompe disease allow for greater flexibility in the treatment of Pompe disease and improve the quality of life and lifestyle of subjects with Pompe disease. C. Administration of Supplemental ERT
[0104] As disclosed herein, the disclosed methods of treating Pompe disease by administering an AAV vector expressing GAA enable a subject to take a break or "holiday" from the normal regimen of administering long-term ERT. That is, according to the methods disclosed herein, a subject administered an AAV vector expressing GAA disclosed herein can have an extended period of time without the administration of long-term ERT. In addition, in some embodiments, a subject administered an AAV vector expressing GAA disclosed herein can be administered supplemental ERT after an initial phase of withdrawal of the administration of long-term ERT for an extended period of time, wherein the supplemental ERT is administered about 6 months, about 1 year, or more than one year after the cessation of long-term ERT. As disclosed herein, the method allows flexibility in the normal long-term ERT administration regimen so that long-term interruptions or omissions from long-term ERT administration do not result in clinical regression - that is, the subject remains clinically stable despite the absence of continuous long-term ERT administration for an extended period of time.
[0105] In some embodiments, the methods disclosed herein include re-administering ERT after ERT administration has ceased for an extended period of time (referred to herein as "supplemental ERT"), and allow flexibility in the normal ERT regimen, as the continued production of AAV-expressed GAA allows for the inclusion of ERT flexibility. In some embodiments, as disclosed herein, supplemental ERT is a pulsed administration of ERT. In some embodiments, supplemental ERT is administered less frequently at intervals, or at a lower dose, or at irregular doses, or at irregular intervals, compared to the previous long-term ERT administration.
[0106] In some embodiments, the methods disclosed herein include restarting ERT (referred to herein as "supplemental ERT") after an extended period of at least 6 months to about 1 year in the absence of long-term ERT. In some embodiments, supplemental ERT can be continued for a shorter period of time and can be followed by a second extended period of ERT administration cessation. In some embodiments, supplemental ERT can be continued for any period of time between 3 months and about 2 years, such as about 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or about 1 year.
[0107] In some embodiments, the method includes administering rAAV expressing GAA to a subject with Pompe disease, wherein long-term ERT continues to be administered after administration of the recombinant AAV. However, ERT is at a lower dose and / or frequency than before administration of the recombinant AAV vector. For example, after administration of the AAV vector, long-term ERT may be administered every 3 weeks, once a month, once every two months, once every 3 months, once every 4 months, once every 5 months, or once every 6 months for at least 24 weeks after administration of AAV-GAA. In one embodiment, the dose of long-term ERT may be reduced. In one method, a pulse administration regimen of long-term ERT after administration of the AAV vector may be used, thereby allowing for irregular dosing schedules and / or amounts to be used. As discussed herein, in some embodiments, as disclosed herein, long-term ERT administration may be withdrawn at 24 weeks or earlier.
[0108] In some embodiments, because the administered AAV vectors continuously express GAA, the methods disclosed herein enable the flexibility to administer both long-term ERT or supplemental ERT, such that if the subject is scheduled to miss or inadvertently or accidentally misses one or more ERT administrations of a long-term ERT or supplemental ERT regimen, the subject will remain clinically stable. Currently, if ERT is missed, a larger amount of ERT is required to return to the same clinical level.
[0109] In some embodiments, the supplemental ERT is administered at less frequent intervals, or at a lower dose, or at irregular doses, or at irregular intervals, compared to the prior long-term ERT administration. For example, in some embodiments, the dose of rhGAA administered in the supplemental ERT is less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55%, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 2%, or less than 1% of the normal dose of rhGAA administered in the long-term ERT regimen.
[0110] In some embodiments, supplemental ERT is administered as a pulse administration. In alternative embodiments, a subject administered with a rAAV vector composition disclosed herein can have interruptions or discontinuations from a conventional administration regimen of supplemental ERT or long-term ERT administration, wherein long-term ERT or supplemental ERT is administered by pulse administration. For example, in some embodiments, administration of long-term ERT or supplemental ERT can be administered by pulse administration. In certain embodiments, a subject administered with a composition can have pulse administration of long-term ERT or supplemental ERT.
[0111] In certain embodiments, pulse administration of supplemental ERT is appropriate provided that the subject has been administered sufficient doses of the AAV vector compositions disclosed herein to sustain expression of GAA to maintain clinical stability and / or to maintain serum GAA levels at or above 189 nmol / hr* (e.g., throughout the duration of an ERT break or "ERT holiday," in which regularly scheduled ERT is not administered). In certain embodiments, the methods disclosed herein allow a subject to be administered pulses of supplemental ERT throughout the subject's lifetime.
[0112] In some embodiments, the administration regimen of supplemental ERT can have intermittent breaks, where the administration of ERT is suspended (eg, the duration of a break or "ERT holiday," where the administration regimen of ERT is suspended).
[0113] In some embodiments, the method comprises administering supplemental ERT by pulse administration, wherein the pulse administration of supplemental ERT occurs at least once a month, at least every other month, at least every 6 months, at least every year, or every other year. Since the methods disclosed herein comprise administering an AAV vector at a sufficient dose to continuously express GAA in a subject and maintain serum GAA levels at or above 189 nmol / hr*, if supplemental ERT is administered, pulse administration can substantially reduce the amount of ERT administered to a patient per dose or per total treatment regimen and improve effectiveness, and allow for increased flexibility in the ERT administration regimen. This represents a significant savings in time, effort, and expense, and more importantly, an improvement in the quality of life of Pompe disease patients, as well as a lower ERT dose, which can mitigate any side effects, including anti-GAA antibodies to the administered rhGAA protein.
[0114] In some embodiments, the administration of supplemental ERT is a pulse administration. In certain embodiments, the pulse administration comprises administering supplemental ERT for about 8 weeks, followed by about 4 weeks without supplemental ERT. In some embodiments, the pulse administration comprises administering supplemental ERT for about 6 weeks (i.e., 6 weekly infusions, or 3 infusions every 2 weeks), followed by about 2 weeks without supplemental ERT. In certain embodiments, the pulse administration comprises administering supplemental ERT for about 4 weeks, followed by about 2 weeks without supplemental ERT. In some embodiments, the pulse administration comprises administering supplemental ERT for about 2 weeks, followed by about 2 weeks without supplemental ERT.
[0115] In some embodiments, the interval frequency of pulse administration of supplemental ERT is less than the conventional regimen of long-term ERT administration, for example, the interval of pulse supplemental ERT can be about every 3 weeks, about every 1 month, or about every 6 weeks, or about every 2 months, or about every 3 months, or about every 4 months. In some embodiments, the intervals between pulse administrations of supplemental ERT can be irregularly spaced, and for distance purposes only, the administration of ERT can be 3 weeks apart, then 4 weeks apart, then 6 weeks apart, then 3 weeks apart, etc., where the intervals are determined based on the clinical stability of the subject disclosed herein, or simply based on the convenience of the schedule and / or plan of supplemental ERT administration.
[0116] In some embodiments, the interval between pulses can be determined by the clinical stability parameters disclosed herein. In alternative embodiments, the interval between pulses of supplemental ERT administration can be calculated by administering another dose of ERT when the administered rhGAA is no longer detectable in the patient or serum GAA levels fall below a certain threshold (e.g., below the drug activity range of 189 nmol / hr*mL) before the delivery of the next pulse. The interval can also be based on or The interval can be calculated based on the in vivo half-life of the rhGAA polypeptide administered in the formulation. The interval can be calculated to be greater than the in vivo half-life, or 2 times, 3 times, 4 times, 5 times or even 10 times higher than the half-life of the composition. For compositions with relatively fast half-lives, the interval can be 25 times, 50 times, 100 times, 150 times, 200 times, 250 times, 300 times or even 500 times the half-life of the rhGAA polypeptide. The number of pulses of supplemental ERT given over an extended period of time can be as few as 2 times, but is generally about 5 to 10 times, 10 to 20 times, 15 to 30 times or more. In some embodiments, patients can receive lifelong supplemental ERT administration through the pulse administration disclosed herein according to the methods of the present invention without the problems and inconveniences associated with current long-term ERT regimens. D. No long-term immunosuppression
[0117] Subjects who have been given rhGAA ERT are usually given immunosuppressants together with ERT therapy to avoid reducing ERT efficacy due to high and continuous anti-GAA antibody titers (HSAT) for rhGAA. Importantly, it has been reported before that part of the explanation for the weakened efficacy of ERT for the treatment of Pompe disease in subjects is the immune response to ERT, in which high and continuous anti-GAA antibody titers (HSAT) are formed. Compared with patients who have not formed or only formed low-titer antibodies, subjects with HSAT show a greatly increased mortality rate (Banugaria et al., 2011). In addition, the ability to prevent antibody formation in subjects at risk of HSAT (which significantly prolongs survival) by immunosuppression confirms the clinical relevance of HSAT (Mendelsohn et al., 2009; Banugaria et al., 2013; Kazi et al., 2017).
[0118] Subjects with Pompe disease are considered cross-reactive immune material (CRIM) positive if they have residual GAA enzyme activity, whereas they are considered CRIM negative if no residual GAA activity is detected. Based on pooled clinical study data, 28% of Pompe disease cases are infantile-onset, of which approximately 85% are classic infantile-onset, and three-quarters of these are CRIM positive (Kemper, Comeau, and Green 2013). Determining CRIM status in newly diagnosed IOPD patients is important because it allows for prophylactic immunomodulatory measures to be taken prior to initiating ERT, thereby counteracting the worst damaging effects of HSAT.
[0119] Pompe disease subjects with negative CRIM develop HSAT and show a significant reduction in the efficacy of ERT with rhGAA (Amalfitano et al., 2001). The relevance of antibody formation to the efficacy of therapy in Pompe disease has been highlighted by the poor response of CRIM-negative subjects to ERT, which is associated with the onset of HSAT (Kishnani et al., 2010). Although no LOPD subjects are CRIM-negative, some subjects develop high antibody responses to rhGAA that can interfere with the optimal efficacy of ERT (Patel et al., 2012; de Vries et al., 2017; "LUMIZYME Prescribing Information" 2014). In addition, all Pompe disease patients develop a certain level of anti-GAA antibody response, which has an unknown effect on the efficacy of ERT.
[0120] Herein, the inventors demonstrate that in Pompe disease subjects who were administered AAV-GAA, production of anti-GAA antibodies to GAA expressed by AAV was minimal. Thus, in some embodiments, the methods disclosed herein include administering AAV-GAA to a subject without ongoing immunosuppression. That is, in some embodiments, immunosuppression is not administered to a subject over a long period of time.
[0121] In some embodiments, an immunosuppressant or immunomodulator (used interchangeably herein) is administered to a subject as immunoprophylaxis to prevent or reduce any immune response to the administered AAV vector, thereby allowing subsequent or booster administration of an AAV vector expressing GAA according to the methods disclosed herein, if desired.
[0122] In some embodiments, an immunomodulator is administered in the initial stage at or approximately when an AAV vector expressing GAA is administered to a subject. For example, an immunomodulator is administered about 24 hr before an AAV vector expressing GAA is administered to a subject. The initial administration phase of an immunomodulator (e.g., methotrexate / prednisone) may alternatively be 2 days, 3 days, 4, 5, 6, or 7 days before rAAV administration. In some embodiments, an immunomodulator is administered about 24 hr before AAV administration, and at least 1 day, or at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days, or at least 6 days, or about 1 week, or more than 1 week is administered after the AAV vector expressing GAA is administered. In some embodiments, an immunomodulator is administered about 24 hr before or approximately before AAV administration, and no more than 1 day, or 2 days, 3 days, or 4 days, or 5 days, or 6 days, or 1 week, or 2 weeks, or 3 weeks, or 1 month is administered after the AAV vector expressing GAA is administered.
[0123] In some embodiments, the immunomodulator is administered to the subject at decreasing doses, e.g., a first dose for a first time period, a second lower dose for a second time period, and a third dose that is lower than the second dose for a third time period, and so on, until no immune response to AAV or GAA is produced. For example, in some embodiments, a first dose of an immunomodulator is initiated at or approximately 24 hr prior to administration of the AAV and is administered for at least 1 day, or at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days, or at least 6 days, or about 1 week, or about 2 weeks, or about 3 weeks, or about 4 weeks, after which the immunomodulator is reduced to a second dose (lower than the first dose) for a second period of time (e.g., at least 1 day, or at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days, or at least 6 days, or about 1 week, or about 2 weeks, or about 3 weeks, or about 4 weeks), after which the immunomodulator is reduced to a third dose (lower than the second dose) for a third period of time (e.g., at least 1 day, or at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days, or at least 6 days, or about 1 week).
[0124] For example purposes only, in some embodiments, the method for treating Pompe disease disclosed herein includes administering prednisone as an immunosuppressant (i.e., immunoprophylaxis) with a first dose (oral) of 60 mg starting 24 hours before the AAV vector is administered. In some embodiments, prednisone is continued to the end of the fourth week after the vector is administered at 60 mg / day po, after which, at the beginning of the 5th week, the prednisone dose is reduced to a second dose level of 55 mg / day po and maintained for 7 days. In some embodiments, at the beginning of the 6th week, the dose is reduced to a third dose level of 50 mg / day po and maintained for 7 days, etc., so that after the initial immunosuppressant dose of 4 weeks, the dose of the immunosuppressant (i.e., prednisone) is reduced by 5 mg / day every week. In some embodiments, the first dose (e.g., prednisone) is less than 60 mg (e.g., 55 mg, 50, 45, 40, 35, 30, 25, 20, 15 or 10 mg). In some embodiments, another corticosteroid (e.g., methylprednisolone) is used instead of prednisone, optionally in a lower amount. In some embodiments, the dosage and regimen are sufficient to maintain T cell reactivity to the vector capsid at substantially low levels.
[0125] In some embodiments, prednisone is combined with another agent (e.g., methotrexate) as an immunosuppressant. In some embodiments, immunosuppression is achieved by administering prednisone, methotrexate, sirolimus, tacrolimus, rapamycin, or any combination thereof. Without being bound by theory, it is believed that the combination therapy of prednisone and methotrexate inhibits CD4 and CD8 cell proliferation. The initial administration phase of the second agent (e.g., methotrexate) need not be simultaneous with the first agent (e.g., prednisone) or follow the same course of treatment, and can be administered on the same day (e.g., 1 hour ago) with AAV or can be administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days before AAV administration.
[0126] In some embodiments, prednisone is combined with methotrexate as an immunosuppressant. For example, prednisone is given as described above (for example, prednisone is given from AAV 24 hours before, 60 mg once a day, for 4 weeks, and then 5 mg is reduced weekly), and additional methotrexate is given (for example, 1 hour before the first day of the study carrier administration). In some embodiments, methotrexate is initially given, for example, for a period of time with a weekly total dose of 30 mg, and then gradually reduced. Typically, methotrexate is given weekly doses in one day. Folic acid (for example, 1 mg / day) can be given on non-methotrexate treatment days, and the dose is maintained during methotrexate reduction until methotrexate ends once it ends. In order to maximize absorption and bioavailability, a single dose of methotrexate should not exceed 15 mg. Doses higher than 15 mg are given with separate schedules (for example, 30 mg is given with 15 mg 2 × per day). In some embodiments, the initial methotrexate dose lasts for 12 weeks. After the initial administration phase, the dose reduction is carried out by reducing the weekly methotrexate dosage by a specific amount (for example, reducing 5mg weekly) every week. For example, in the 13th week, in order to achieve the weekly total dose of 25mg methotrexate, the second daily dose of methotrexate is reduced by 5mg, so that 15mg is given in the morning, and then 10mg is given in the evening. In the 14th week, in order to achieve the weekly total dose of 20mg methotrexate, the first daily dose of methotrexate is reduced by 5mg, so that 10mg is given in the morning, and then 10mg is given in the evening. In the 15th, 16th and 17th weeks, methotrexate can be given in a single dose. In the 15th week, in order to achieve the weekly total dose of 15mg methotrexate, the methotrexate of a 15mg dosage is given. In the 16th week, in order to achieve the weekly total dose of 10mg methotrexate, the methotrexate of a 10mg dosage is given. In the 17th week, in order to achieve the weekly total dose of 5mg methotrexate, the methotrexate of a 5mg dosage is given. At week 18, methotrexate will no longer be given.
[0127] The dosage and / or administration regimen of prednisone and methotrexate can be modified based on AST / ALT elevation as needed.In some embodiments, dosage and regimen are sufficient to maintain the T cell reactivity for the carrier capsid at a substantially low level.In some embodiments, prednisone is given as described above (prednisone is given from AAV 24 hours before, 60 mg once a day, for 4 weeks, then weekly reduction of 5 mg), and initially (for example, 1 hour before the first day of the study to give the carrier) with a weekly dose lower than 30 mg / week (for example, 25 mg / week, 20 mg / week, 15 mg / week, 10 mg / week, 7.5 mg / week or 5 mg / week) give other methotrexate for a period of time, then the dosage can be reduced as needed (for example, after 12 weeks).In some embodiments, it is after the initial stage (for example, 12 weeks) that the dosage of methotrexate is reduced to 2.5 mg / week for the initial dose. Folic acid can be given (e.g., 1 mg / day) on non-methotrexate treatment days, and the dosage is maintained during methotrexate reduction to end once methotrexate ends. In a preferred embodiment, the initial methotrexate dosage is 5 mg / week to 7.5 mg / week (e.g., 5 mg / week, 5.5 mg / week, 6 mg / week, 6.5 mg / week, 7 mg / week or 7.5 mg / week) for 12 weeks, followed by reduction (e.g., with 2.5 mg / week). In some embodiments, methotrexate and folic acid are not reduced to 0, but are given low doses in the extended time period or indefinitely.
[0128] The use of prednisone is used herein as an example of an immunosuppressant for immunoprophylaxis according to the methods disclosed herein. However, it is contemplated that prednisone can be easily replaced by different immunomodulators and administration regimens known to those of ordinary skill in the art.
[0129] In some embodiments, normal immunoprophylaxis for preventing immune reactivity to expressed GAA is withheld or withdrawn shortly before or after, or on day 1, administration of a rAAV expressing GAA according to the methods disclosed herein. (i) Immunomodulation and immunosuppression:
[0130] As disclosed herein, in some embodiments, the methods disclosed herein include administering AAV-GAA to a subject without ongoing immunosuppression. That is, in some embodiments, immunosuppression is not administered to a subject over a long period of time, but is administered only for a short and predetermined period of time, including an initial phase (at an initial dose) and a tapering phase (at a gradually decreasing dose) after administering an AAV vector expressing GAA to a subject. Thus, in some embodiments, immunosuppression is administered for between 4 weeks and up to about 15 weeks after administering an AAV vector expressing GAA to a subject, and may be administered at an initial dose and tapering dose as disclosed herein.
[0131] Thus, in some embodiments, the methods and compositions for treating Pompe disease using the AAV vectors and AAV genomes described herein further comprise administering an immunomodulatory agent during the initial phase followed by a tapering phase. In some embodiments, the immunomodulatory agent may be administered during, before, or after administration of the rAAV vector.
[0132] In any embodiment of the methods and compositions disclosed herein, an immunosuppressant is also administered to a subject to whom the rAAV vector or rAAV genome disclosed herein is administered. A variety of methods are known to cause immunosuppression of the immune response of patients administered AAV. Methods known in the art include administering an immunosuppressant, such as a proteasome inhibitor, to a patient. One such proteasome inhibitor known in the art is bortezomib, as disclosed in, for example, U.S. Patent No. 9,169,492 and U.S. Patent Application No. 15 / 796,137 (both of which are incorporated herein by reference). In another embodiment, the immunosuppressant may be an antibody, including polyclonal antibodies, monoclonal antibodies, scFv or other molecules derived from antibodies that can suppress immune responses by, for example, eliminating or inhibiting cells that produce antibodies. In a further embodiment, the immunosuppressive element may be a short hairpin RNA (shRNA). In such embodiments, the coding region of the shRNA is contained in the rAAV box and is generally located downstream of the 3' end of the poly-A tail. shRNAs can be targeted to reduce or eliminate the expression of immunostimulatory agents such as cytokines, growth factors including transforming growth factor β1 and β2, TNF and other well-known factors.
[0133] In some embodiments, the immunomodulator is an immunoglobulin degrading enzyme, such as IdeS, IdeZ, IdeS / Z, Endo S, or a functional variant thereof. Non-limiting examples of references to such immunoglobulin degrading enzymes and their uses are described in US 7,666,582, US 8,133,483, US20180037962, US20180023070, US20170209550, US8,889,128, WO2010 / 057626, US 9,707,279, US 8,323,908, US 20190345533, US20190262434, and WO2020 / 016318, each of which is incorporated herein by reference in its entirety.
[0134] In some embodiments, the immunomodulator or immunosuppressant is a proteasome inhibitor. In certain aspects, the proteasome inhibitor is bortezomib. In some aspects of the embodiments, the immunomodulator includes bortezomib and the anti-CD20 antibody rituximab. In other aspects of the embodiments, the immunomodulator includes bortezomib, rituximab, methotrexate and intravenous gamma globulin. Non-limiting examples of such references disclose proteasome inhibitors and combinations thereof with rituximab, methotrexate and intravenous gamma globulin, as described in US 10,028,993, US 9,592,247 and US 8,809,282, each of which is incorporated herein by reference in its entirety. One such proteasome inhibitor known in the art is bortezomib, such as disclosed in U.S. Patent No. 9,169,492 and U.S. Patent Application No. 15 / 796,137, both of which are incorporated herein by reference.
[0135] In another embodiment, the immunosuppressant can be an antibody, including polyclonal antibodies, monoclonal antibodies, scFv or other molecules derived from antibodies that inhibit immune responses by, for example, eliminating or inhibiting cells that produce antibodies. In a further embodiment, the immunosuppressive element can be a short hairpin RNA (shRNA). In such embodiments, the coding region of the shRNA is contained in the rAAV box and is generally located 3' downstream of the poly-A tail. The shRNA can be targeted to reduce or eliminate the expression of an immunostimulant, such as a cytokine, a growth factor (including transforming growth factor β1 and β2, TNF and other known factors).
[0136] In alternative embodiments, the immunomodulator is an inhibitor of the NF-kB pathway. In certain aspects of the embodiments, the immunomodulator is rapamycin or a functional variant. Non-limiting examples of references to rapamycin and uses thereof as described in US10,071,114, US20160067228, US20160074531, US20160074532, US20190076458, US10,046,064 are disclosed, incorporated in their entirety. In other aspects of the embodiments, the immunomodulator is a synthetic nanocarrier comprising an immunosuppressant. Such as US20150320728, US 20180193482, US20190142974, US20150328333, US20160243253, US 10,039,822, US20190076522, US20160022650, US10,441,651, US 10,420,835, US20150320870, US2014035636, US10,434,088, US 10,335,395, US20200069659, US10,357,483, US20140335186, US 10,668,053, US10,357,482, US20160128986, US20160128987, US 20200038462, US20200038463, immunosuppressants coupled to synthetic nanocarriers, synthetic nanocarriers comprising rapamycin and / or tolerogenic synthetic nanocarriers, their dosages, administration and uses, non-limiting examples of references, each of which is incorporated herein by reference in its entirety.
[0137] In some embodiments, the immunomodulator is a synthetic nanotransporter comprising rapamycin (ImmTOR TM Nanoparticles) (Kishimoto, et al., 2016, Nat Nanotechnol, 11(10):890-899; Maldonado, et al., 2015, PNAS, 112(2):E156-165), as disclosed in US20200038463, U.S. Patent 9,006,254, each of which is incorporated herein by reference in its entirety. In some embodiments, the immunomodulator is an engineered cell, for example, an immune cell modified using SQZ technology, as disclosed in WO2017192786, which is incorporated herein by reference in its entirety.
[0138] In some embodiments, the immunomodulator is selected from the group consisting of poly-ICLC, 1018ISS, aluminum salts, Amplivax, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, GM-CSF, IC30, IC31, Imiquimod, ImuFact IMP321, IS Patch, ISS, ISCOMATRIX, Juvlmmune, LipoVac, MF59, monophosphoryl lipid A, Montanide IMS1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, OK-432, OM-174, OM-197-MP-EC, ONTAK, PEPTEL, carrier system, PLGA microparticles, resiquimod, SRL172, virosomes and other virus-like particles, YF-17D, VEGF trap, R848, β-glucan, Pam3Cys and the QS21 stimulator of Aquila. In another further embodiment, the immunomodulator or adjuvant is poly-ICLC.
[0139] In some embodiments, immunomodulators are small molecules that inhibit the innate immune response in cells, such as chloroquine (a TLR signaling inhibitor) and 2-aminopurine (a PKR inhibitor) can also be administered in combination with the compositions disclosed herein comprising at least one rAAV. Some non-limiting examples of commercially available TLR signaling inhibitors include BX795, chloroquine, CLI-095, OxPAPC, polymyxin B, and rapamycin (all available from INVIVOGEN TM In addition, inhibitors of pattern recognition receptors (PRRs) (which are involved in innate immune signaling) (e.g., 2-aminopurine, BX795, chloroquine, and H-89) can also be used in the compositions and methods disclosed herein comprising at least one rAAV vector for in vivo protein expression disclosed herein.
[0140] In some embodiments, the rAAV vector may also encode a negative regulator of innate immunity, such as NLRX1. Therefore, in some embodiments, the rAAV vector may also optionally encode one or more of NLRX1, NS1, NS3 / 4A or A46R or any combination thereof. In addition, in some embodiments, the composition disclosed herein comprising at least one rAAV vector may also include a synthetic, modified RNA encoding an inhibitor of the innate immune system to avoid the innate immune response generated by the tissue or subject.
[0141] In some embodiments, the immunomodulator for the administration method disclosed herein is an immunosuppressant. As used herein, the term "immunosuppressive drug or agent" is intended to include pharmaceutical preparations that inhibit or interfere with normal immune function. Examples of immunosuppressants suitable for the methods disclosed herein include agents that inhibit T cell / B cell co-stimulation pathways, such as agents that interfere with T cell and B cell coupling through CTLA4 and B7 pathways, as disclosed in U.S. Patent Publication No. 2002 / 0182211. In one embodiment, the immunosuppressant is cyclosporin A. Other examples include mycophenolate mofetil, rapamycin, and antithymocyte globulin. In one embodiment, the immunosuppressive drug is administered with a composition comprising at least one rAAV vector disclosed herein, or it can be administered in a separate composition, but is administered synchronously, before, or after the composition comprising at least one rAAV vector according to the administration method disclosed herein. The immunosuppressive drug is administered in a formulation compatible with the administration route, and is administered to the subject in a dose sufficient to achieve the desired therapeutic effect. In some embodiments, an immunosuppressive drug is administered briefly for a sufficient period of time to induce tolerance to the rAAV vectors disclosed herein.
[0142] A variety of methods are known to cause immunosuppression of the immune response of patients given AAV. Methods known in the art include administering immunosuppressants, such as proteasome inhibitors, to patients. One such proteasome inhibitor known in the art is bortezomib, as disclosed in, for example, U.S. Patent No. 9,169,492 and U.S. Patent Application No. 15 / 796,137 (both of which are incorporated herein by reference). In some embodiments, the immunosuppressant may be an antibody, including polyclonal antibodies, monoclonal antibodies, scFv or other molecules derived from antibodies that can suppress immune responses by, for example, eliminating or inhibiting cells that produce antibodies. In further embodiments, the immunosuppressive element may be a short hairpin RNA (shRNA). In such embodiments, the coding region of the shRNA is contained in the rAAV box and is generally located 3' downstream of the poly-A tail. The shRNA may be targeted to reduce or eliminate the expression of an immunostimulant, such as a cytokine, a growth factor (including transforming growth factor β1 and β2, TNF and other well-known factors).
[0143] The use of such immunomodulators facilitates the use of multiple doses (e.g., multiple administrations) over months and / or years. This allows the use of multiple agents as described below, such as rAAV vectors encoding multiple genes, or multiple administrations to a subject. E. Pharmaceutical Compositions
[0144] The rAAV vectors disclosed herein (e.g., rAAV vectors expressing GAA), for example, for use in the methods of administration disclosed herein, can be formulated in a pharmaceutical composition together with a pharmaceutically acceptable excipient (i.e., one or more pharmaceutically acceptable carrier substances and / or additives, such as buffers, carriers, excipients, stabilizers, etc.). The pharmaceutical composition can be provided in the form of a kit. Pharmaceutical compositions comprising the rAAV vectors disclosed herein for use in the methods of administration disclosed herein and their uses are known in the art.
[0145] Therefore, another aspect of the present invention provides a pharmaceutical composition comprising a rAAV vector disclosed herein for use in the administration method disclosed herein. The relative amounts of the active ingredient (e.g., the rAAV vector disclosed herein), the pharmaceutically acceptable excipient, and / or any additional ingredients in the pharmaceutical composition according to the present disclosure may vary, depending on the identity, size, and / or condition of the subject being treated, and also on the route by which the composition is to be administered. For example, the composition may contain 0.1% to 99% (w / w) of the active ingredient. For example, the composition may contain 0.1% to 100%, for example, .5% to 50%, between 1%-30%, between 5%-80%, at least 80% (w / w) of the active ingredient.
[0146] One or more excipients or diluents may be used to formulate a pharmaceutical composition to (1) increase stability; (2) increase cell transfection or transduction; (3) allow for sustained or delayed release of a payload; (4) alter biodistribution (e.g., targeting viral particles to specific tissues or cell types); (5) increase translation of the encoded protein; (6) alter the release profile of the encoded protein and / or (7) allow for regulated expression of the payload of the invention. In some embodiments, a pharmaceutically acceptable excipient may be at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipient is approved for human and veterinary use. In some embodiments, the excipient may be approved by the U.S. Food and Drug Administration. In some embodiments, the excipient may be pharmaceutical grade. In some embodiments, the excipient may conform to the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or the International Pharmacopoeia. Excipients used herein include, but are not limited to, any and all solvents, dispersion media, diluents or other liquid vehicles, dispersion or suspension aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, etc. suitable for the desired particular dosage form. Various excipients for formulating pharmaceutical compositions and techniques for preparing such compositions are known in the art (see Remington: The Science and Practice of Pharmacy, 21st edition, A.R. Gennaro, Lippincott, Williams and Wilkins, Baltimore, MD, 2006; incorporated herein by reference in its entirety). The use of conventional excipient media may be considered within the scope of the present disclosure, unless any conventional excipient media may be incompatible with the substance or its derivatives, such as producing any undesirable biological effects or interacting in a deleterious manner with any other ingredients of the pharmaceutical composition.
[0147] The rAAV vector disclosed herein for the administration method disclosed herein can be used in combination with one or more other therapeutic, preventive, research or diagnostic agents. "Combination" is not intended to imply that the agents must be administered at the same time and / or formulated for delivery together, although these delivery methods are within the scope of the present invention. The composition can be administered at the same time, before or after one or more other desired treatments or medical procedures. In some embodiments, the delivery of one treatment (e.g., a gene therapy vector) is still ongoing when the delivery of the second treatment (e.g., one or more therapeutic agents) begins, so there is overlap in the administration. This is sometimes referred to as "synchronous" or "simultaneous delivery" in this article. In other embodiments, the delivery of one treatment ends before the delivery of another treatment begins. In some embodiments of either case, the treatment is more effective due to combined administration. For example, the second treatment is more effective than what would be observed if the second treatment was given without the first treatment, for example, an equivalent effect can be observed with less second treatment, or the second treatment can alleviate symptoms to a greater extent, or a similar situation can be observed for the first treatment. In some embodiments, delivery causes a reduction in symptoms or other parameters associated with the disorder greater than the reduction observed when one treatment is delivered without another treatment. The effects of the two treatments can be partially cumulative, completely cumulative, or greater than cumulative. Delivery can be such that the effect of the first treatment delivered can still be detected when the second treatment is delivered. The compositions described herein and the at least one additional therapy can be administered synchronously, in the same or separate compositions, or sequentially. For sequential administration, the gene therapy vector described herein can be administered first, and the one or more therapeutic agents can be administered secondly, or the order of administration can be reversed. The gene therapy vector and the one or more therapeutic agents can be administered during the active disorder stage, or during the disease remission or less active disease stage. The gene therapy vector can be administered before another treatment, at the same time as the treatment, after the treatment, or during the disease remission.
[0148] When administered in combination, the rAAV vector disclosed herein and the one or more therapeutic agents (e.g., a second or third therapeutic agent) or all of the administration methods disclosed herein can be administered in an amount or dose that is higher, lower, or the same as the amount or dose used alone (e.g., as a monotherapy). In certain embodiments, the rAAV vector disclosed herein and the one or more therapeutic agents (e.g., a second or third agent) or all of the administration methods disclosed herein are administered in an amount or dose that is lower than the amount or dose used alone (e.g., at least 20%, at least 30%, at least 40%, or at least 50%). In other embodiments, the amount or dose of the rAAV vector disclosed herein and the one or more therapeutic agents (e.g., a second or third agent) or all of the administration methods disclosed herein that produces the desired effect (e.g., treatment of cardiovascular disease or heart disease) is lower than the amount or dose required to achieve the same therapeutic effect alone (e.g., at least 20%, at least 30%, at least 40%, or at least 50%).
[0149] In some embodiments, methods of administering the rAAV vectors disclosed herein can deliver the rAAV vectors disclosed herein alone or in combination with an additional agent (eg, an immunomodulator disclosed herein).
[0150] In some embodiments, the AAV vector expressing GAA disclosed herein is not administered simultaneously or in combination with ERT. In alternative embodiments, the AAV vector expressing GAA disclosed herein is administered in combination with ERT for a period of up to 24 weeks or less after administration of AAV expressing ERT. In some embodiments, the AAV vector expressing GAA disclosed herein is administered in combination with an immunomodulator in an initial phase and an optional taper phase after administration of AAV expressing ERT.
[0151] Thus, in one aspect, provided herein are compositions (e.g., pharmaceutical compositions) comprising the recombinant AAV vector particles described herein. Typically, the composition is in the form of about 1 e 9 vg / mL to about 1e 15 vg / mL concentration of the recombinant AAV vector particles described herein. In some embodiments, the composition is at about 1e 10 vg / mL to about 1e 14 vg / mL concentration of the recombinant AAV vector particles described herein. In some embodiments, the composition is at about 1e 12 vg / mL to about 1e 14 vg / mL concentration of the recombinant AAV vector particles described herein. In some embodiments, the composition is at about 1e 12 vg / mL to about 1e 15vg / mL concentration of the recombinant AAV vector particles described herein. For example, the composition contains about 3e 12 vg / mL to about 3e 13 vg / mL, about 2.5e 12 vg / mL to about 1e 14 vg / mL, about 3e 13 vg / mL to about 1e 14 vg / mL, or 1e 13 vg / mL to about 1e 14 The recombinant AAV vector particles described herein are contained at a concentration of vg / mL.
[0152] In some embodiments, the composition comprises a recombinant AAV vector particle described herein at a concentration of about 1 e 12 vg / mL, or about 1.5e 12 vg / mL, or about 2e 12 vg / mL, or about 2.5e 12 vg / mL, or about 3e 12 vg / mL, or about 3.5e 12 vg / mL, or about 4e 12 vg / mL, or about 4.5e 12 vg / mL, or about 5e 12 vg / mL, or about 5.5e 12 vg / mL, or about 6e 12 vg / mL, or about 6.5e 12 vg / mL, or about 7e 12 vg / mL, or about 7.5e 12 vg / mL, or about 8e 12 vg / mL, or about 8.5e 12 vg / mL, or about 9e 12 vg / mL, or about 9.5e 13 vg / mL, or about 1e 13 vg / mL, or about 1.5e 13 vg / mL, or about 2e 13 vg / mL, or about 2.5e 13 vg / mL, or about 3e 13 vg / mL, or about 3.5e 13 vg / mL, or about 4e 13 vg / mL, or about 4.5e 13 vg / mL, or about 5e 13 vg / mL, or about 5.5e 13 vg / mL, or about 6e 13vg / mL, or about 6.5e 13 vg / mL, or about 7e 13 vg / mL, or about 7.5e 13 vg / mL, or about 8e 13 vg / mL, or about 8.5e 13 vg / mL, or about 9e 13 vg / mL, or about 9.5e 13 vg / mL, or about 1e 14 vg / mL.
[0153] In some embodiments, the composition comprises a buffer. It is noteworthy that any physiological buffer can be used. Non-limiting examples of buffers include, but are not limited to, PBS, Tris.HCl, phosphate, citric acid, histidine, tromethamine, succinic acid, malic acid, α-ketoglutaric acid, carbonate (bicarbonate-carbonate buffer) and protein buffer. In some embodiments, the buffer is PBS. In some embodiments, the buffer comprises Tris. In some embodiments, the buffer is Tris.HCl. In some embodiments, the buffer is a histidine buffer.
[0154] Typically, the salt concentration of the buffer is about 50mM to about 750mM. For example, the salt concentration of the buffer is about 75mM to about 700mM, about 100mM to about 650mM, about 120mM to about 600mM, or about 140mM to about 550mM. In some embodiments, the salt concentration of the buffer is about 150mM to about 400mM. In some embodiments, the salt concentration of the buffer is about 150mM, about 175mM, about 200mM, about 225mM, about 250mM, about 275mM, about 300mM, about 325mM, about 350mM, about 375mM, about 400mM, about 425mM, about 450mM or about 475mM. In some preferred embodiments, the salt concentration of the buffer is about 150mM, about 200mM or about 365mM.
[0155] In some embodiments, the ionic strength of the composition is at least about 100 mM. For example, the ionic strength of the composition is about 125 mM to about 750 mM, or about 150 mM to about 500 mM, or about 175 mM to about 700 mM, about 200 mM to about 600 mM, or about 225 mM to about 550 mM, or about 250 mM to about 500 mM, or about 275 mM to about 450 mM, or about 300 mM to about 400 mM. In some embodiments, the ionic strength of the composition is at least about 125 mM, at least about 150 mM, at least about 175 mM, at least about 200 mM, at least about 225 mM, at least about 250 mM, at least about 275 mM, at least about 300 mM, at least about 325 mM, at least about 350 mM, at least about 375 mM, at least about 400 mM, at least about 425 mM, at least about 450 mM, at least about 475 mM, or at least about 500 mM. In some embodiments, the ionic strength of the composition is less than 100 mM, such as about 95 mM, about 90 mM, about 85 mM, about 80 mM, about 75 mM, about 70 mM, about 65 mM, about 60 mM, about 55 mM, about 50 mM, or even lower.
[0156] The osmotic pressure of the composition is maintained at a near isotonic level. For example, the osmotic pressure of the composition can be about 100 mOsm to about 600 mOsm, such as about 125 mOsm to about 500 mOsm, or about 130 mOsm to about 350 mOsm, or about 140 mOsm to about 400 mOsm, or about 140 mOsm to about 350 mOsm, or about 200 mOsm to about 400 mOsm, or about 500 mOsm to about 600 mOsm, or about 200 mOsm to about 600 mOsm, or about 350 mOsm. In some embodiments, the composition comprises an isotonic solution.
[0157] Typically, the pH of the composition is from about 6.5 to about 8.0. For example, the pH of the composition is from about 6.5 to about 7.5. In some embodiments, the pH of the composition is from about 7 to about 8. For example, the pH of the composition is from about 7.3 to about 7.9. In some other non-limiting examples, the pH of the composition is from about 7.4 to about 7.8 or from about 7.4 to about 7.7. In some embodiments, the pH of the composition is from about 7.3 to about 7.6, for example, from about 7.3 to about 7.55. In some preferred embodiments, the pH of the composition is less than about 7.5. For example, the pH of the composition is about 7.4 or lower, about 7.3 or lower, about 7.2 or lower, about 7.1 or lower, about 7.0 or lower, about 6.9 or lower, about 6.8 or lower, about 6.7 or lower, about 6.6 or lower, or about 6.5 or lower.
[0158] The composition may include one or more ions and / or salts thereof. Exemplary ions include, but are not limited to, sodium, potassium, chloride, magnesium, ammonium, carbonate, nitrate, chlorate, chlorite, and calcium. The ions may be provided as salts, such as halide (F, Cl, Br, I) salts of sodium, potassium, magnesium, and / or calcium, non-limiting examples of which include NaCl, KCl, MgCl 2 , CaCl 2 and combinations thereof. Other exemplary salts that may be used include, but are not limited to, carboxylates such as acetates, propionates, pyrrolidonecarboxylates (or pidolates), or sorbates; polyhydroxylated carboxylates such as gluconates, heptagluconates, ketogluconates, lactate gluconates, ascorbates, or pantothenates; mono- or poly-carboxylic acid hydroxy acid salts such as citrates or lactates; amino acid salts such as aspartates or glutamates; and fulvates. The salts are individually included at a concentration of about 500 μM to about 500 mM.
[0159] In some embodiments, the composition comprises one or more multivalent ions and / or salts thereof. Exemplary multivalent ions include, but are not limited to, calcium, citrate, sulfate, magnesium, and phosphate. The multivalent ions and / or salts thereof can be individually included in the composition at a concentration of about 500 μM to about 500 mM, for example, at a concentration of about 500 μM, about 750 μM, about 1 mM, about 1.3 mM, about 1.5 mM, about 1.7 mM, about 2.3 mM, about 2.5 mM, about 2.7 mM, about 3.3 mM, about 3.5 mM, about 3.7 mM, about 4.3 mM, about 4.5 mM, about 4.7 mM, about 5 mM, about 10 ... In some embodiments, the present invention relates to a salt of at least about 25 mM, about 50 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 125 mM, about 150 mM, about 175 mM, about 200 mM, about 225 mM, about 250 mM, about 275 mM, about 300 mM, about 325 mM, about 350 mM, about 375 mM, about 400 mM, about 425 mM, about 450 mM, about 475 mM, or about 500 mM. Non-limiting examples of salts are NaCl, KCl, CaCl 2 、CaSO 4 MgSO 4 、Na 3 PO 4 、CaCO 3 、NaNO 3 、Al 2 (SO 4 ) 3 .
[0160] In some embodiments, the composition comprises NaCl. When present, the concentration of NaCl can be from about 100mM to about 500mM, or from about 125mM to about 450mM, or from about 100mM to about 200mM, or from about 150mM to about 200mM. For example, the composition can comprise NaCl at a concentration of from about 150mM to about 425mM, from about 175mM to about 400mM, or from about 175mM to about 375mM, or from about 200mM to about 375mM.
[0161] In some embodiments, the composition comprises KCl. When present, the concentration of KCl can be about 1 mM to about 10 mM. For example, the composition can comprise KCl at a concentration of about 1.5 mM to about 7.5 mM.
[0162] In some embodiments, the composition comprises CaCl 2 When present, CaCl 2 The concentration of CaCl may be about 0.1 mM to about 2 mM. For example, the composition may include CaCl at a concentration of about 0.5 mM to about 1.5 mM. 2In some embodiments, the composition may include CaCl at a concentration of about 0.75 mM to about 1.25 mM. 2 .
[0163] In some embodiments, the composition comprises MgCl 2 When present, MgCl 2 The concentration of MgCl may be about 0.1 mM to about 1.5 mM. For example, the composition may include MgCl at a concentration of about 0.25 mM to about 1 mM or about 0.25 mM to about 0.75 mM. 2 .
[0164] In some embodiments, the composition comprises MgSO 4 When present, MgSO 4 The concentration of MgSO can be about 5 mM to about 150 mM. For example, the composition can include MgSO at a concentration of about 10 mM to about 120 mM, or about 10 mM to about 50 mM, or about 15 mM to about 45 mM, or about 75 mM to about 125 mM, or about 80 mM to about 100 mM, or about 85 mM to about 95 mM, or about 15 mM to about 100 mM. 4 .
[0165] In some embodiments, the composition comprises a phosphate, such as a monobasic phosphate or a dibasic phosphate or a salt thereof. When present, the phosphate, such as a monobasic phosphate or a dibasic phosphate or a salt thereof, may be present in a concentration of about 5 mM to about 30 mM. For example, the composition may comprise a phosphate, such as a monobasic phosphate or a dibasic phosphate or a salt thereof, at a concentration of about 7.5 mM to about 25 mM. In some embodiments, the composition comprises a phosphate, such as a monobasic phosphate or a dibasic phosphate or a salt thereof, at a concentration of about 10 mM to about 20 mM.
[0166] In some embodiments, the composition comprises monobasic phosphate or a salt thereof at a concentration of about 0.25 mM to about 3 mM. For example, the composition comprises monobasic phosphate or a salt thereof at a concentration of about 0.5 mM to about 2.75 mM, or about 0.75 mM to about 2.5 mM, or about 1 mM to about 2.25 mM. In some embodiments, the monobasic phosphate or a salt thereof is potassium dihydrogen phosphate.
[0167] In some embodiments, the composition comprises dibasic phosphate or a salt thereof at a concentration of about 5 mM to about 15 mM. For example, the composition comprises dibasic phosphate or a salt thereof at a concentration of about 7.5 mM to about 12.5 mM or about 8 mM to about 10 mM. In some embodiments, the dibasic phosphate or a salt thereof is disodium hydrogen phosphate. In some embodiments, the composition is substantially free of dibasic phosphate, such as disodium hydrogen phosphate.
[0168] In some embodiments, the composition comprises Tris (e.g., Tris.HCl) or a salt thereof at a concentration of about 1 mM to about 50 mM. For example, the composition comprises Tris (e.g., Tris.HCl) or a salt thereof at a concentration of about 5 mM to about 40 mM, or about 7.5 mM to about 35 mM, or about 10 mM to about 30 mM, or about 15 mM to about 25 mM.
[0169] In some embodiments, the composition comprises histidine or a salt thereof at a concentration of about 1 mM to about 50 mM. For example, the composition comprises histidine or a salt thereof at a concentration of about 5 mM to about 40 mM, or about 7.5 mM to about 35 mM, or about 10 mM to about 30 mM, or about 15 mM to about 25 mM.
[0170] The pharmaceutical composition may also include an extender. Exemplary extenders include, but are not limited to, sugars, polyols, and (PVPK24). Exemplary polyols include, but are not limited to, polyhydroxy hydrocarbons, monosaccharides, disaccharides, and trisaccharides. Some exemplary polyols include, but are not limited to, sorbitol, mannitol, glycerol, propylene glycol, polyethylene glycol, dulcitol, sucrose, lactose, maltose, trehalose, and dextran. In some embodiments, the polyol is sorbitol, sucrose, or mannitol. In some embodiments, the extender is sorbitol. In some embodiments, the extender is sucrose. In some embodiments, the extender is mannitol. In some embodiments, the extender is trehalose, such as dehydrated trehalose. In some embodiments, the extender is dextran, such as dextran T40 and / or dextran T10.
[0171] When present, the bulking agent can be present in a concentration of about 0.5% (w / v) to about 10% (w / v). For example, the composition can include a bulking agent, such as a polyol or polyvidone (PVP K24), in a concentration of about 1% (w / v) to about 7.5% (w / v), such as about 1% (w / v) to about 4% (w / v) or about 4% (w / v) to about 6% (w / v).
[0172] In some embodiments, the composition comprises glycerol, sorbitol, sucrose or mannitol at a concentration of about 1% (w / v) to about 10% (w / v). In some embodiments, the composition comprises glycerol, sorbitol, sucrose or mannitol at a concentration of about 1% (w / v) to about 10% (w / v). In some embodiments, the composition comprises sorbitol at a concentration of about 3% (w / v) to about 6% (w / v). In some embodiments, the composition comprises sorbitol at a concentration of about 1% (w / v), about 2% (w / v), about 3% (w / v), about 4% (w / v), about 5% (w / v), about 6% (w / v), about 7% (w / v), about 8% (w / v), about 9% (w / v) or about 10% (w / v). In some embodiments, the composition comprises sucrose at a concentration of about 3% (w / v) to about 6% (w / v). In some embodiments, the composition comprises sucrose at a concentration of about 1% (w / v), about 2% (w / v), about 3% (w / v), about 4% (w / v), about 5% (w / v), about 6% (w / v), about 7% (w / v), about 8% (w / v), about 9% (w / v), or about 10% (w / v). In some embodiments, the composition comprises mannitol at a concentration of about 3% (w / v) to about 6% (w / v). In some embodiments, the composition comprises mannitol at a concentration of about 1% (w / v), about 2% (w / v), about 3% (w / v), about 4% (w / v), about 5% (w / v), about 6% (w / v), about 7% (w / v), about 8% (w / v), about 9% (w / v), or about 10% (w / v).
[0173] The composition may also contain a nonionic surfactant. The nonionic surfactant may be selected from the group consisting of polyoxyethylene fatty alcohol ethers, polyoxyethylene alkylphenyl ethers, polyoxyethylene-polyoxypropylene block copolymers, alkyl glucosides, alkylphenol ethoxylates, preferably polysorbates, polyoxyethylene alkylphenyl ethers, and any combination thereof. Non-limiting examples of suitable nonionic surfactants include polyoxyethylene (12) isooctylphenyl ether (e.g., CA-270 polyoxyethylene (12) isooctylphenyl ether), polyoxyethylene sorbitan monooleate (e.g., 80 polyoxyethylene sorbitan monooleate), polyethylene glycol octadecyl ether (e.g., S20 polyethylene glycol stearyl ether), seed oil surfactants (e.g., Ecosurf™ SA-15 seed oil surfactant), poloxamer 188 (copolymer of polyoxyethylene and polyoxypropylene), nonylphenol ethoxylates (e.g., Tergitol™ NP-10 nonylphenol ethoxylate), and combinations thereof. In some embodiments, the nonionic surfactant is selected from the group consisting of: TWEEN 60 nonionic detergent, PPG-PEG-PPG Pluronic 10R5, Pluronic F-68 (PF 68), polyoxyethylene (18) tridecyl ether, polyoxyethylene (12) tridecyl ether, MERPOL SH surfactant, MERPOL OJ surfactant, MERPOL HCS surfactant, poloxamer P188, poloxamer P407, poloxamer P 338, IGEPAL CO-720, IGEPAL CO-630, IGEPALCA-720, Brij S20, Brij S10, Brij 010, Brij C10, BRIJ 020, ECOSURF EH-9, ECOSURF EH-14, TERGITOL 15-S-7, ECOSURF SA-15, TERGITOL 15-S-9, TERGITOL In some embodiments, the nonionic surfactant is TERGITOL NP-15-S-12, TERGITOL L-64, TERGITOL NP-7, TERGITOL NP-8, TERGITOL NP-9, TERGITOL NP-9.5, TERGITOL NP-10, TERGITOL NP-11, TERGITOL NP-12, TERGITOL NP-13, polysorbate 20, and any combination thereof. In some embodiments, the nonionic surfactant is poloxamer P 188, poloxamer P407, Pluronic F-68, Ecosurf SA-15, Brij S20, Tergitol NP-10, IGEPAL CA 720, or Tween 80. In some embodiments, the composition is substantially free of nonionic surfactants. In some embodiments, the nonionic surfactant is not polysorbate, such as Tween 80 (also referred to as polysorbate 80 or PS80).
[0174] When present, the nonionic surfactant can be present at a concentration of 0.0001% (w / v) to about 0.01% (w / v). For example, the composition can include the nonionic surfactant at a concentration of about 0.0005% (w / v) to about 0.0015% (w / v). In some embodiments, the composition can include the nonionic surfactant at a concentration of about 0.0001% (w / v), about 0.0002% (w / v), about 0.0003% (w / v), about 0.0004% (w / v), about 0.0005% (w / v), about 0.0006% (w / v), about 0.0007% (w / v), about 0.0008% (w / v), About 0.0009% (w / v), about 0.001% (w / v), about 0.002% (w / v), about 0.003% (w / v), about 0.004% (w / v), about 0.005% (w / v), about 0.006% (w / v), about 0.007% (w / v), about 0.008% (w / v), about 0.009% (w / v) or about 0.01% (w / v). In some preferred embodiments, the composition comprises a nonionic surfactant at a concentration of about 0.0005% (w / v) or about 0.001% (w / v).
[0175] In some embodiments, in addition to rAAV, the composition further comprises a buffer (e.g., PBS, Tris.HCl, phosphate, citric acid, histidine, tromethamine, succinic acid, malic acid, α-ketoglutaric acid, carbonate buffer), a bulking agent (e.g., a polyol such as sorbitol, mannitol, glycerol, propylene glycol, polyethylene glycol, dulcitol, sucrose, lactose, maltose, trehalose and dextran) and a non-ionic surfactant (e.g., poloxamer P 188, poloxamer P407, Pluronic F-68, Ecosurf SA-15, Brij S20, Tergitol NP-10, IGEPAL CA 720 or Tween 80).
[0176] In some embodiments, in addition to rAAV, the composition further comprises a buffer (e.g., PBS, Tris.HCl, phosphate, citric acid, histidine, tromethamine, succinic acid, malic acid, α-ketoglutaric acid, carbonate buffer), a bulking agent (e.g., a polyol such as sorbitol, mannitol, glycerol, propylene glycol, polyethylene glycol, dulcitol, sucrose, lactose, maltose, trehalose and dextran), a non-ionic surfactant (e.g., poloxamer P 188, poloxamer P407, Pluronic F-68, Ecosurf SA-15, Brij S20, Tergitol NP-10, IGEPAL CA 720 or Tween 80) and a multivalent ion (e.g., a multivalent ion selected from the group consisting of calcium, citrate, sulfate and magnesium).
[0177] In some embodiments, in addition to rAAV, the composition further comprises a buffer (e.g., PBS, Tris.HCl, phosphate, citric acid, histidine, tromethamine, succinic acid, malic acid, α-ketoglutaric acid, carbonate buffer), a bulking agent (e.g., a polyol such as sorbitol, mannitol, glycerol, propylene glycol, polyethylene glycol, dulcitol, sucrose, lactose, maltose, trehalose and dextran) and a multivalent ion (e.g., a multivalent ion selected from the group consisting of calcium, citrate, sulfate and magnesium).
[0178] It is worth noting that any one of the specific buffers or groups of buffers listed in the description of the composition can be used with any one of the specific extenders or groups of extenders listed in the description of the composition and with any one of the specific nonionic surfactants or groups of surfactants listed in the description of the composition and with any one of the specific multivalent ions and groups of multivalent ions listed in the description of the composition. Likewise, any one of the specific extenders or groups of extenders listed in the description of the composition can be used with any one of the specific buffers or groups of buffers listed in the description of the composition and with any one of the specific nonionic surfactants or groups of surfactants listed in the description of the composition and with any one of the specific multivalent ions and groups of multivalent ions listed in the description of the composition. Likewise, any one of the specific nonionic surfactants or groups of surfactants listed in the description of the composition can be used with any one of the specific buffers or groups of buffers listed in the description of the composition and with any one of the specific extenders or groups of extenders listed in the description of the composition and with any one of the specific multivalent ions and groups of multivalent ions listed in the description of the composition. Likewise, any specific multivalent ion and group of multivalent ions listed in the description of the composition can be used with any specific buffer or group of buffers listed in the description of the composition and with any specific extender or group of extenders listed in the description of the composition and with any specific nonionic surfactant or group of surfactants listed in the description of the composition. In other words, all individual specific combinations of buffers, groups of buffers, extenders, groups of extenders, nonionic surfactants, groups of nonionic surfactants, multivalent ions, and groups of multivalent ions listed in the description of the composition are specifically contemplated. Exemplary compositions
[0179] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 10 mM phosphate pH 7.4, about 200 mM NaCl, about 5 mM KCl, about 1% (w / v) mannitol, and about 0.0005% (w / v) IGEPAL CA 720. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0180] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 20 mM phosphate pH 7.4, about 300 mM NaCl, about 3 mM KCl, about 3% (w / v) mannitol, and about 0.001% (w / v) Brij S20. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0181] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 20 mM phosphate pH 7.4, about 300 mM NaCl, about 3 mM KCl, about 3% (w / v) sorbitol, and about 0.001% (w / v) Ecosurf SA-15. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0182] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 10 mM phosphate pH 7.4, about 350 mM NaCl, about 2.7 mM KCl, about 5% (w / v) sorbitol, and about 0.001% (w / v) poloxamer 188. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0183] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., a pharmaceutical composition) further comprises about 10 mM phosphate pH 6.95-7.2, about 137 mM NaCl, about 2.7 mM KCl, about 0.9 mM CaCl 2 , about 0.5 mM MgCl 2 and about 0.001% (w / v) Pluronic F-68. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0184] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 10 mM phosphate pH 7.3, about 180 mM NaCl, about 2.7 mM KCl, about 5% (w / v) sorbitol, and about 0.001% (w / v) poloxamer 188. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0185] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 15 mM phosphate pH 7.4, about 375 mM NaCl, about 3.5 mM KCl, about 5% (w / v) sorbitol, and about 0.0005% (w / v) Tergitol NP-10. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×1014 vg / mL.
[0186] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 15 mM phosphate pH 7.4, about 375 mM NaCl, about 3.5 mM KCl, about 3% (w / v) glycerol, and about 0.0005% (w / v) Tween 80. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0187] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 10 mM phosphate pH 7.6, about 137 mM NaCl, about 2.7 mM KCl, about 5% (w / v) sorbitol, and about 0.01% Pluronic F-68. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0188] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., a pharmaceutical composition) further comprises about 10 mM phosphate pH 7.4, about 137 mM NaCl, about 2.7 mM KCl, about 5% (w / v) sorbitol, about 0.01% Pluronic F-68, and about 20 mM MgSO 4 The rAAV particles described herein have a concentration of approximately 1.0 × 10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13About 1.0×10 14 vg / mL.
[0189] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., pharmaceutical composition) further comprises about 10 mM phosphate pH 7.6, about 137 mM NaCl, about 2.7 mM KCl, about 5% (w / v) mannitol, and about 0.01% Pluronic F-68. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0190] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., a pharmaceutical composition) further comprises about 10 mM phosphate pH 7.3, about 137 mM NaCl, about 2.7 mM KCl, about 5% (w / v) mannitol, about 0.01% Pluronic F-68, and about 20 mM MgSO 4 The rAAV particles described herein have a concentration of approximately 1.0 × 10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0191] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., a pharmaceutical composition) further comprises about 10 mM phosphate pH 7.4, about 137 mM NaCl, about 2.7 mM KCl, about 5% (w / v) sorbitol, and about 20 mM MgSO 4 The rAAV particles described herein have a concentration of approximately 1.0 × 10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×1013 About 1.0×10 14 vg / mL.
[0192] In some embodiments, in addition to the rAAV (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA), the composition (e.g., a pharmaceutical composition) further comprises about 10 mM phosphate pH 7.4, about 137 mM NaCl, about 2.7 mM KCl, about 5% (w / v) mannitol, and about 20 mM MgSO 4 The rAAV particles described herein have a concentration of approximately 1.0 × 10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0193] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises a recombinant AAV vector (rAAV) (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA) in 10 mM phosphate pH 7.4, 200 mM NaCl, 5 mM KCl, 1% (w / v) mannitol, 0.0005% (w / v) IGEPAL CA720, to a fill volume of 5 mL. In some embodiments, the fill volume is 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0194] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises a recombinant AAV vector (rAAV) (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA) in 20 mM phosphate pH 7.4, 300 mM NaCl, 3 mM KCl, 3% (w / v) mannitol, 0.001% (w / v) Brij S20, to a fill volume of 5 mL. In some embodiments, the fill volume is 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 The particle concentration of the rAAV described herein is approximately 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0195] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises a recombinant AAV vector (rAAV) (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA) in 20 mM phosphate pH 7.4, 300 mM NaCl, 3 mM KCl, 3% (w / v) sorbitol, 0.001% (w / v) Ecosurf SA-15, to a fill volume of 5 mL. In some embodiments, the fill volume is 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0196] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises a recombinant AAV vector (rAAV) (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA) in 10 mM phosphate pH 7.4, 350 mM NaCl, 2.7 mM KCl, 5% (w / v) sorbitol, 0.001% (w / v) poloxamer 188, to a fill volume of 5 mL. In some embodiments, the fill volume is 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0197] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises a recombinant AAV vector (rAAV) (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA) in 15 mM phosphate pH 7.4, 375 mM NaCl, 3.5 mM KCl, 5% (w / v) sorbitol, 0.0005% (w / v) Tergitol NP-10, to a fill volume of 5 mL. In some embodiments, the fill volume is 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0198] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises a recombinant AAV vector (rAAV) (e.g., AAV8-LSP-hGAA) comprising human GAA (hGAA) in 15 mM phosphate pH 7.4, 375 mM NaCl, 3.5 mM KCl, 3% (w / v) glycerol, 0.0005% (w / v) Tween 80, to a fill volume of 5 mL. In some embodiments, the fill volume is 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL. The particle concentration of the rAAV described herein is about 1.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.0×10 13 vg / mL to about 1.0×10 14 vg / mL, or about 2.5×10 13 About 1.0×10 14 vg / mL.
[0199] Other exemplary compositions / compositions comprising rAAV are described in International Publication No. WO2022159679, the contents of which are incorporated herein by reference in their entirety.
[0200] All compositions can be stored at -60°C or below. II. Subjects Suitable for Treatment A. Pompe disease
[0201] The recombinant AAV expressing GAA protein disclosed herein can be used for the treatment of Pompe disease. Pompe disease is a rare genetic disorder caused by the deficiency of acid alpha-glucosidase (GAA), an enzyme required for the breakdown of glycogen (a storage form of sugar for energy). Pompe disease is also known as glycogen storage disease type II, GSD II, glycogen storage disease type II, glycogenosis type II, acid maltase deficiency, alpha-1,4-glucosidase deficiency, diffuse glycogenous cardiomegaly, and the cardiac form of systemic glycogenosis. The increase in glycogen leads to progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscle, liver, respiratory system, and nervous system.
[0202] Glycogen storage disease type II, also known as Pompe disease, is a rare metabolic disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA) that is inherited in an autosomal recessive manner. The disorder causes lysosomal glycogen accumulation and destruction of skeletal, smooth, and cardiac muscle. The severity of Pompe disease ranges from severe infantile-onset myopathy with severe hypotonia and hypertrophic cardiomyopathy (infantile-onset Pompe disease [IOPD]) to late-onset myopathy (LOPD). GAA deficiency can range from complete to partial deficiency of GAA, which correlates with clinical severity. LOPD manifests with proximal leg weakness and, in some cases, respiratory insufficiency without significant cardiac involvement and can progress to fatal respiratory failure.
[0203] Early-onset (or infantile form, IOPD) is the result of a complete or near-complete deficiency of GAA. Symptoms begin in the first few months of life and progress rapidly with feeding problems, poor weight gain, muscle weakness, floppiness, and head lag. Breathing difficulties are often complicated by lung infections. The heart is severely enlarged. Many infants with Pompe disease also have an enlarged tongue. Most infants die from cardiac or respiratory complications before their first birthday if not treated with Lumizyme.
[0204] Late-onset (or juvenile / adult-onset, LOPD) Pompe disease is the result of a partial deficiency of GAA. Onset can occur as early as the first decade of childhood or as late as the sixth decade of adulthood, so it is characterized by a slow progression. The main symptom is proximal muscle weakness, which progresses to respiratory weakness and death from respiratory failure after a course of several years. The heart is usually spared.
[0205] The clinical manifestations of Pompe disease can vary widely depending on the age of disease onset and the residual GAA activity. The residual GAA activity is associated with the amount and tissue distribution of glycogen accumulation and the severity of the disease. Infantile-onset Pompe disease (less than 1% of normal GAA activity) is the most severe form and is characterized by hypotonia, generalized muscle weakness and hypertrophic cardiomyopathy, as well as massive glycogen accumulation in the myocardium and other muscle tissues. Death usually occurs within one year of birth due to cardiopulmonary failure. Juvenile-onset (1%-10% of normal GAA activity) and adult-onset (10%-40% of normal GAA activity) Pompe disease are more clinically heterogeneous, with greater variation in age of onset, clinical manifestations, and disease progression. Juvenile-onset and adult-onset Pompe disease are often characterized by the absence of severe cardiac involvement, a later age of onset, and slower disease progression, but eventually respiratory or limb muscle involvement leads to significant morbidity and mortality. Although life expectancy may vary, death is usually due to respiratory failure.
[0206] In any embodiment of the methods disclosed herein, the GAA enzyme suitable for treating Pompe disease includes wild-type human GAA or a fragment or sequence variant thereof that retains the ability to cut α1-4 linkages in linear oligosaccharides. In some embodiments of the methods and compositions disclosed herein, the GAA protein is encoded by a wild-type GAA nucleic acid sequence (e.g., SEQ ID NO: 11 or SEQ ID NO: 72 disclosed in International Application WO2021102107 (incorporated herein by reference)). In some embodiments of the methods and compositions disclosed herein, the GAA protein is encoded by a GAA nucleic acid sequence that is codon-optimized, for example, for any one or more of the following: (1) enhancing in vivo expression, (2) reducing CpG islands, or (3) reducing innate immune responses. In some embodiments of the methods and compositions disclosed herein, the GAA protein is encoded by a codon-optimized GAA nucleic acid sequence, for example, any nucleic acid sequence selected from any one of the following: SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75 and SEQ ID NO: 76 or SEQ ID NO: 182 disclosed in International Application WO2021102107 (incorporated herein by reference), or a nucleic acid sequence having at least 60%, or 70%, or 80%, or 85%, or 90%, or 95%, or 98%, or 99% sequence identity to SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 182 disclosed in International Application WO2021102107 (incorporated herein by reference).
[0207] In some embodiments of the methods and compositions disclosed herein, the rAAV vectors described herein transduce the liver of a subject and secrete hGAA polypeptides into the blood perfusing the patient's tissues, where they are taken up by cells and transported to lysosomes, where GAA enzymes act to eliminate material that has accumulated in the lysosomes due to enzyme deficiency. In order for lysosomal enzyme replacement therapy to be effective, the therapeutic enzyme must be delivered to the lysosomes in the appropriate cells of the tissue in which the storage defect is manifested.
[0208] In some embodiments, after administration, the AAV vector selectively expresses and secretes GAA from transduced hepatocytes. The primary mechanism of action of the AAV vector expressing the hGAA polypeptide as disclosed herein is to secrete sustained low levels of endogenous GAA from the liver into the systemic circulation to provide therapeutic exposure levels of GAA to tissues (e.g., muscle, but not limited to muscle), resulting in glycogen removal and restoration of cellular structure and function. B. Increased GAA activity in subjects with Pompe disease
[0209] In any embodiment of the methods disclosed herein, administration of an AAV vector expressing GAA delivers GAA to muscle and can be performed by any suitable method, including intravenous administration, intraarterial administration, and / or intraperitoneal administration. Exemplary modes of administration include oral, rectal, transmucosal, intranasal, inhalation (e.g., by aerosol), buccal (e.g., sublingual), vaginal, intrathecal, intraocular, transdermal, intrauterine (or intraocular), parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular [including administration to skeletal muscle, diaphragm, and / or myocardium], intradermal, intrapleural, intracerebral, and intraarticular), topical (e.g., administration to both skin and mucosal surfaces, including airway surfaces and transdermal administration), intralymphatic, etc., and direct tissue or organ injection (e.g., injection to the liver, skeletal muscle, myocardium, diaphragm, or brain). Administration can also be given to a tumor (e.g., in or near a tumor or lymph node). In any given case, the most appropriate route will depend on the nature and severity of the condition being treated and / or prevented, as well as on the nature of the specific vector used.
[0210] In some embodiments of one or more aspects of the invention, an AAV vector expressing GAA is administered into the cephalic vein via an IV catheter. In some embodiments, a composition containing an AAV vector is infused in a volume of 20 mL over about 30 minutes. The infusion may be preceded by a 10 mL rinse with lactated Ringer's solution, and may be further followed by a 40 mL rinse with lactated Ringer's solution. The rinse and vector may be administered at a rate of 60 mL / hour.
[0211] In any embodiment of the method disclosed herein, according to the present invention, the administration of the AAV vector expressing GAA disclosed herein is administered to skeletal muscle, and includes but is not limited to administration to skeletal muscles of the limbs (e.g., upper arms, lower arms, thighs and / or calves), back, neck, head (e.g., tongue), chest, abdomen, pelvis / perineum and / or fingers. Suitable skeletal muscles for injection are disclosed in International Application WO2021102107, which is incorporated herein by reference in its entirety.
[0212] In any embodiment of the method disclosed herein, the rAAV vector and / or rAAV genome are administered to the skeletal muscle, liver, diaphragm, costal muscle and / or myocardial cells of the subject. For example, a conventional syringe and needle can be used to inject the rAAV virion suspension into an animal. The parenteral administration of the injected rAAV vector and / or rAAV genome can be performed by, for example, bolus injection or continuous infusion. The injection formulation can be present in a unit dose form, for example, in a multi-dose container or ampoule with an added preservative. The composition can take the form of a suspension, solution or emulsion such as in an oily or aqueous solvent, and can include reagents for pharmaceutical preparations, such as suspending agents, stabilizers and / or dispersants. Alternatively, the rAAV vector and / or rAAV genome disclosed herein can be in powder form (e.g., lyophilized) to be constituted with a suitable solvent (e.g., sterile pyrogen-free water) before use.
[0213] In certain embodiments, more than one administration (e.g., two, three, four, five, six, seven, eight, nine, ten, etc., or more administrations) may be used to achieve the desired level of GAA expression over time periods at different intervals (e.g., hourly, daily, weekly, monthly, yearly, etc.). Administration may be a single dose or cumulative dose (continuous administration) and may be readily determined by one skilled in the art. As disclosed herein, it is contemplated that treatment of Pompe disease according to the methods disclosed herein comprises a one-time administration of an effective dose of a pharmaceutical composition comprising an AAV vector encoding a GAA polypeptide.
[0214] However, in alternative embodiments, when the subject is not given long-term ERT, treating a subject with Pompe disease may include multiple administrations of a pharmaceutical composition comprising an AAV vector encoding a GAA polypeptide, wherein the multiple administrations may be performed over a range of time periods, for example, once a year, or every 6 months, or about every 2 years, or about every 3 years, or about every 4 years, or about every 5 years, or at intervals of more than 5 years. The timing of administration may vary from individual to individual, depending on factors such as the severity of the individual's symptoms. For example, in some embodiments, an effective dose of an AAV vector encoding a GAA polypeptide disclosed herein may be administered to an individual once a year, or once every two years, or once every six months for an indefinite period of time, or until the individual no longer requires treatment. One of ordinary skill in the art will recognize that the condition of the individual can be monitored throughout the treatment process, and the effective amount of the AAV vector encoding a GAA polypeptide disclosed herein administered can be adjusted accordingly.
[0215] Injections containing the AAV vector encoding the GAA polypeptide disclosed herein can be prepared in conventional forms, as a liquid solution or suspension, a solid form suitable for a solution or suspension before injection, or as an emulsion. Alternatively, the AAV vector encoding the GAA polypeptide disclosed herein can be administered in a local rather than systemic manner (e.g., in a depot or sustained-release formulation). In addition, the viral vector and / or viral capsid can be attached to a surgically implantable matrix for delivery (e.g., as described in U.S. Patent Publication No. US-2004-0013645-A1). In some embodiments, the AAV vector encoding the GAA polypeptide disclosed herein can be administered to the lungs of the subject by any suitable means, optionally by administering an aerosol suspension of inhalable particles consisting of viral vectors and / or viral capsids, and the suspension is inhaled by the subject. Inhalable particles can be liquid or solid. As known to those skilled in the art, aerosols of liquid particles containing viral vectors and / or viral capsids can be produced by any suitable method, such as using a pressure-driven aerosol nebulizer or ultrasonic nebulizer. See, eg, US Patent No. 4,501,729. Aerosols of solid particles comprising viral vectors and / or capsids may likewise be generated using any solid particle pharmaceutical aerosol generator by techniques known in the pharmaceutical arts.
[0216] In some embodiments, the AAV vectors encoding the GAA polypeptide disclosed herein can be formulated in a solvent, emulsion, or other diluent in an amount sufficient to dissolve the rAAV vector disclosed herein. In other aspects of this embodiment, the rAAV vectors and / or rAAV genomes encoding GAA polypeptides disclosed herein can be formulated in a solvent, emulsion or diluent in an amount of, for example, less than about 90% (v / v), less than about 80% (v / v), less than about 70% (v / v), less than about 65% (v / v), less than about 60% (v / v), less than about 55% (v / v), less than about 50% (v / v), less than about 45% (v / v), less than about 40% (v / v), less than about 35% (v / v), less than about 30% (v / v), less than about 25% (v / v), less than about 20% (v / v), less than about 15% (v / v), less than about 10% (v / v), less than about 5% (v / v) or less than about 1% (v / v). In other aspects, the rAAV vectors and / or rAAV genomes encoding GAA polypeptides disclosed herein can contain a solvent, emulsion or other diluent in an amount ranging from about 1% (v / v) to 90% (v), about 1% (v / v) to 70% (v / v), about 1% (v / v) to 60% (v / v), about 1% (v / v) to 50% (v / v), about 1% (v / v) to 40% (v / v). (v / v), about 1% (v / v) to 30% (v / v), about 1% (v / v) to 20% (v / v), about 1% (v / v) to 10% (v / v), about 2% (v / v) to 50% (v / v), about 2% (v / v) to 40% (v / v), about 2% (v / v) to 30% (v / v), about 2% (v / v) to 20% (v / v), about 2% (v / v) to 10% (v / v). / v), about 4% (v / v) to 50% (v / v), about 4% (v / v) to 40% (v / v), about 4% (v / v) to 30% (v / v), about 4% (v / v) to 20% (v / v), about 4% (v / v) to 10% (v / v), about 6% (v / v) to 50% (v / v), about 6% (v / v) to 40% (v / v), about 6% (v / v) to 30% (v / v) ), about 6% (v / v) to 20% (v / v), about 6% (v / v) to 10% (v / v), about 8% (v / v) to 50% (v / v), about 8% (v / v) to 40% (v / v), about 8% (v / v) to 30% (v / v), about 8% (v / v) to 20% (v / v), about 8% (v / v) to 15% (v / v) or about 8% (v / v) to 12% (v / v).
[0217] In any embodiment of the methods disclosed herein, the AAV vector encoding the GAA polypeptide can be an AAV of any serotype, including but not limited to being encapsidated by any AAV3b capsid selected from the group consisting of: AAV3b capsid (SEQ ID NO: 44); AAV3b265D capsid (SEQ ID NO: 46), AAV3b ST (S663V + T492V) capsid (SEQ ID NO: 48), AAV3b265D549A capsid (SEQ ID NO: 50); AAV3b549A capsid (SEQ ID NO: 52); AAV3bQ263Y capsid (SEQ ID NO: 54) or AAV3bSASTG capsid (i.e., an AAV3b capsid comprising Q263A / T265 mutations), wherein SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52 and SEQ ID NO: 53. NO:54 is disclosed in international application WO2021102107, which is incorporated herein by reference in its entirety.
[0218] To facilitate delivery of the AAV vector encoding the GAA polypeptide disclosed herein, it can be mixed with a carrier or excipient. Carriers and excipients that may be used include saline (particularly sterile, pyrogen-free saline), saline buffers (e.g., citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohol, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. USP-grade carriers and excipients are particularly useful for delivering virions to human subjects.
[0219] In addition to the formulations previously described, the AAV vectors encoding GAA polypeptides disclosed herein can also be formulated as long-acting formulations. Such long-acting formulations can be administered by implantation (e.g., subcutaneous or intramuscular) or by IM injection. Thus, for example, the rAAV vectors and / or rAAV genomes disclosed herein can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or an ion exchange resin or as a sparingly soluble derivative.
[0220] In any embodiment of the methods disclosed herein, the method is directed to treating Pompe disease caused by GAA deficiency in a subject, wherein an AAV vector encoding a GAA polypeptide disclosed herein is administered to a patient suffering from Pompe disease, and following administration, GAA is secreted from cells in the liver, and the secreted GAA is taken up by cells in skeletal muscle tissue, cardiac muscle tissue, diaphragm tissue, or a combination thereof, wherein the uptake of the secreted GAA causes a decrease in lysosomal glycogen storage in tissues, including but not limited to muscle. In some embodiments, the AAV vector encoding the GAA polypeptide disclosed herein is encapsidated in a capsid, for example, encapsidated by any AAV3b capsid selected from the following: AAV3b capsid (SEQ ID NO: 44), AAV3b265D capsid (SEQ ID NO: 46), AAV3b ST (S663V+T492V) capsid (SEQ ID NO: 48), AAV3b265D549A capsid (SEQ ID NO: 50), AAV3b549A capsid (SEQ ID NO: 52), AAV3bQ263Y capsid (SEQ ID NO: 54), the sequences of which are disclosed in international application WO2021102107, which is incorporated herein by reference.
[0221] In a specific embodiment, at least about 1.6×10 12 About 4.0×10 12 vg / kg. In further embodiments, the dose of the viral vector and / or capsid to be administered to a subject depends on the mode of administration, the severity and type of Pompe disease (i.e., LOPD or IOPD) to be treated and / or prevented, the condition, age and sex of the individual subject, as well as the specific viral vector or capsid, the nucleic acid encoding the GAA polypeptide to be delivered, etc., and can be determined in a routine manner. An exemplary dose to achieve a therapeutic effect is at least about 1.5×10 11 vg / kg, or at least about 1.5×10 12 vg / kg, or at least about 4.0×10 12 vg / kg titer. Included is that the dosage for achieving the therapeutic effects disclosed herein can also be determined by the strength of the liver-specific promoter (LSP) operably linked to the nucleic acid encoding the GAA polypeptide, as well as the specific signal sequence and the ability of the cell to cleave the signal sequence when secreted from the cell. Conversely, when the liver-specific promoter is stronger than the LPS used in the AAV8-LSPhGAA vector exemplified in the Examples herein, the dosage of the AAV encoding the GAA polypeptide disclosed herein can be less than about 1.6×10 12However, the dose of AAV should be titrated and determined based on the level of GAA expressed in the cells (as determined by the transduction efficiency of the AAV capsid and LSP) and the ability of the cells to secrete the expressed GAA polypeptide to avoid GAA accumulation in the transfected cells and any associated cytotoxicity.
[0222] In another aspect, disclosed herein is a method for treating Pompe disease by administering a nucleic acid encoding GAA to a cell, the method comprising contacting the cell with a rAAV vector and / or rAAV genome disclosed herein under conditions where the nucleic acid is introduced into the cell and expressed to produce GAA. In some embodiments, the cell is a cell in vivo. In some embodiments, the cell is a mammalian cell in vivo. C. Enhancement of motor neuron function in mammals
[0223] In any of the embodiments of the methods disclosed herein, the AAV vectors encoding GAA polypeptides disclosed herein can be used in methods of enhancing phrenic nerve activity in a mammal having Pompe disease and / or insufficient levels of GAA. For example, an AAV vector encoding a GAA polypeptide disclosed herein, e.g., a rAAV vector and / or rAAV genome encapsidated in a capsid, e.g., encapsidated by AAV8 or any AAV3b capsid selected from the group consisting of: AAV3b capsid (SEQ ID NO: 44); AAV3b265D capsid (SEQ ID NO: 46), AAV3b ST (S663V+T492V) capsid (SEQ ID NO: 48), AAV3b265D549A capsid (SEQ ID NO: 50); AAV3b549A capsid (SEQ ID NO: 52); AAV3bQ263Y capsid (SEQ ID NO: 54), the sequence of which is disclosed in International Application No. WO2021102107 (incorporated herein by reference). In another embodiment, retrograde transport of the AAV vectors encoding GAA polypeptides disclosed herein from the diaphragm (or other muscles) to the phrenic nerve or other motor neurons can result in biochemical and physiological correction of Pompe disease. These same principles can be applied to other neurodegenerative diseases.
[0224] In an embodiment, the rAAV capsid of the rAAV virion used to treat Pompe disease is any one listed in Table 1 disclosed in International Applications WO2020 / 102645 and WO2020 / 102667 (each of which is incorporated herein in its entirety), and includes any one of AAV8 or AAV3 or AAV3b (including but not limited to AAV3b serotypes AAV3b265D, AAV3b265D549A, AAV3b549A, AAV3bQ263Y, AAV3bSASTG (i.e., AAV3b capsid comprising Q263A / T265 mutations) serotypes, which are used in patients with In patients with Pompe disease, any one or more of the following symptoms can be reduced, for example, by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85% compared to patients not receiving the same treatment: , at least 90% or at least 95%. In other aspects of this embodiment, any serotype of AAVGAA is capable of reducing any one or more of the symptoms of (i) weakness in the patient's lower extremities (including legs, trunk and / or arms), ii) shortness of breath, difficulty moving, lung infection, large spinal curvature, difficulty breathing during sleep, enlarged liver, swollen tongue and / or joint stiffness, (iii) in patients with Pompe disease by, for example, about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, or about 60% to about 100% compared to patients not receiving the same treatment. From about 60% to about 100%, from about 70% to about 100%, from about 80% to about 100%, from about 10% to about 90%, from about 20% to about 90%, from about 30% to about 90%, from about 40% to about 90%, from about 50% to about 90%, from about 60% to about 90%, from about 70% to about 90%, from about 10% to about 80%, from about 20% to about 80%, from about 30% to about 80%, from about 40% to about 80%, from about 50% to about 80%, or from about 60% to about 80%, from about 10% to about 70%, from about 20% to about 70%, from about 30% to about 70%, from about 40% to about 70%, or from about 50% to about 70%.
[0225] In any embodiments of the methods and compositions disclosed herein, at least one symptom associated with Pompe disease or at least one adverse side effect associated with Pompe disease is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%, and the severity of at least one symptom associated with Pompe disease or at least one adverse side effect is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In another embodiment, at least one symptom associated with Pompe disease or at least one adverse side effect associated with Pompe disease is reduced, for example, by about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 100%. To about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%. III. Recombinant AAV expressing GAA
[0226] In all aspects disclosed herein, recombinant AAV (rAAV) vectors and constructs for delivering GAA polypeptides to subjects in the methods for treating Pompe disease disclosed herein are disclosed in International Patent Applications WO2020102645 and WO2021102107, both of which are incorporated herein by reference in their entireties.
[0227] As disclosed herein, one aspect of the technology relates to a method for treating Pompe disease using a rAAV vector, the vector comprising a capsid and comprising a nucleotide sequence within the capsid called a "rAAV vector genome". The rAAV vector genome (also referred to as "rAAV genome") includes multiple elements, including but not limited to two inverted terminal repeats (ITRs, such as 5'-ITR and 3'-ITR), and located between the ITRs are additional elements, including a promoter, a heterologous gene encoding a GAA polypeptide, and a poly-A tail.
[0228] In some embodiments, the rAAV genome disclosed herein comprises 5'ITR and 3'ITR sequences, and a promoter (e.g., a liver-specific promoter sequence disclosed herein) located between the 5'ITR and 3'ITR, and the promoter is operably linked to a heterologous nucleic acid encoding an alpha-glucosidase (GAA) polypeptide. In one embodiment, the heterologous nucleic acid sequence may optionally further comprise one or more of the following elements: an intron sequence, a nucleic acid encoding a secretion signal peptide, and a poly A sequence. A. α-glucosidase (GAA) polypeptide
[0229] The GAA gene (NM_000152.3) is approximately 18.3 kilobases (kb) long and contains 20 exons (Dasouki et al., 2014). Its complementary DNA has a coding sequence of 2,859 nucleotides, encoding an immature enzyme of 952 amino acids. GAA is synthesized as a membrane-bound, catalytically inactive (relative to the natural substrate glycogen) precursor that is sequestered in the endoplasmic reticulum. It undergoes sugar chain modification in the Golgi complex and is then transported to the (secondary) secretory pathway or lysosomes, where it is trimmed in a stepwise process at both the amino and carboxyl termini. Phosphorylation of mannose residues ensures efficient transport of the enzyme to lysosomes via the mannose 6-phosphate receptor. In the lysosome, GAA catalyzes the hydrolysis of the α1→4 glycosidic bond in glycogen to glucose in a low potential hydrogen (pH) environment. During maturation, specificity for the natural substrate (glycogen) is acquired.
[0230] There are many normal allelic variants in GAA, which are responsible for the three known isozymes (GAA1, GAA2, and GAA4). More than 450 mutations in GAA have been reported in individuals with Pompe disease. Nonsense mutations, large and small gene rearrangements, and splicing defects have been observed, many of which may be family, geographic region, or ethnicity specific. Combinations of mutations that cause complete or almost complete loss of GAA enzyme activity (usually <1% of normal activity in skin fibroblasts) are more common in individuals with IOPD, while those combinations that allow partial enzyme activity (approximately 2%-40% of normal activity in skin fibroblasts) often have LOPD manifestations. GAA mutations result in messenger RNA instability and / or severely truncated acid α-glucosidase or an enzyme with significantly reduced activity. GAA dysfunction or loss leads to accumulation of glycogen in the lysosomes and cytoplasm of a variety of tissues, causing destruction of skeletal, smooth, and cardiac muscle. The effects of the enzyme deficiency may extend to the vesicular system connected to the lysosomes and may also affect receptors that circulate through these organelles, such as glucose transporter 4. Evidence also suggests that productive autophagy fails and autophagosomes accumulate, disrupting the contractile apparatus in myofibers, which is associated with the lack of correction in skeletal muscle during ERT.
[0231] α-Glucosidase (GAA) polypeptide is a member of glycoside hydrolase family 31. Human GAA is synthesized as a 110 kDal precursor (Wisselaar et al., (1993) J. Biol. Chem. 268 (3): 2223-31). The mature form of the enzyme is a mixture of monomers of 70 kDal and 76 kDal (Wisselaar et al., (1993) J. Biol. Chem. 268 (3): 2223-31). The precursor enzyme has seven potential glycosylation sites, and four of them are retained in the mature enzyme (Wisselaar et al., (1993) J. Biol. Chem. 268 (3): 2223-31). The protein cleavage event that produces the mature enzyme occurs in the late endosome or lysosome (Wisselaar et al., (1993) J. Biol. Chem. 268 (3): 2223-31).
[0232] The rAAV vector genome may encode a GAA polypeptide, which may include, for example, amino acid residues 40-952 of human GAA, or a smaller portion, such as amino acid residues 40-790.
[0233] The C-terminal 160 amino acids are absent from the mature 70 kDal and 76 kDal GAA polypeptide forms. However, certain Pompe disease alleles that result in a complete loss of GAA activity map to this region, such as Val949Asp (Becker et al., (1998) J. Hum. Genet. 62: 991). The phenotype of this mutant indicates that the C-terminal portion of the protein, although not part of the 70 kDal or 76 kDal forms, plays an important role in the function of the protein. It has also been reported that the C-terminal portion of the protein, although cleaved from the rest of the protein during processing, is still associated with the major forms (Moreland et al., (November 1, 2004) J. Biol. Chem., manuscript 404008200). Therefore, the C-terminal residue may play a direct role in the catalytic activity of the protein and / or may be involved in promoting proper folding of the N-terminal portion of the protein.
[0234] The native GAA gene encodes a precursor polypeptide having the following: a signal sequence and an adjacent putative transmembrane domain, a trefoil domain (PFAM PF00088) (which is a cysteine-rich domain of about 45 amino acids containing three disulfide bonds) (Thim (1989) FEBS Lett. 250: 85), a domain defined by a mature 70 / 76 kDal polypeptide, and a C-terminal domain. It has been reported that both the trefoil domain and the C-terminal domain are required for the production of functional GAA, and that the C-terminal domain can interact with the trefoil domain during protein folding, which may promote the formation of appropriate disulfide bonds in the trefoil domain.
[0235] GAA polypeptides are described in U.S. Patents 5,962,313 and 6,537,785, which are incorporated herein by reference in their entirety. One of ordinary skill in the art will appreciate the specific position of GAA to which the secretory signal peptide (SS) can be fused. Therefore, in one aspect, the present invention relates to a GAA fusion protein, wherein SS is fused to the 40th, 68th, 69th, 70th, 71st, 72nd, 779th, 787th, 789th, 790th, 791st, 792th, 793rd, or 796th amino acid of a human GAA of SEQ ID NO: 10 disclosed in International Application WO2021102107, or a modified GAA protein of SEQ ID NO: 170-SEQ ID NO: 174, or a portion thereof.
[0236] In some embodiments of the methods and compositions disclosed herein, the human GAA protein expressed by AAV comprises the amino acids of SEQID NO: 10, or a fragment or variant thereof, such as a human GAA protein starting with any residue selected from the group consisting of residues 40, 68, 69, 70, 71, 72, 779, 787, 789, 790, 791, 792, 793, or 796 of SEQ ID NO: 10 or SEQ ID NO: 170-SEQID NO: 174 disclosed in International Application WO2021102107, incorporated herein by reference. In some embodiments of the methods and compositions disclosed herein, the human GAA protein expressed by AAV comprises the amino acids of SEQ ID NO: 10, or a protein that is at least 60%, or 70%, or 80%, 85%, or 90%, or 95%, or 98%, or 99% identical to SEQ ID NO: 10 or SEQ ID NO: 170-SEQ ID NO: 174 disclosed in International Application WO2021102107 (incorporated herein by reference). In some embodiments of the methods and compositions disclosed herein, the human GAA protein expressed by AAV comprises an amino acid that starts with any residue selected from the group consisting of a human GAA protein, or a protein that is at least 60%, or 70%, or 80%, 85%, or 90%, or 95%, or 98%, or 99% identical thereto: residues 40, 68, 69, 70, 71, 72, 779, 787, 789, 790, 791, 792, 793, or 796 of SEQ ID NO: 10 or SEQ ID NO: 170-SEQ ID NO: 174 disclosed in International Application WO2021102107 (incorporated herein by reference). In some embodiments, the human GAA protein expressed by AAV comprises an amino acid starting with any residue selected from the group consisting of residues 40, 68, 69, 70, 71, 72, 779, 787, 789, 790, 791, 792, 793, or 796 of any one of SEQ ID NO: 170 (modGAA; H199R, R223H) or SEQ ID NO: 171 (modGAA; H199R, R223H, H201L), or a protein that is at least 60%, or 70%, or 80%, 85%, or 90%, or 95%, or 98%, or 99% identical thereto, wherein SEQ ID NO: 170 and SEQ ID NO: 171 are disclosed in international application WO2021102107.
[0237] In some embodiments, the human GAA protein expressed by AAV comprises a GAA polypeptide of SEQ ID NO:600, or a protein that is at least 60%, or 70%, or 80%, 85%, or 90%, or 95%, or 98%, or 99% identical to SEQ ID NO:600, or a fragment of SEQ ID NO:600, wherein the fragment begins at any residue selected from the group consisting of residues 40, 68, 69, 70, 71, 72, 779, 787, 789, 790, 791, 792, 793, or 796 of SEQ ID NO:600 (modGAA; H199R, R223H, V780I) or a protein that is at least 60%, or 70%, or 80%, 85%, or 90%, or 95%, or 98%, or 99% identical to SEQ ID NO:600, wherein SEQ ID NO:600 has the following amino acid sequence: (i) Modified GAA (modGAA)
[0238] In some embodiments, the homologous leader sequence of GAA (i.e., amino acids 1-27 of SEQ ID NO: 175, or SEQ ID NO: 170, disclosed in International Application WO2021102107) is replaced with a non-endogenous signal sequence of SEQ ID NO: 176 (also referred to herein as a "leader sequence"), or an IL2 wild-type leader peptide (SEQ ID NO: 178), a modified IL2 leader peptide (SEQ ID NO: 180), or a leader peptide having at least 90% sequence identity to SEQ ID NO: 176, SEQ ID NO: 178, or SEQ ID NO: 180, wherein SEQ ID NO: 176, SEQ ID NO: 178, or SEQ ID NO: 180 is disclosed in International Application WO2021102107, which is incorporated herein in its entirety.
[0239] In some embodiments, the modified human GAA protein comprises a polypeptide having at least one modification selected from H199R, R223H, V780R, V780I or H201L of SEQ ID NO: 10 disclosed in International Application WO2021102107 (incorporated herein in its entirety), or a variant having at least 80%, 90%, 95% or 99% homology with at least 500, 550, 600, 650, 700, 750, 800, 850 or 900 amino acids of SEQ ID NO: 10 having at least one of these modifications. In some embodiments, the modified human GAA protein comprises a polypeptide comprising at least two modifications selected from H199R, R223H, V780R, V780I or H201L of SEQ ID NO: 10 disclosed in International Application WO2021102107, or a variant having at least 80%, 90%, 95% or 99% homology with at least 500, 550, 600, 650, 700, 750, 800, 850 or 900 amino acids of SEQ ID NO: 10 having at least two of these modifications. In some embodiments, the modified human GAA protein comprises a polypeptide having three modifications selected from H199R, R223H, V780R, V780I and H201L of SEQ ID NO: 10 (GAA-H199R-H201L-R223H or GAA-H199R-H201L-V780R), or a variant having at least 80%, 90%, 95% or 99% homology with at least 500, 550, 600, 650, 700, 750, 800, 850 or 900 amino acids of SEQ ID NO: 10 disclosed in International Application WO2021102107 having these three modifications.
[0240] In some embodiments, the homologous GAA leader peptide (also called "signal sequence") of amino acids 1-27 of SEQ ID NO: 10 (i.e., MGVRHPPC SHRLLAVCALV S LATAALL, as disclosed in international application WO2021102107 as SEQ ID NO: 175) is replaced with a different signal peptide (leader peptide). For example, the homologous leader peptide of GAA (SEQ ID NO: 175) can be replaced by any of the following: (i) an IgG1 leader peptide (referred to herein as "201 leader peptide" or "2011p") having an amino acid sequence: MEFGLSWVFLVALLKGVQCE (SEQ ID NO: 176), encoded by the nucleic acid sequence SEQ ID NO: 177, (ii) wtIL2 1p: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 178), encoded by the nucleic acid sequence SEQ ID NO: 179, or (iii) mutiL2 1p: MYRMQLLLLIALSLALVTNS (SEQ ID NO: 180), encoded by the nucleic acid sequence SEQ ID NO: 181. In some embodiments, the homologous GAA leader peptide (SEQ ID NO: 175) is still present and an additional signal peptide is added, such as any one or more of the following: signal peptide AAT; FN1; IgG1 leader peptide (referred to herein as "201 leader peptide" or "2011p") having an amino acid sequence: MEFGLSWVFLVALLKGVQCE (SEQ ID NO: 176), encoded by the nucleic acid sequence SEQ ID NO: 177; (ii) wtIL2 lp: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 178), encoded by the nucleic acid sequence SEQ ID NO: 179; or (iii) mutIL2 1p: MYRMQLLLLIALSLALVTNS (SEQ ID NO: 180), encoded by the nucleic acid sequence SEQ ID NO: 181, as disclosed in international application WO2021102107.
[0241] In some embodiments, GAA is modified to add or remove glycosylation sites, such as N-linked glycosylation sites, O-linked glycosylation sites, or both. In certain embodiments, the addition or removal of glycosylation sites is achieved by N-terminal deletion, C-terminal deletion, internal deletion, random point mutagenesis, or site-directed mutagenesis. In some embodiments, exemplary GAA modifications involve adding one or more asparagine (Asn) residues, or generating one or more mutations of asparagine (Asn) residues, or deleting one or more asparagine (Asn) residues. In certain embodiments, all or some of the N-linked and / or O-linked glycosylation sites present in GAA are mutated. In some embodiments, GAA modifications will generate information related to the biological activity, physical structure, and / or substrate binding potential of GAA. (ii) Nucleic acid encoding GAA
[0242] In some embodiments, the rAAV genome that can be used in the methods for treating Pompe disease disclosed herein comprises a heterologous nucleic acid sequence encoding a secretion signal peptide, which is fused in frame to the 3' end of a GAA nucleic acid sequence encoding the entire GAA polypeptide (e.g., N-terminal / catalytic domain and C-terminal domain). For example, a heterologous nucleic acid sequence encoding a secretion signal peptide is fused in frame to the 3' end of a GAA nucleic acid sequence encoding a 70 kDa and 76 kDa GAA polypeptide, such that both polypeptides are expressed from the rAAV genome when the rAAV vector transduces mammalian cells. In some embodiments, expression of the GAA nucleic acid can be driven by two promoters in the rAA genome or by one promoter driving expression of a bicistronic construct.
[0243] In some embodiments of the methods and compositions disclosed herein, the rAAV vector comprises a nucleic acid sequence encoding a GAA protein, which is a wild-type GAA nucleic acid sequence, such as SEQ ID NO: 11 or SEQ ID NO: 72 or SEQ ID NO: 182 disclosed in International Application WO2021102107 (incorporated herein by reference in its entirety). In some embodiments of the methods and compositions disclosed herein, the rAAV vector comprises a nucleic acid sequence encoding a GAA protein, which is a GAA nucleic acid sequence codon-optimized for any one or more of the following: (i) enhanced in vivo expression, (ii) reduction of CpG islands, (iii) reduction of innate immune responses. Exemplary codon-optimized GAA nucleic acid sequences for use in the methods and rAAV compositions disclosed herein can be selected from any of the following: SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76 or SEQ ID NO:182 as disclosed in International Application WO2021102107, or a nucleic acid sequence having at least 60%, or 70%, or 80%, 85% or 90% or 95%, or 98%, or 99% sequence identity to SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76 or SEQ ID NO:182. B. Secretion signal peptide
[0244] The native GAA signal peptide is not cleaved in the ER, thereby allowing the native GAA polypeptide to be associated with the membrane in the ER (Tsuji et al., (1987) Biochem. Int. 15(5):945-95). Disruption of GAA membrane association can be achieved by replacing the endogenous (or homologous) GAA signal peptide (and optionally adjacent sequences) with an alternative signal peptide of GAA.
[0245] Thus, in representative embodiments, the rAAV vectors and rAAV genomes useful in the methods for treating Pompe disease disclosed herein further comprise a heterologous nucleic acid encoding a GAA polypeptide to be transferred to a target cell, the heterologous nucleic acid being attached to a heterologous nucleic acid sequence encoding a secretion signal peptide that replaces the endogenous GAA signal peptide. The heterologous nucleic acid is operably associated with the fragment encoding the secretion signal peptide, such that upon transcription and translation, a fusion polypeptide is produced that comprises a secretion signal sequence that is operably associated with the GAA polypeptide (e.g., directs its secretion).
[0246] In some embodiments, the AAV vector encodes a GAA polypeptide comprising an endogenous GAA signal peptide (e.g., amino acids 1-27 of SEQ ID NO: 10) (also referred to as an "intrinsic GAA" or "homologous GAA" signal peptide). In some embodiments, the AAV vector encodes a GAA polypeptide comprising an endogenous GAA signal peptide (e.g., amino acids 1-27 of SEQ ID NO: 10 as disclosed in International Application WO2021102107) (also referred to as an "intrinsic GAA" or "homologous GAA" signal peptide) and an additional heterologous (non-native) signal sequence. In some embodiments, a GAA polypeptide lacking an endogenous signal peptide of amino acids 1-27 of GAA is fused to a secretion signal. In some embodiments of the compositions and methods described herein, the general purpose of the secretion signal is to facilitate the secretion of the GAA polypeptide from hepatocytes into the blood, where it can travel and target the lysosomes of mammalian cells (e.g., human cardiac and skeletal muscle cells as described herein). In some embodiments, the heterologous secretion signal is selected from any one of the following: AAT signal peptide, fibronectin signal peptide (FN1), GAA signal peptide, or an active fragment of AAT, FN1 or GAA signal peptide having secretion signal activity.
[0247] In some embodiments, the secretion signal peptide is heterologous (i.e., foreign or exogenous) to the polypeptide of interest. For example, the heterologous secretion signal peptide is a fibronectin secretion signal peptide, and the polypeptide of interest is not fibronectin. In some embodiments, the secretion signal peptide is selected from any one of the following: an AAT signal peptide, a fibronectin signal peptide (FN1), or an active fragment of an AAT, FN1 or GAA signal peptide having secretion signal activity. In an alternative embodiment, the secretion signal peptide is not heterologous to GAA, i.e., the signal peptide is a GAA signal peptide (i.e., residues 1-27 of a native GAA polypeptide).
[0248] In some embodiments, the homologous GAA signal peptide at amino acids 1-27 of SEQ ID NO: 10 (i.e., MGVRHPPCSHRLLAVCALVSLATAALL, SEQ ID NO: 175) is replaced with a different or heterologous leader peptide. For example, the homologous leader peptide of GAA (SEQ ID NO: 175) can be replaced with any heterologous signal peptide selected from the group consisting of: (i) an IgG1 leader peptide (referred to herein as "201 leader peptide" or "2011p") having the amino acid sequence: MEFGLSWVFLVALLKGVQCE (SEQ ID NO: 176), encoded by the nucleic acid sequence SEQ ID NO: 177, (ii) wtIL2 1p: MYRMQLLSCIALSLALVTNS (SEQ ID NO: 178), encoded by the nucleic acid sequence SEQ ID NO: 179, or (iii) mutIL2 1p: MYRM Q LLLLIA LS LALVTN S (SEQ ID NO: 180), encoded by the nucleic acid sequence SEQ ID NO: 181, or a leader peptide having at least 90% sequence identity to any one of SEQ ID NO: 176, SEQ ID NO: 178 or SEQ ID NO: 180.
[0249] Typically, the secretory signal peptide will be located at the amino terminus (N-terminus) of the GAA polypeptide (i.e., the nucleic acid fragment encoding the secretory signal peptide is located 5' to the heterologous nucleic acid encoding the GAA peptide in the rAAV vector or rAAV genome disclosed herein). Alternatively, the secretory signal can be located at the carboxyl terminus of the GAA polypeptide or embedded within the GAA polypeptide, so long as the secretory signal is operably associated therewith and directs secretion of the GAA polypeptide or GAA fusion polypeptide of interest from the cell (regardless of whether the signal peptide is cleaved from the GAA polypeptide).
[0250] The secretion signal is operably associated with the GAA polypeptide and targets the secretion pathway. In other words, the secretion signal is operably associated with the GAA polypeptide so that the GAA polypeptide is secreted from the cell at a higher level (i.e., a greater amount) than without the secretion signal peptide. In general, when the signal peptide is connected, at least about 20%, 30%, 40%, 50%, 70%, 80%, 85%, 90%, 95% or more of the GAA polypeptide is usually secreted from the cell compared to when there is no secretion signal peptide connected. In other embodiments, substantially all detectable polypeptides (alone and / or in the form of fusion polypeptides) are secreted from the cell.
[0251] The phrase "secreted from a cell" means that the polypeptide can be secreted into any compartment (e.g., fluid or space) outside the cell, including but not limited to: interstitial space, blood, lymph, cerebrospinal fluid, renal tubules, airway passages (e.g., alveoli, bronchioles and bronchi, nasal passages, etc.), gastrointestinal tract (e.g., esophagus, stomach, small intestine, colon, etc.), vitreous humor in the eye and endolymph in the cochlea, etc.
[0252] Thus, in some embodiments, the GAA-expressing AAV useful in the methods for treating Pompe disease disclosed herein comprises a 5'ITR and a 3'ITR sequence, and located between the 5'ITR and the 3'ITR is a liver-specific promoter operably linked to a heterologous nucleic acid encoding a secretory peptide and a nucleic acid encoding an alpha-glucosidase (GAA) polypeptide (i.e., the heterologous nucleic acid encodes a GAA polypeptide comprising a signal peptide-GAA polypeptide).
[0253] In an alternative embodiment, the GAA-expressing AAV useful in the methods of treating Pompe disease disclosed herein comprises 5'ITR and 3'ITR sequences, and a promoter located between the 5'ITR and 3'ITR, the promoter being operably linked to a heterologous nucleic acid encoding a secreted peptide and a nucleic acid encoding an alpha-glucosidase (GAA) polypeptide.
[0254] Typically, the secretory signal peptide is cleaved in the endoplasmic reticulum, and in some embodiments, the secretory signal peptide is cleaved from the GAA polypeptide prior to secretion. However, as long as the secretion of the GAA polypeptide from the cell is enhanced and the GAA polypeptide is functional, cleavage of the secretory signal peptide is not necessary. Therefore, in some embodiments, the secretory signal peptide is partially or completely retained.
[0255] In some embodiments, the rAAV genome or isolated nucleic acid disclosed herein comprises a nucleic acid encoding a chimeric polypeptide comprising a GAA polypeptide operably linked to a secretory signal peptide, and the chimeric polypeptide is expressed and produced from a cell transduced with an rAAV vector, and the GAA polypeptide is secreted from the cell. The GAA polypeptide may be secreted after cutting all or part of the secretory signal peptide. Alternatively, the GAA polypeptide may retain the secretory signal peptide (i.e., the secretory signal is not cut). Therefore, in this context, a "GAA polypeptide" may be a chimeric polypeptide comprising a secretory peptide.
[0256] A large number of secreted proteins and sequences that direct secretion from cells are known in the art and are disclosed in US Pat. No. 9,873,868, which is herein incorporated by reference in its entirety. Exemplary secreted proteins (and their secretion signals) include, but are not limited to, erythropoietin, coagulation factor IX, cystatin, lactotransferrin, plasma proteinase C1 inhibitor, apolipoproteins (e.g., APO A, C, E), MCP-1, alpha-2-HS-glycoprotein, alpha-1-microglobulin, complement (e.g., C1Q, C3), vitronectin, lymphotoxin-alpha, azurocidin, VIP, inhibitor of metalloproteinase 2, glypican-1, pancreatic hormone, clusterin, hepatocyte growth factor, insulin, alpha-1-antichymotrypsin, growth hormone, type IV collagenase, guanylin, properdin, proenkephalin A, inhibin beta (e.g., A chain), prealbumin, angiogenin, luteinizing hormone (e.g., beta chain), insulin-like growth factor binding protein 1 and 2, activator precursor polypeptide, fibrinogen (e.g.,β chain), gastric triglyceride lipase, midkine, neutrophil defensins 1, 2, and 3, α-1-antitrypsin, matrix gla-protein, α-tryptase, bile salt-activated lipase, chymosinogen B, elastin, IG λ chain V region, platelet factor 4 variant, chromogranin A, WNT-1 proto-oncogene protein, oncostatin M, β-neoendorphin-dynorphin, von Willebrand factor, plasma serine protease inhibitor, serum amyloid A protein, nestin, fibronectin, renin, osteonectin, histatin 3 (histatin 3), phospholipase A2, cartilage matrix protein, GM-CSF, matrix dissolving factor, neuroendocrine protein 7B2, placental protein 11, gelsolin, M-CSF, transcobalamin I, lactase-phloridzin hydrolase, elastase 2B, pepsinogen A, MIP1-β, prolactin, trypsinogen II, gastrin-releasing peptide 2, atrial natriuretic peptide, secretory alkaline phosphatase, pancreatic α-amylase, secretory granulin I, β-casein, serum transferrin, tissue factor pathway inhibitors, follicle-stimulating hormone beta chain, coagulation factor XII, growth hormone releasing factor, prostatic seminal protein, interleukins (such as 2, 3, 4, 5, 9, 11), inhibins (such as alpha chain), angiotensinogen, thyroglobulin, IG heavy chain or light chain, plasminogen activator inhibitor-1, lysozyme C, plasminogen activator, antileukoproteinase 1, statherin, fibrin-1, isoform B, urinary regulation thyroxine-binding globulin, axonin-1, endometrial alpha-2 globulin, interferons (e.g., alpha, beta, gamma), beta-2-microglobulin, procholecystokinin, progastricsin, prostatic acid phosphatase, bone sialoprotein 2, colipase, Alzheimer's amyloid A4 protein, PDGF (e.g., A or B chain), coagulation factor V, triacylglycerol lipase, haptoglobin 2, corticosteroid binding globulin, triacylglycerol lipase, prorelaxin H2, follistatin 1 and 2, platelet glycoprotein IX, GCSF, VEGF, heparin cofactor II, antithrombin III, leukemia inhibitory factor, interstitial collagenase, pleiotrophin, small inducible cytokine A1, melanin-concentrating hormone, angiotensin-converting enzyme, trypsin inhibitor, coagulation factor VIII, alpha-fetoprotein, alpha-lactalbumin, senogelin II, kappa casein, glucagon, thyrotropin beta chain, transcobalamin II, thrombospondin 1, parathyroid hormone, vasopressin and copeptin, tissue factor, motilin, MPIF-1, kininogen, neuroendocrine converting enzyme 2, stem cell factor procollagen alpha 1 chain, plasma kallikrein, keratinocyte growth factor,and any other secreted hormones, growth factors, cytokines, enzymes, coagulation factors, milk proteins, immunoglobulin chains, etc.
[0257] In some embodiments, other secretion signal peptides encoded in the rAAV vectors disclosed herein and encoded by the rAAV genome can be selected from, but are not limited to, secretion signal sequences from: prepro-cathepsin L (e.g., GenBank Accession Nos. KHRTL, NP_037288, NP_034114, AAB81616, AAA39984, P07154, CAA68691; the disclosures of which are incorporated herein by reference in their entireties), and pre-α2 collagen (e.g., GenBank Accession Nos. CAA98969, CAA26320, CGHU2S, NP_000080, BAA25383, P08123; the disclosures of which are incorporated herein by reference in their entireties), and allelic variants, modifications, and functional fragments thereof (as discussed above for the fibronectin secretion signal sequence). For procathepsinogen L (for Rattus norvegicus, exemplary secretion signal sequences include MTPLLLLAVLCLGTALA [SEQ ID NO: 27]; Accession No. CAA68691), and for pro-α2 collagen (for Homo sapiens, exemplary secretion signal sequences include MLSFVDTRTLLLLAVTLCLATC [SEQ ID NO: 28]; Accession No. CAA98969). Also contemplated are longer amino acid sequences comprising the full-length secretion signal sequences from procathepsinogen L and pro-α2 collagen or functional fragments thereof (as discussed above for the fibronectin secretion signal sequence).
[0258] In some embodiments, the secretory signal peptide is partially or completely derived from a secreted polypeptide produced by hepatocytes. In some embodiments, the secretory signal peptide may further be synthetic or artificial in whole or in part. Synthetic or artificial secretory signal peptides are known in the art, see, for example, Barash et al., "Human secretory signal peptide description by hidden Markov model1 and generation of a strong artificial signal peptide for secreted protein expression", Biochem. Biophys. Res. Comm. 294: 835-42 (2002); the disclosure of which is incorporated herein by reference in its entirety. In a specific embodiment, the secretory signal peptide comprises, consists essentially of, or consists of the following artificial secretory signal: MWWRLWWLLLLLLLLWPMVWA (SEQ ID NO: 29) or a variant thereof having 1, 2, 3, 4 or 5 amino acid substitutions (optionally, conservative amino acid substitutions, which are known in the art).
[0259] Exemplary signal peptides for use in the methods and compositions disclosed herein can be selected from any signal peptide disclosed in Table 2 or a functional variant thereof. An exemplary signal peptide is fibronectin (FN1) or AAT. In some embodiments of the methods and compositions disclosed herein, the rAAV vector composition comprises a nucleic acid encoding a secretory signal peptide, such as a nucleic acid encoding a secretory signal peptide selected from an AAT signal peptide (e.g., SEQ ID NO: 17), a fibronectin signal peptide (FN1) (e.g., SEQ ID NO: 18-SEQ ID NO: 21), a GAA signal peptide, a hIGF2 signal peptide (e.g., SEQ ID NO: 22), or an active fragment thereof having secretory signal activity, such as a nucleic acid encoding an amino acid sequence having at least about 75%, or 80%, or 85%, or 90%, or 95%, or 98%, or 99% sequence identity with SEQ ID NO: 17-SEQ ID NO: 22, wherein SEQ ID NO: 17-SEQ ID NO: 22 is disclosed in International Application No. WO2021102107 (incorporated herein by reference).
[0260] In some embodiments of the methods and compositions disclosed herein, the nucleic acid encoding the secretion signal is selected from any one of SEQ ID NO: 17, SEQ ID NO: 81-SEQ ID NO: 21, SEQ ID NO: 22-SEQ ID NO: 26, or a nucleic acid sequence having at least 75%, 80%, 85%, 90%, 95%, 98%, 99% sequence identity to any one of SEQ ID NO: 17 or SEQ ID NO: 22-SEQ ID NO: 26, wherein SEQ ID NO: 17 and SEQ ID NO: 22-SEQ ID NO: 26 are disclosed in International Application WO2021102107 (incorporated herein by reference).
[0261] Fibronectin secretion signal peptide:
[0262] In some embodiments, the secretion signal peptide is a fibronectin secretion signal peptide, which term includes modifications of the naturally occurring sequence (as described in more detail below).
[0263] In some embodiments, the secretion signal peptide is a fibronectin signal peptide, such as a signal sequence of human fibronectin or a signal sequence from rat fibronectin. Fibronectin (FN1) signal sequences and modified FN1 signal peptides that are contemplated for use in the rAAV genome and rAAV vector described herein are disclosed in U.S. Patent No. 7,071,172, which is incorporated herein by reference in its entirety, and Table 3 of International Application No. WO2021102107 or Provisional Application No. 62 / 937,556 filed on November 19, 2019, which is incorporated herein by reference. Examples of exemplary fibronectin secretion signal sequences include, but are not limited to, those listed in Table 1 of U.S. Patent No. 7,071,172 (incorporated herein by reference in its entirety).
[0264] Table 2: Exemplary fibronectin (FN1) secretion signal peptides
[0265] Peptidase cleavage site
[0266] In some embodiments, one or more exogenous peptidase cleavage sites can be inserted into the secretion signal peptide-GAA polypeptide, for example, between the secretion signal peptide and the GAA polypeptide. In a specific embodiment, an autoprotease (e.g., foot-and-mouth disease virus 2A autoprotease) is inserted between the secretion signal peptide and the GAA polypeptide. In other embodiments, a protease recognition site (e.g., Lys-Arg recognition site of trypsin, Lys-Arg recognition site of Aspergillus KEX2-like protease, recognition site of metalloprotease, recognition site of serine protease, etc.) that can be controlled by adding an exogenous protease is used. Modification of the GAA polypeptide to delete the native protease site or to inactivate the native protease site is included herein, and is disclosed in U.S. Provisional Application 62,937,556, filed on November 19, 2019, and International Application WO2021102107, which are incorporated herein by reference. C. GAA polypeptide spacer and fusion junction
[0267] When GAA is expressed with a non-GAA secretory signal peptide (e.g., SS-GAA polypeptide), the signal peptide can be fused directly to the GAA polypeptide or can be separated from the GAA polypeptide by a linker. An amino acid linker (also referred to herein as a "spacer") incorporates one or more amino acids that are different from those that occur at that position in the native protein. Spacers can generally be designed to be flexible or to insert a structure, such as an alpha-helix, between two protein portions.
[0268] Thus, in some embodiments of the methods and compositions disclosed herein, the recombinant AAV vector comprises a heterologous nucleic acid sequence encoding a GAA polypeptide, wherein the GAA protein further comprises a spacer located at the N-terminus of the GAA polypeptide, wherein the spacer comprises a nucleotide sequence of at least 1 amino acid in length.
[0269] In one embodiment, the spacer is at least 50% identical to the sequence GGGTVGDDDDK (SEQ ID NO: 35).
[0270] In some embodiments, the spacer or linker can be relatively short, for example at least 1, 2, 3, 4 or 5 amino acids, or such as the sequence Gly-Ala-Pro (SEQ ID NO: 31) or Gly-Gly-Gly-Gly-Gly-Pro (SEQ ID NO: 32), or can be longer, for example 5-10 amino acids in length or 10-25 amino acids in length. For example, a flexible repeat linker with 3-4 copies of the sequence (GGGGS (SEQ ID NO: 33)) and an α-helical repeat linker with 2-5 copies of the sequence (EAAAK (SEQ ID NO: 34)) have been described (Arai et al., (2004) Proteins: Structure, Function and Bioinformatics 57: 829-838).
[0271] The use of another linker, GGGTVGDDDDK (SEQ ID NO: 35), has also been reported (DiFalco et al., (1997) Biochem. J. 326: 407-413) and is contemplated for use. Linkers that incorporate the alpha-helical portion of human serum albumin can be used to minimize the immunogenicity of the linker region.
[0272] In some embodiments, the spacer is encoded by the nucleic acid GGC GCG CCG (SEQ ID NO: 30), which encodes an amino acid spacer comprising the amino acids GAP or Gly-Ala-Pro (SEQ ID NO: 31).
[0273] The site of the fusion junction of the GAA polypeptide to the signal peptide (to generate an SS-GAA fusion protein) should be carefully selected to promote proper folding and activity of each polypeptide in the fusion protein and to prevent premature separation of the signal peptide from the GAA polypeptide.
[0274] In some embodiments, the spacer has a helical structure. In another specific embodiment, the spacer is at least 50% identical to the sequence GGGTVGDDDDK (SEQ ID NO: 35). In some embodiments of the methods and compositions disclosed herein, the spacer is SEQ ID NO: 31 (encoded by the nucleic acid of SEQ ID NO: 30). In some embodiments of the methods and compositions disclosed herein, the spacer is selected from any one of the following: SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, or SEQ ID NO: 35.
[0275] In some embodiments, the signal peptide can be fused directly or through a spacer to amino acid position 40 or amino acid position 70 of GAA, which allows expression of the protein, catalytic activity of the GAA protein, and proper secretion of the GAA polypeptide, as described in the Examples herein. Alternatively, the signal sequence or signal peptide can be fused at or near the cleavage site that separates the C-terminal domain of GAA from the mature polypeptide. This allows the synthesis of a GAA protein with an internal signal peptide that can be optionally cleaved to release the mature polypeptide or C-terminal domain from the signal sequence, depending on the location of the cleavage site. Alternatively, the mature polypeptide can be synthesized as a fusion protein at about position 791 without introducing a C-terminal signal peptide sequence into the open reading frame of the expression construct.
[0276] To facilitate signal peptide folding, the GAA amino acid residues adjacent to the fusion junction can be modified. For example, since GAA cysteine residues may interfere with proper folding of the signal peptide, the terminal GAA cysteine at position 952 can be deleted or replaced with serine to accommodate a C-terminal signal peptide. The signal peptide can also be fused just before the last Cys952. The penultimate cys938 can be changed to proline, while the last Cys952 can be mutated to serine. D.CS sequence
[0277] In some embodiments of the methods and compositions disclosed herein, the recombinant AAV vector comprises a heterologous nucleic acid sequence further comprising a collagen stabilizing (CS) sequence located 3' and 5' of the 3' ITR sequence of the nucleic acid encoding the GAA polypeptide. r The AAV genome comprises a heterologous nucleic acid sequence, which may optionally comprise a collagen stabilizing sequence (CS or CSS) located 3' of the GAA gene and 5' of the poly A signal. In some embodiments, the CS sequence may be replaced by a 3'UTR sequence disclosed herein.
[0278] Exemplary collagen stabilizing sequences include CCCAGCCCACTTTTCCCCAA (SEQ ID NO: 65) or a sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. Exemplary collagen stabilizing sequences may have the amino acid sequence of PSPLFP (SEQ ID NO: 66) or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto. The CS sequence is disclosed in Holick and Liebhaber, Proc. c.Nat.Acad.Sci.94:2410-2414, 1997 (see, e.g., FIG. 3 , p. 5205 ), which is incorporated herein by reference in its entirety. E. Liver-specific promoter (LSP)
[0279] In some embodiments, in order to achieve an appropriate level of GAA expression, the rAAV genotype comprises a liver-specific promoter (LSP). LSP enables operably linked genes to be expressed in the liver, and in some embodiments may be an inducible LSP. In one embodiment, LSP is located 5' upstream and operably linked to a heterologous nucleic acid sequence encoding a GAA protein. According to the methods disclosed herein, exemplary liver-specific promoters that can be used in AAV to treat Pompe disease are disclosed in international applications WO2020102645 and WO2021102107, which are incorporated herein by reference in their entirety. Exemplary liver-specific promoters include, but are not limited to, thyroxine transporter promoter (TTR), LSP promoter (LSP), and synthetic liver-specific promoters.
[0280] In some embodiments of the methods and compositions disclosed herein, the promoter is a liver-specific promoter (LSP) and can be selected from any liver-specific promoter, including but not limited to the thyroxine transporter promoter (TTR), a liver-specific promoter (LSP) (e.g., disclosed in 5,863,541 (TTR promoter)) or an LSP promoter (PNAS, 96: 3906-3910, 1999, see e.g., page 3906, Materials and Methods, rAAV construction), a synthetic liver promoter, the references of which are incorporated herein by reference in their entirety. Other liver promoters, such as synthetic liver promoters, can be used.
[0281] In some embodiments, the promoter is the LP1 promoter (which is SEQ ID NO:432 disclosed in WO2021102107, which is incorporated herein by reference in its entirety), or at least a variant having a sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity thereto.
[0282] In some embodiments, the TTR promoter is a truncated TTR promoter (e.g., comprising SEQ ID NO: 12 disclosed in International Application WO2020102645, which is herein incorporated by reference in its entirety), or at least a variant having a sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity thereto.
[0283] In some embodiments, the LSP is a TBG promoter (e.g., comprising SEQ ID NO:435 disclosed in International Application WO2021102107, which is incorporated herein by reference in its entirety), or at least a variant having a sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity thereto.
[0284] Other liver-specific promoters include, but are not limited to, promoters of LDL receptor, factor VIII, factor IX, phenylalanine hydroxylase (PAH), ornithine transcarbamylase (OTC), and alpha 1-antitrypsin (hAAT), and HCB promoter. Other liver-specific promoters include AFP (alpha-fetoprotein) gene promoter and albumin gene promoter (such as disclosed in EP patent publication 0415 731), alpha-1 antitrypsin gene promoter (such as disclosed in Rettenger, Proc. Natl. Acad. Sci. 91 (1994) 1460-1464), fibrinogen gene promoter, APO-A1 (apolipoprotein A1) gene promoter, and promoter genes of liver transferases (such as SGOT, SGPT, and gamma-glutamyl transferase). See also 2001 / 0051611 and PCT patent publications WO 90 / 07936 and WO 91 / 02805, which are incorporated herein by reference in their entirety. In some embodiments, the liver-specific promoter is a recombinant liver-specific promoter, for example, as disclosed in US20170326256A1 (incorporated herein by reference in its entirety).
[0285] In some embodiments, the liver-specific promoter is a hepatitis B X gene promoter and a hepatitis B core protein promoter. In some embodiments, the liver-specific promoters can be used with their respective enhancers. The enhancer element can be connected at the 5' end or the 3' end of the nucleic acid encoding the GAA polypeptide. The hepatitis B X gene promoter and its enhancer can be obtained from the viral genome as a 332 base pair EcoRV-NcoI DNA fragment using the method described in Twu, J Virol. 61 (1987) 3448-3453. The hepatitis B core protein promoter can be obtained from the viral genome as a 584 base pair BamHI-BglII DNA fragment using the method described in Gerlach, Virol 189 (1992) 59-66. Before inserting the BamHI-BglII fragment, it may be necessary to remove the negative regulatory sequence therein.
[0286] In some embodiments, the synthetic liver-specific promoter is selected from any one of the following: SEQ ID NO:86, SEQ ID NO:91-SEQ ID NO:96, or SEQ ID NO:146-SEQ ID NO:150, or SEQ ID NO:270-SEQ ID NO:430 disclosed in International Application WO2021102107 (incorporated herein by reference in its entirety), or a nucleic acid sequence that is at least 80%, or at least 90% or 95% identical thereto or to a source regulatory nucleic acid sequence.
[0287] In some embodiments, the liver-specific promoter (LSP) in the AAV expressing GAA that can be used in the methods for treating Pompe disease disclosed herein comprises a nucleic acid sequence selected from any of the promoters listed below: SEQ ID NOS: 86 (CRM 0412), SEQ ID NO: 91 (SP0412) or SEQ ID NO: 92 (SP0422), SEQ ID NOS: 93 (SP0239), SEQ ID NO: 94 (SP0265), SEQ ID NO: 95 (SP0240) or SEQ ID NO: 96 (SP0246), or SEQ ID NO: 146 (SP0265-UTR), SEQ ID NO: 147 (SP0239-UTR), SEQ ID NO: 148 (SP0240-UTR), SEQ ID NO: 149 (SP0246-UTR) or SEQ ID NO: 150 (SP0131-A1-UTR) disclosed in the international application, or a functional fragment or variant thereof, or a nucleic acid sequence selected from SEQ ID NOS: 86 (CRM 0412), SEQ ID NO: 91 (SP0412) or SEQ ID NO: 92 (SP0422), SEQ ID NOS: 93 (SP0239), SEQ ID NO: 94 (SP0265), SEQ ID NO: 95 (SP0240) or SEQ ID NO: 96 (SP0246), or SEQ ID NO: 146 (SP0265-UTR), SEQ ID NO: 147 (SP0239-UTR), SEQ ID NO: 148 (SP0240-UTR), SEQ ID NO: 149 (SP0246-UTR) or SEQ ID NO: 150 (SP0131-A1-UTR) disclosed in the international application, or a functional fragment or variant thereof Any LSP of NO:270-SEQ ID NO:341 or SEQ ID NO:342-SEQ ID NO:430 or a functional fragment or variant thereof, wherein SEQ ID NO:86, SEQ ID NO:91-SEQ ID NO:96, or SEQID NO:146-SEQ ID NO:150, or SEQ ID NO:270-SEQ ID NO:430 is disclosed in international application WO2021102107, which is incorporated herein by reference in its entirety.
[0288] In some embodiments, the rAAV vector genome can include one or more constitutive promoters, such as viral promoters or promoters from mammalian genes that are normally active in promoting transcription.
[0289] It is contemplated that a liver-specific promoter for expression of a GAA polypeptide is selected in conjunction or in combination with the selection of a signal sequence. In particular, without being bound by theory, if a strong liver-specific promoter is selected, a signal sequence should be selected that is sufficient to secrete the expressed GAA out of the cell to avoid accumulation of GAA in the cell and any associated cytotoxicity, and / or to avoid the production of anti-GAA antibodies.
[0290] It is contemplated that the LSP is selected in conjunction with the signal sequence so that the strength of the liver-specific promoter (LSP) operably linked to the nucleic acid encoding the GAA polypeptide can be balanced with the ability of the cell to secrete the expressed GAA protein. Therefore, if the liver-specific promoter is strong, the specific signal sequence must be effective enough to allow the expressed GAA to be secreted from the cell so that GAA does not accumulate and produce cytotoxicity and / or induce an immune response. Therefore, the cellular secretion pathway and the selected signal sequence must be able to match the level of GAA expressed by the AAV, where the level of GAA expression depends on both the AAV transduction efficiency (determined by the AAV dose and capsid) and the strength of the liver-specific promoter.
[0291] In some embodiments of the methods for treating Pompe disease disclosed herein, the synthetic liver-specific promoter that can be used for the AAV vector is disclosed in Table 4 of International Application WO2021102107, or is selected from any LSP promoter of SEQ ID NO:86, SEQ ID NO:91-SEQ ID NO:96, SEQ ID NO:146-SEQ ID NO:150 of International Application WO2021102107, or is selected from any LSP of SEQ ID NO:270-SEQ ID NO:341 or SEQ ID NO:342-SEQ ID NO:430 of International Application WO2021102107, the synthetic liver-specific promoter is capable of promoting liver-specific transgene expression and its activity in hepatocytes is the LSP promoter of SEQ ID NO:86, SEQ ID NO:91-SEQ ID NO:96, SEQ ID NO:146-SEQ ID NO:150 of International Application WO2021102107. at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350% or 400% of the activity of the TTR promoter of NO:431.
[0292] In some embodiments of the method for treating Pompe disease disclosed herein, the synthetic liver-specific promoter is selected from any one of the LSPs disclosed herein in Table 4 of International Application WO2021102107, or selected from any LSP promoter of SEQ ID NO:86, SEQ ID NO:91-SEQ ID NO:96, SEQ ID NO:146-SEQID NO:150 disclosed in International Application WO2021102107, or selected from any LSP of SEQ ID NO:270-SEQ ID NO:341 or SEQ ID NO:342-SEQ ID NO:430 disclosed in International Application WO2021102107, wherein the synthetic liver-specific promoter is capable of promoting liver-specific transgene expression and its activity in hepatocytes is SEQ ID NO:86, SEQ ID NO:91-SEQ ID NO:96, SEQ ID NO:146-SEQID NO:150 disclosed in International Application WO2021102107. at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350% or 400% of the activity of the TBG promoter of NO:435.
[0293] In some embodiments, a liver-specific promoter that is a functional variant of a given promoter element preferably retains at least 80% of its activity, more preferably at least 90% of its activity, more preferably at least 95% of its activity, and still more preferably 100% of its activity (compared to a reference promoter comprising an unmodified promoter element). Suitable assays for assessing liver-specific promoter activity are disclosed in Examples 12 and 13 of International Application WO2021102107 (incorporated herein by reference in its entirety). F. Regulatory and Intronic Sequences
[0294] In some embodiments, the liver-specific promoter as shown above is operably connected to one or more additional regulatory sequences. The additional regulatory sequences can, for example, enhance expression compared to a liver-specific promoter that is not operably connected to the additional regulatory sequences. Generally, it is preferred that the additional regulatory sequences do not substantially reduce the specificity of the liver-specific promoter.
[0295] For example, a liver-specific promoter may be operably linked to a sequence encoding a UTR (e.g., 5' and / or 3' UTR), an intron, etc. In some embodiments, a liver-specific promoter may be operably linked to a sequence encoding a UTR (e.g., 5' UTR). The 5' UTR may include various elements that may regulate gene expression. The 5' UTR in a natural gene begins at the transcription start site and ends at one nucleotide before the start codon in the coding region. It should be noted that the 5' UTR referred to herein may be the entire naturally occurring 5' UTR, or it may be a part of the naturally occurring 5' UTR. The 5' UTR may also be partially or entirely synthetic. In eukaryotes, the median length of the 5' UTR is about 150 nt, but in some cases, they may be much longer. International application WO2021102107 (incorporated herein in its entirety by reference) discloses regulatory sequences that may be found in the 5' UTR.
[0296] Introns in 5'UTR are relevant to the regulation of gene expression and mRNA output.In some embodiments, the liver-specific promoter as shown above is operably connected to the sequence of the 5'UTR of the major immediate gene (CMV-IE gene) of coding and is derived from CMV.For example, 5'UTR from CMV-IE gene suitably comprises CMV-IE gene exon 1 and CMV-IE gene exon 1, or its part.In some cases, promoter elements can be modified in view of the connection to 5'UTR, for example, the sequence (for example, replacing with 5'UTR) downstream of transcription start site (TSS) can be removed in promoter elements.
[0297] CMV-IE 5'UTR is described in Simari et al., Molecular Medicine 4:700-706, 1998 "Requirements for Enhanced Transgene Expression by Untranslated Sequences from the Human Cytomegalovirus Immediate-Early Gene", which is incorporated herein by reference. Variants of the CMV-IE 5'UTR sequence discussed in Simari et al. are also listed in WO2002 / 031137 (incorporated by reference), and the regulatory sequences disclosed therein can also be used. Other UTRs that can be used in combination with promoters are known in the art, such as Leppek, K., Das, R. & Bama, M. "Functional 5'UTR mRNA structures ineukaryotic translation regulation and how to find them". Nat Rev Mol Cell Biol 19, 158-174 (2018), incorporated by reference.
[0298] In some embodiments, the sequence encoding the 5'UTR includes SEQ ID NO: 145 disclosed in International Application WO2021102107, or a functional variant thereof. In some embodiments, the functional variant may have a sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical thereto. SEQ ID NO: 145 encodes CMV-IE 5'UTR.
[0299] In some embodiments, the 5'UTR comprises a nucleic acid motif that serves as a protein translation start site, such as a sequence that defines a Kozak sequence in the mRNA produced. For example, in some embodiments, the sequence encoding the 5'UTR comprises the sequence motif GCCACC (SEQ ID NO: 153) at or near its 3' end. Other Kozak sequences or other protein translation initiation sites can be used, as known in the art (e.g., Marilyn Kozak, "Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes" Cell, Vol. 44, 283-292, January 31, 1986; Marilyn Kozak "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells" J. Mol. Rid. (1987) 196, 947-950; Marilyn Kozak "An analysis of 5'-noncoding sequences from 699 vertical messenger RNAs" Nucleic Acids Research. Vol. 15 (20) 1987, all incorporated herein by reference). The protein translation initiation site (e.g., Kozak sequence) is preferably located adjacent to the start codon.
[0300] In some embodiments, the sequence encoding the 5'UTR includes SEQ ID NO: 438 disclosed in International Application WO2021102107, or a functional variant thereof. In some embodiments, the functional variant may have a sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical thereto. The 5'UTR comprises six nucleotides of SEQ ID NO: 153 disclosed in International Application WO2021102107, which defines a Kozak sequence at the 3' end of the CMV-IE 5'UTR.
[0301] In some embodiments, the rAAV expressing GAA used in the methods for treating Pompe disease disclosed herein comprises an intron sequence located 3' to the promoter sequence and 5' to the secretion signal peptide. The intron sequence is used to increase one or more of the following: mRNA stability, mRNA transport out of the nucleus and / or expression and / or regulation of the expressed GAA polypeptide. In alternative embodiments, the rAAV genotype does not comprise an intron sequence.
[0302] In some embodiments, the intron sequence is an MVM intron sequence, such as, but not limited to, the intron sequence of SEQ ID NO: 13 disclosed in international application WO2020102645, or a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity thereto.
[0303] In some embodiments, the intron sequence is a HBB2 intron sequence, such as but not limited to the intron sequence of SEQ ID NO: 14 disclosed in international application WO2020102645, or a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity thereto.
[0304] In some embodiments of the methods and compositions disclosed herein, the recombinant AAV vector comprises a heterologous nucleic acid sequence, further comprising an intron sequence located 5' of the sequence encoding the secretory signal peptide and 3' of the promoter. In some embodiments, the intron sequence comprises an MVM sequence or an HBB2 sequence, wherein the MVM sequence comprises the nucleic acid sequence of SEQ ID NO: 13 disclosed in International Application WO2020102645, or a nucleic acid sequence having at least about 75%, or 80%, or 85%, or 90%, or 95%, or 98%, or 99% sequence identity to SEQ ID NO: 13, and the HBB2 sequence comprises the nucleic acid sequence of SEQ ID NO: 14 disclosed in International Application WO 2020102645, or a nucleic acid sequence having at least about 75%, or 80%, or 85%, or 90%, or 95%, or 98%, or 99% sequence identity to SEQ ID NO: 14.
[0305] In some embodiments, the rAAV genotype comprises an intron sequence selected from the group consisting of: human beta globin b2 (or HBB2) intron, FIX intron, chicken beta-globin intron, and SV40 intron. In some embodiments, the intron is optionally a modified intron, such as a modified HBB2 intron (see, e.g., SEQ ID NO: 17 of WO2018046774A1), a modified FIX intron (see, e.g., SEQ ID NO: 19 in WO2018046774A1), or a modified chicken beta-globin intron (see, e.g., SEQ ID NO: 21 in WO2018046774A1), or a modified HBB2 or FIX intron disclosed in WO2015 / 162302, which are incorporated herein by reference in their entirety. G.Poly-A
[0306] In some embodiments, the rAAV vector genome comprises at least one poly-A tail, which is located downstream and 3' of the heterologous nucleic acid gene encoding the GAA polypeptide. In some embodiments, the polyA signal is the 3' end of the stability sequence or CS sequence as defined herein. Any polyA sequence can be used, including but not limited to hGH polyA, synpA polyA, etc. In some embodiments, polyA is a synthetic polyA sequence. In some embodiments, the rAAV vector genome comprises two polyA tails, such as an hGH polyA sequence and another polyA sequence, wherein the spacer nucleic acid sequence is located between the two polyA sequences. In some embodiments, the rAAV genome comprises the following elements at 3' of the nucleic acid encoding the GAA polypeptide, or at 3' of the CS sequence: a first polyA sequence, a spacer nucleic acid sequence (between 100-400bp, or about 250bp), a second poly A sequence, a spacer nucleic acid sequence, and a 3'ITR. In some embodiments, the first and second poly A sequences are hGH poly A sequences, and in some embodiments, the first and second poly A sequences are synthetic poly A sequences. In some embodiments, the first poly A sequence is a hGH poly A sequence and the second poly A sequence is a synthetic sequence, or vice versa - that is, in alternative embodiments, the first poly A sequence is a synthetic poly A sequence and the second poly A sequence is a hGH poly A sequence. An exemplary poly A sequence is, for example, SEQ ID NO: 15 (hGH poly A sequence) disclosed in International Application WO2021102107, or a poly A nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity to SEQ ID NO: 15 disclosed in International Application WO2021102107. In some embodiments, the hGH poly sequence contemplated for use is described in Anderson et al., J. Biol. Chem 264 (14); 8222-8229, 1989 (see, e.g., page 8223, second column, first paragraph), which is incorporated herein by reference in its entirety. In one embodiment, the recombinant AAV disclosed herein comprises a transcription terminator signal sequence or a transcription pause signal sequence in the reverse direction between poly A and 3'ITR in its genome. In one embodiment, the recombinant AAV disclosed herein comprises a transcription terminator signal sequence or a transcription pause signal sequence in the 3'-5' direction between poly A and 3'ITR in its genome.
[0307] In some embodiments, the poly-A tail can be engineered to stabilize RNA transcripts transcribed from the rAAV vector genome, including transcripts of heterologous genes, which in one embodiment are GAA; and in alternative embodiments, the poly-A tail can be engineered to contain a destabilizing element.
[0308] In some embodiments of the methods for treating Pompe disease disclosed herein, the recombinant AAV vector comprises at least one polyA sequence located 3' and 5' of the 3'ITR sequence of the nucleic acid encoding the GAA gene. In some embodiments, poly A is a full-length poly A (fl-poly A) sequence. In some embodiments, poly A is a truncated polyA sequence, as disclosed in International Application WO2021102107, which is incorporated herein in its entirety.
[0309] In one embodiment, the poly-A tail can be engineered into a destabilizing element by changing the length of the poly-A tail. In one embodiment, the poly-A tail can be lengthened or shortened. In some embodiments, the 3' untranslated region comprises a GAA 3'UTR (SEQ ID NO: 85) or a 3'UTR (SEQ ID NO: 77) as disclosed in International Application WO2021102107 (incorporated herein in its entirety by reference).
[0310] In another embodiment, the destabilizing element is a microRNA (miRNA) that is capable of silencing (inhibiting translation and promoting degradation) RNA transcripts encoding heterologous genes to which the miRNA binds. In embodiments, the addition or deletion of a seed region within the poly-A tail can increase or decrease the expression of a protein, such as a GAA protein or a modified GAA polypeptide.
[0311] In another embodiment, the seed region can also be engineered into the 3' untranslated region between the heterologous gene and the poly-A tail. In a further embodiment, the destabilizing agent can be siRNA. The coding region of the siRNA can be included in the rAAV vector genome and is generally located downstream, 3' of the poly-A tail.
[0312] In all aspects of the methods for treating Pompe disease disclosed herein, the rAAV genome may further comprise a stuffer DNA nucleic acid sequence. An exemplary stuffer DNA sequence is SEQ ID NO: 71 disclosed in International Application WO2021102107, or a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% nucleotide sequence identity thereto. In some embodiments, the stuffer sequence is located, for example, at 3' of the poly A tail and at 5' of the '3ITR sequence. In some embodiments, the stuffer DNA sequence comprises a synthetic polyadenylation signal in the reverse direction.
[0313] In some embodiments, the stuffing region nucleic acid sequence (also referred to as a "spacer" nucleic acid fragment) can be located between the poly A sequence and the 3' ITR (i.e., the stuffing region nucleic acid sequence is located 3' to the poly A sequence and 5' to the 3' ITR) (see, e.g., FIG. 7- Figure 8 ). Such a stuffing region nucleic acid sequence may be about 30 bp, 50 bp, 75 bp, 100 bp, 150 bp, 200 bp, 250 bp, 300 bp or longer than 300 bp. In some embodiments of the methods and compositions disclosed herein, the stuffing region nucleic acid fragment is between 20-50 bp, 50-100 bp, 100-200 bp, 200-300 bp, 300-500 bp, or any integer between 20-500 bp. An exemplary filling region (or spacer) nucleic acid sequence can be selected from any of the following: SEQ ID NO: 16, SEQ ID NO: 71 or SEQ ID NO: 78 disclosed in international application WO2021102107, or a nucleic acid sequence that is at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 16, SEQ ID NO: 71 or SEQ ID NO: 78 disclosed in international application WO2021102107. H.AAV ITR
[0314] The rAAV vectors or genomes disclosed herein for use in methods of treating Pompe disease can comprise AAV ITRs having desired characteristics and can be designed to modulate the activity of and cellular responses to vectors incorporating the ITRs. In another embodiment, the AAV ITRs are synthetic AAV ITRs having desired characteristics and can be designed to manipulate the activity of and cellular responses to vectors comprising one or two synthetic ITRs, including as set forth in U.S. Pat. No. 9,447,433, which is incorporated herein by reference.
[0315] In some embodiments, the 5'ITR of the AAV-GAA vector of the compositions and methods described herein has the nucleotide sequence TGGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT (SEQ ID NO: 601). In some embodiments, the 3'ITR of the AAV-GAA vector of the compositions and methods described herein has the nucleotide sequence AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCG A GCGCGC A G A G A GGGAC A G AT CCG (SEQ ID NO: 602).
[0316] In another embodiment, the ITR exhibits modified transcriptional activity relative to a naturally occurring ITR (e.g., ITR2 from AAV2). It is known that the ITR2 sequence inherently has promoter activity. It also inherently has termination activity similar to a poly (A) sequence. Although at a reduced level relative to ITR2, the minimal functional ITR of the present invention exhibits transcriptional activity as shown in the examples. Therefore, in some embodiments, the ITR has a transcriptional function. In other embodiments, the ITR is defective for transcription. In certain embodiments, the ITR can act as a transcription insulator, for example, to prevent transcription of a transgenic box present in the vector when the vector is integrated into a host chromosome.
[0317] One aspect of the invention relates to a rAAV vector genome comprising at least one synthetic AAV ITR, wherein the nucleotide sequence of one or more transcription factor binding sites in the ITR is deleted and / or replaced relative to the sequence of a naturally occurring AAV ITR (e.g., ITR2). In some embodiments, one or more transcription factor binding sites are deleted and / or replaced with a minimal functional ITR. In some embodiments, at least one transcription factor binding site is deleted and / or replaced, for example, at least 5 or more or 10 or more transcription factor binding sites, for example, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 transcription factor binding sites.
[0318] In another embodiment, the rAAV vector comprising the rAAV vector genome described herein comprises a polynucleotide comprising at least one synthetic AAV ITR, wherein one or more CpG islands (cytosine bases are immediately followed by guanine bases (CpG), wherein the cytosines arranged in this way tend to be methylated) that are usually present at or near the transcription start site in the ITR are deleted and / or replaced. In an embodiment, the absence or reduction in the number of CpG islands can reduce the immunogenicity of the rAAV vector. This is due to the reduction or complete inhibition of TLR-9 binding to rAAV vector DNA sequences (occurring at CpG islands). It is also well known that methylation of CpG motifs leads to transcriptional silencing. It is expected that the removal of CpG motifs in ITRs will lead to a reduction in TLR-9 recognition and / or a reduction in methylation, and thus a reduction in transgene silencing. In some embodiments, the one or more CpG islands that are deleted and / or replaced are minimal functional ITRs. In an embodiment, it is known that AAV ITR2 contains 16 CpG islands, one or more or all 16 of which can be deleted.
[0319] In some embodiments, at least 1 CpG motif is deleted and / or replaced, such as at least 4 or more or 8 or more CpG motifs, such as at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 CpG motifs.
[0320] In another embodiment, the synthetic ITR comprises, consists essentially of, or consists of one of the nucleotide sequences listed in Table 7. In other embodiments, the synthetic ITR comprises, consists essentially of, or consists of a nucleotide sequence that is at least 80% identical (e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical) to any of the nucleotide sequences listed in Table 7. In some embodiments, the ITR is Samulski et al., 1983, Cell, 33; 135-143 (referred to as "Samulski et al., 1983", which is incorporated herein by reference in its entirety). Figure 1 The sequence disclosed in Figure 1 In some embodiments, the ITR sequence comprises or consists of the following nucleotide sequence: the nucleotide sequence is the same as that disclosed in Samulski et al., 1983 Figure 1 The ITR sequence is at least 80% identical, such as at least 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to one of the ITR sequences in Samulski et al., 1983. Figure 1 In some embodiments, the ITR sequence of pSM 609right disclosed in the middle subgraph of (lacking 9 bp) is at least 80% identical, such as at least 85%, 90%, 95%, 96%, 97%, 98% or 99% or 99.5% identical. In some embodiments, the ITR sequence comprises or consists of a nucleotide sequence that is at least 80% identical, such as at least 85%, 90%, 95%, 96%, 97%, 98% or 99% or 99.5% identical to the ITR sequence of any one of SEQ ID NO: 446 to SEQ ID NO: 449.
[0321] In some embodiments, the ITR sequence, such as the right ITR (or 3' ITR), is SEQ ID NO: 442 or a nucleotide sequence that is at least 80% identical, such as at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% identical to SEQ ID NO: 442. In some embodiments, the ITR sequence, such as the left ITR (or 5' ITR), is SEQ ID NO: 446 or a nucleotide sequence that is at least 80% identical, such as at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% identical to SEQ ID NO: 446.
[0322] Table 7: Exemplary synthetic ITR sequences IV. Vectors and Viruses
[0323] In one embodiment, the rAAV vector disclosed herein (also referred to as rAAV virion) comprises a capsid protein and an rAAV genome in the capsid protein. The rAAV capsid of the rAAV virion for treating Pompe disease is any one listed in Table 1 disclosed in USSN 62 / 937,556 (PCT / US2020 / 061223; WO 2021 / 102107) filed on November 19, 2019 (incorporated herein in its entirety by reference), or any combination thereof.
[0324] In one embodiment, the rAAV capsid of the rAAV virion for treating Pompe disease is any one listed in Table 1 disclosed in International Applications WO2020 / 102645 and WO2020 / 102667 (each of which is incorporated herein by reference in its entirety). In one embodiment, the rAAV capsid of the rAAV virion for treating Pompe disease is an AAV8 capsid. In one embodiment, the rAAV vector is a rAAV8 vector.
[0325] In one embodiment, the AAV vector disclosed herein (also referred to as rAAV virion) comprises a capsid protein from any one disclosed in WO2019 / 241324 (incorporated herein in its entirety by reference). In some embodiments, the rAAV vector comprises a liver-specific capsid, for example, a liver-specific capsid selected from XL32 and XL32.1 disclosed in WO2019 / 241324 (incorporated herein in its entirety by reference). In some embodiments, the rAAV vector is AAVXL32 or AAVXL32.1 disclosed in WO2019 / 241324 (incorporated herein in its entirety by reference).
[0326] Exemplary chimeric or variant capsid proteins that can be used as AAV capsids in the rAAV vectors described herein can be selected from Table 2 of U.S. Provisional Application 62,937,556, filed on November 19, 2019 (expressly incorporated herein by reference), or can be used in any combination with wild-type capsid proteins and / or other chimeric or variant capsid proteins now known or later identified, and each is incorporated herein. In some embodiments, the rAAV vectors encompassed for use are chimeric vectors, for example, as disclosed in 9,012,224 and US 7,892,809, which are incorporated herein by reference in their entirety.
[0327] In some embodiments, the rAAV vector is a haploid rAAV vector (as disclosed in U.S. applications US2018 / 0371496 and PCT / US18 / 22725), or a polyploid rAAV vector (e.g., as disclosed in PCT / US2018 / 044632 filed on July 31, 2018 and in U.S. application Ser. No. 16 / 151,110), each of which is incorporated herein by reference in its entirety. In some embodiments, the rAAV vector is a rAAV3 vector, as disclosed in 9,012,224 and WO 2017 / 106236, which are incorporated herein by reference in their entirety.
[0328] In a specific embodiment, rAAV is AAVXL32 or AAVXL32.1 AAV vector, as disclosed in WO2019 / 241324, which is incorporated herein by reference in its entirety. In some embodiments, the rAAV vector comprises a capsid disclosed in WO2019241324A1 or international patent application PCT / US2019 / 036676, which is incorporated herein by reference in its entirety. In some embodiments, the AAV vector is an AAV8 vector or a rationalized haploid comprising an AAV8 capsid protein. In some embodiments, the recombinant AAV vector is a chimeric AAV vector, a haploid AAV vector, a hybrid AAV vector, or a polyploid AAV vector. In some embodiments, the recombinant AAV vector is an AAV vector from any AAV serotype, such as an AAV vector from any AAV serotype disclosed in Table 1 disclosed in International Applications WO2020 / 102645 and WO2020 / 102667 (each incorporated herein in its entirety), a rationalized haploid vector, a mosaic AAV vector, or a chemically modified AAV vector.
[0329] In one embodiment, as disclosed herein, the rAAV vector that can be used to treat Pompe disease is an AAV3b capsid. The AAV3b capsids covered for use are described in 2017 / 106236, and 9,012,224 and 7,892,809 and international applications PCT / US19 / 61653 filed on November 15, 2019, and international applications WO2020 / 102645 and WO2020 / 102667, each of which is incorporated herein in its entirety. In addition, the AAV3b capsids of the AAV vectors used according to the methods disclosed herein are disclosed in international patent applications WO 2020 / 102645 and WO2021102107 (incorporated herein in their entirety by reference).
[0330] In some embodiments, the AAV3b capsid comprises SEQ ID NO: 44 disclosed in International Patent Applications WO 2020 / 102645 and WO2021102107. In embodiments, the AAV capsid used in the treatment of Pompe disease may be a modified AAV capsid derived in whole or in part from the AAV capsid shown in SEQ ID NO: 44. In some embodiments, the amino acids from the AAV3b capsid shown in SEQ ID NO: 44 may be amino acids from another capsid of a different AAV serotype, or replaced by amino acids from another capsid of a different AAV serotype, wherein the replaced and / or inserted amino acids may be from any AAV serotype and may include naturally occurring amino acids or partially or completely synthetic amino acids.
[0331] In another embodiment, the AAV capsid used in the treatment of Pompe disease is an AAV3b265D capsid. In this particular embodiment, the AAV3b265D capsid comprises a modification in the amino acid sequence of the two-fold axis loop of the AAV3b capsid by replacing the amino acid G265 of the AAV3b capsid with D265. In some embodiments, the AAV3b265D capsid includes SEQ ID NO: 46. However, the modified viral capsid of the present invention is not limited to the AAV capsid shown in SEQ ID NO: 46 shown in international patent applications WO 2020 / 102645 and WO2021102107. In some embodiments, the amino acids from AAV3b265D shown in SEQ ID NO: 46 can be amino acids from the capsids of AAVs of different serotypes, or replaced by amino acids from the capsids of AAVs of different serotypes, wherein the replaced and / or inserted amino acids can be from any AAV serotype and can include naturally occurring amino acids or partially or completely synthesized amino acids.
[0332] In another embodiment, the rAAV vector useful in the treatment of Pompe disease as disclosed herein is an AAV3b265D549A capsid. In this particular embodiment, the AAV3b265D549A capsid comprises a modification in the amino acid sequence of the double-column of the AAV3b capsid by replacing the amino acid G265 of the AAV3b capsid with D265 and replacing the amino acid T549 of the AAV3b capsid with A549. In some embodiments, the AAV3b265D549A capsid includes SEQ ID NO: 50. However, the modified viral capsids of the present invention are not limited to the AAV capsids shown in SEQ ID NO: 50 disclosed in international patent applications WO 2020 / 102645 and WO2021102107. In some embodiments, the amino acids from AAV3b265D549A shown in SEQ ID NO: 50 can be amino acids from the capsid of AAV of different serotypes, or replaced by amino acids from the capsid of AAV of different serotypes, wherein the replaced and / or inserted amino acids can be from any AAV serotype and can include naturally occurring amino acids or partially or completely synthetic amino acids. In some embodiments, the amino acids from AAV3bSASTG (i.e., an AAV3b capsid comprising Q263A / T265 mutations) can be amino acids from the capsid of AAV of different serotypes, or replaced by amino acids from the capsid of AAV of different serotypes, wherein the replaced and / or inserted amino acids can be from any AAV serotype and can include naturally occurring amino acids or partially or completely synthetic amino acids.
[0333] In another embodiment, the rAAV vector useful in the treatment of Pompe disease as disclosed herein is an AAV3b549A capsid. In this particular embodiment, the AAV3b549A capsid comprises a modification in the amino acid sequence of the double-column loop of the AAV3b capsid by replacing the amino acid T549 of the AAV3b capsid with A549. In some embodiments, the AAV3b549A capsid comprises SEQ ID NO: 52 disclosed in international patent applications WO 2020 / 102645 and WO2021102107. However, the modified viral capsid of the present invention is not limited to the AAV capsid shown in SEQ ID NO: 52. In some embodiments, the amino acids from AAV3b549A shown in SEQ ID NO: 52 can be amino acids from capsids of AAVs of different serotypes, or replaced by amino acids from capsids of AAVs of different serotypes, wherein the replaced and / or inserted amino acids can be from any AAV serotype and can include naturally occurring amino acids or partially or completely synthesized amino acids.
[0334] In another embodiment, the rAAV vector useful in the treatment of Pompe disease as disclosed herein is an AAV3bQ263Y capsid. In this particular embodiment, the AAV3bQ263Y capsid comprises a modification in the amino acid sequence of the double-column loop of the AAV3b capsid by replacing the amino acid Q263 of the AAV3b capsid with Y263. In some embodiments, the AAV3b549A capsid comprises SEQ ID NO: 54 disclosed in international patent applications WO 2020 / 102645 and WO2021102107. However, the modified viral capsids of the present invention are not limited to the AAV capsids shown in SEQ ID NO: 54. In some embodiments, the amino acids from AAV3bQ263Y shown in SEQ ID NO: 54 can be amino acids from the capsid of an AAV of a different serotype, or be replaced by amino acids from the capsid of an AAV of a different serotype, wherein the replaced and / or inserted amino acids can be from any AAV serotype and can include naturally occurring amino acids or partially or completely synthetic amino acids.
[0335] In another embodiment, the rAAV vector useful in the treatment of Pompe disease as disclosed herein is of the AAV3bSASTG serotype or comprises an AAV3bSASTG capsid. In this particular embodiment, the AAV3b SASTG capsid comprises modifications in the amino acid sequence to comprise a SASTG mutation, in particular by introducing these modifications at similar positions in the AAV3b capsid, the AAV3b capsid is modified to be similar to the AAV2 Q263A / T265 subtype (as disclosed in Messina EL et al., Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. Hum. Gene Ther. 2012 Oct: 23(10): 1031-4; Piacentino III, Valentino et al., "X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector." Human gene therapy 23.6(2012): 635-646, both of which are incorporated herein by reference in their entirety). Thus, in some embodiments, the rAAV vector useful in the treatment of Pompe disease as disclosed herein is an AAV3bSASTG serotype or comprises an AAV3bSASTG capsid comprising an AAV3b Q263A / T265 capsid. In some embodiments, the amino acids from AAV3bSASTG can be amino acids from a capsid of an AAV of a different serotype, or replaced by amino acids from a capsid of an AAV of a different serotype, wherein the replaced and / or inserted amino acids can be from any AAV serotype and can include naturally occurring amino acids or partially or completely synthetic amino acids.
[0336] To facilitate its introduction into cells, the rAAV vector genome useful in the present invention is a recombinant nucleic acid construct comprising: (1) a heterologous sequence to be expressed (in one embodiment, a polynucleotide encoding a GAA polypeptide), and (2) a viral sequence element that promotes the integration and expression of the heterologous gene. The viral sequence element may include those sequences of the cis-AAV vector genome required for DNA replication and packaging of the DNA (e.g., functional ITRs) into the AAV capsid. In one embodiment, the heterologous gene encodes GAA, which is useful for correcting GAA deficiency in patients with Pompe disease. In an embodiment, such rAAV vector genomes may also include a marker or reporter gene. In an embodiment, the rAAV vector genome may have one or more AAV3b wild-type (WT) cis genes that are replaced or deleted in whole or in part, but retain functional flanking ITR sequences. V. Optimized rAAV Vector Genome
[0337] In some embodiments of the methods and compositions disclosed herein, an optimized rAAV vector genome is created from any of the elements disclosed herein and in any combination, including: nucleic acid sequences encoding promoters, ITRs, poly-A tails, elements capable of increasing or decreasing heterologous gene expression, and in one embodiment, nucleic acid sequences codon-optimized for in vivo expression of GAA protein (i.e., coGAA or codon-optimized GAA), and optionally one or more elements to reduce immunogenicity. Such optimized rAAV vector genomes can be used with any AAV capsid that is tropistic for the tissues and cells in which the rAAV vector genome is to be transduced and expressed.
[0338] In some embodiments, the rAAV genome lacks the AAV P5 promoter or a fragment thereof that is typically located upstream of the liver-specific promoter disclosed herein. Typically, the P5 promoter controls the expression of the AAV rep / cap protein during AAV replication. In some embodiments, this P5 promoter fragment is present in the rAAV vector disclosed herein, which contains predicted transcription factor binding sites, such as cyclic AMP response element binding protein 3 (CREB3), which can be activated by endoplasmic reticulum (ER) / Golgi stress (Sampieri 2019); activating transcription factor 2 (ATF2), which is also involved in stress response (Watson 2017); nuclear receptor subfamily 1 group I member 2 (NR1I2) (also known as pregnane X receptor [PXR]) is known to be enriched in the liver and activated by pregnane steroids, rifampicin and other molecules including dexamethasone (NR1I2_HGNC) (Xing 2020). Therefore, in some embodiments, a fragment of the AAV P5 promoter in the rAAV genome is removed without affecting the expected performance of the GAA box. In some embodiments, the rAAV vector further comprises an RNA polymerase II termination sequence located between the polyA signal and the 3'ITR. An exemplary terminal sequence is SEQ ID NO: 450, which introduces two stop codons and a restriction site (e.g., XhoI) instead of TAG and is located immediately downstream of the last encoded amino acid of hGAA and immediately upstream of the 3'UTR. VI. Definitions
[0339] The following terms are used in this specification and the appended claims:
[0340] Unless otherwise specified herein or clearly contradictory to the context, the terms "a / an", "the", and similar references used in the context of describing the present invention (particularly in the context of the following claims) should be interpreted as covering both the singular and the plural. In addition, unless otherwise specifically stated, the sequential indicators (such as "first", "second", "third", etc.) used to identify elements are used to distinguish elements without indicating or implying the required or limited number of such elements, and without indicating the specific position or order of such elements. Unless otherwise specified herein or clearly contradictory to the context, all methods described herein can be implemented in any suitable order. The use of any and all examples or exemplary language (such as "such as") provided herein is intended only to better illustrate the present invention, without limiting the scope of the present invention otherwise claimed. Any language in this specification should not be interpreted as indicating any unclaimed elements essential to the implementation of the present invention.
[0341] In addition, the term "about" as used herein, when referring to a measurable value of an amount such as the length of a polynucleotide or polypeptide sequence, dosage, time, temperature, and the like, is intended to encompass variations of ±20%, ±10%, ±5%, ±1%, ±0.5% or even ±0.1% of the indicated amount.
[0342] Also as used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as refers to and encompasses the lack of a combination when interpreted in the alternative ("or").
[0343] As used herein, the transitional phrase "consisting essentially of" means that the scope of the claim will be interpreted to cover the specified materials or steps described in the claim, as well as "those materials or steps which do not materially affect the basic and novel characteristics of the claimed invention." See In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (emphasis in the original); see also MPEP §2111.03. Therefore, when used in the claims of the present invention, the term "consisting essentially of" is not intended to be interpreted as equivalent to "comprising." Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination.
[0344] When expressing a mathematical quantity, the use of an E followed directly by a number should be interpreted as if the number following the E were a superscript. For example, 5E11 is intended to represent the same as 5E 11 Same amount.
[0345] Furthermore, the present invention also contemplates that in some embodiments of the present invention, any feature or combination of features described herein may be excluded or omitted.
[0346] To further illustrate, for example, if the specification indicates that a particular amino acid can be selected from A, G, I, L, and / or V, the language also indicates that the amino acid can be selected from any subset of these amino acids: e.g., A, G, I, or L; A, G, I, or V; A or G; only L; etc., as if each such subcombination is expressly set forth herein. In addition, such language also indicates that one or more of the specified amino acids can be disclaimed (e.g., by a negative proviso). For example, in a specific embodiment, the amino acid is not A, G, or I; is not A; is not G or V; etc., as if each such possible disclaimer is expressly set forth herein.
[0347] As used herein, the term "parvovirus" encompasses Parvoviridae, including autonomous replicating parvoviruses and dependent viruses. Autonomous parvoviruses include members of the genus Parvovirus, the genus Erythrovirus, the genus Densovirus, the genus Iteravirus, and the genus Contravirus. Exemplary autonomous parvoviruses include, but are not limited to, minute viruses of mice, bovine parvovirus, canine parvovirus, chicken parvovirus, feline panleukopenia virus, feline parvovirus, goose parvovirus, H1 parvovirus, duck parvovirus, B19 virus, and any other autonomous parvovirus currently known or found in the future. Other autonomous parvoviruses are known to those skilled in the art. See, for example, BERNARD N.FIELDS et al., VIROLOGY, Vol. 2, Chapter 69 (4th Edition, Lippincott-Raven Publishers).
[0348] As used herein, the term "adeno-associated virus" (AAV) includes, but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including type 3A and type 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, and any other AAV currently known or later discovered. See, e.g., BERNARD N. FIELDS et al., VIROLOGY, Vol. 2, Chapter 69 (4th ed., Lippincott-Raven Publishers). Many relatively new AAV serotypes and evolutionary branches have been identified (see, for example, Gao et al., (2004) J. Virology 78:6381-6388; Moris et al., (2004) Virology 33:375-383; and Table 1 disclosed in U.S. Provisional Application No. 62,937,556 filed on November 19, 2019, and Table 1 in International Applications WO2020 / 102645 and WO2020 / 102667, each of which is incorporated herein in its entirety).
[0349] The genomic sequences of various serotypes of autonomous parvovirus and AAV, as well as the sequences of natural inverted terminal repeats (ITRs), Rep proteins and capsid subunits are known in the art. Such sequences can be found in the literature or public databases such as GenBank. See, for example, GenBank accession numbers NC_002077, NC_001401, NC_001729, NC_001863, NC_001829, NC_001862, NC_000883, NC_001701, NC_001510, NC_006152, NC_006261, AF063497, U89790, AF043303, AF028705 , AF028704, J02275, J01901, J02275, X01457, AF288061, AH009962, AY028226, AY028223, NC_001358, NC_001540, AF513851, AF513852, AY530579; the disclosures of which are incorporated herein by reference for teaching parvovirus and AAV nucleic acid and amino acid sequences. See also, e.g., Srivistava et al., (1983) J Virology 45:555; Chiarini et al., (1998) J. Virology 71:6823; Chiarini et al., (1999) J. Virology 73:1309; Bantel-Schaal et al., (1999) J. Virology 73:939; Xiao et al., (1999) J. Virology 73:3994; Muramatsu et al., (1996) Virology 221:208; Shade et al., (1986) J. Viral. 58:921; Gao et al., (2002) Proc. Nat. Acad. Sci. USA 99:11854; Morris et al., (2004) Virology 33:375-383; International Patent Publication No. WO 00 / 28061, WO 99 / 61601, WO 98 / 11244; and U.S. Patent No. 6,156,303; the disclosures of which are incorporated herein by reference for teaching parvovirus and AAV nucleic acid and amino acid sequences. See also Tables 1 and 5 disclosed in 62,937,556 filed on November 19, 2019, or Table 1 disclosed in International Applications WO2020 / 102645 and WO2020 / 102667, each of which is incorporated herein in its entirety.The capsid structures of the autonomous parvoviruses and AAV are described in more detail in BERNARD N. FIELDS et al., VIROLOGY, Vol. 2, Chapters 69 & 70 (4th edition, Lippincott-Raven Publishers). See also the description of the crystal structures of AAV2 (Xie et al., (2002) Proc. Nat. Acad. Sci. 99: 10405-10), AAV4 (Padron et al., (2005) J. Viral. 79: 5047-58), AAV5 (Walters et al., (2004) J. Viral. 78: 3361-71), and CPV (Xie et al., (1996) J. Mal. Biol. 6: 497-520 and Tsao et al., (1991) Science 251: 1456-64).
[0350] As used herein, the term "tropism" refers to the preferential entry of a virus into certain cells or tissues and the subsequent expression (e.g., transcription and optionally translation) of sequences carried by the viral genome in the cells, e.g., for a recombinant virus, expression of a heterologous nucleic acid of interest.
[0351] As used herein, "systemic tropism" and "systemic transduction" (and equivalent terms) indicate that the viral capsid or viral vector of the invention exhibits tropism for and / or transduces tissues throughout the body (e.g., brain, lung, skeletal muscle, heart, liver, kidney and / or pancreas).
[0352] As used herein, "selective tropism" or "specific tropism" refers to the delivery of a viral vector to certain target cells and / or certain tissues, and / or the specific transduction of certain target cells and / or certain tissues.
[0353] Unless otherwise indicated, "efficient transduction" or "efficient tropism" or similar terms may be determined by reference to an appropriate control (e.g., at least about 50%, 60%, 70%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350%, 400%, 500% or more of the transduction or tropism, respectively, of the control). In a specific embodiment, the viral vector efficiently transduces hepatocytes and muscle cells, or has an efficient tropism for hepatocytes and muscle cells. Appropriate controls will depend on a variety of factors, including the desired tropism and / or transduction characteristics.
[0354] Similarly, by reference to appropriate controls, it can be determined whether a virus "does not efficiently transduce" or "does not have an effective tropism" or similar terms for a target tissue. In specific embodiments, the viral vector does not efficiently transduce (i.e., does not have an effective tropism) for kidney, gonads, and / or germ cells. In specific embodiments, the transduction (e.g., undesired transduction) of a tissue (e.g., kidney) is less than 20%, less than 10%, less than 5%, less than 1%, less than 0.1% of the transduction level of a desired target tissue (e.g., liver, skeletal muscle, diaphragm, myocardium, and / or cells of the central nervous system).
[0355] Unless otherwise indicated, the term "polypeptide" as used herein encompasses peptides and proteins.
[0356] A "polynucleotide" is a sequence of nucleotide bases, and may be RNA, DNA, or a DNA-RNA hybrid sequence (including both naturally occurring and non-naturally occurring nucleotides), but in representative embodiments is a single-stranded or double-stranded DNA sequence.
[0357] The terms "heterologous nucleotide sequence" and "heterologous nucleic acid molecule" are used interchangeably herein and refer to a non-naturally occurring nucleic acid sequence in a virus. Typically, a heterologous nucleic acid molecule or heterologous nucleotide sequence comprises an open reading frame encoding a polypeptide of interest and / or a non-translated RNA (e.g., for delivery to a cell and / or a subject).
[0358] "Chimeric nucleic acid" comprises two or more nucleic acid sequences covalently linked together to encode a fusion polypeptide. The nucleic acid can be DNA, RNA or a hybrid thereof.
[0359] The term "fusion polypeptide" includes two or more polypeptides covalently linked together, usually by peptide bonds.
[0360] As used herein, an "isolated" polynucleotide (e.g., "isolated DNA" or "isolated RNA") refers to a polynucleotide that is at least partially separated from at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the polynucleotide is normally found. In representative embodiments, the "isolated" nucleotide is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more, compared to the starting material.
[0361] Likewise, an "isolated" polypeptide refers to a polypeptide that is at least partially separated from at least some other components of a naturally occurring organism or virus, such as cellular or viral structural components or other polypeptides or nucleic acids with which the polypeptide is normally found. In representative embodiments, the "isolated" polypeptide is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more, compared to the starting material.
[0362] "Isolated cells" refer to cells that are separated from other components, with which they are typically associated in their native state. For example, isolated cells can be cells in culture medium and / or cells in a pharmaceutically acceptable excipient of the present invention. Thus, isolated cells can be delivered to and / or introduced into a subject. In some embodiments, isolated cells can be cells removed from a subject and returned to a subject after ex vivo manipulation as described herein.
[0363] The virion population can be generated by any of the methods described herein. In one embodiment, the population is at least 10 1 In one embodiment, the population is at least 10 2 Viruses, at least 10 3 Viruses, at least 10 4 Viruses, at least 10 5 Viruses, at least 10 6 Viruses, at least 10 7 Viruses, at least 10 8 Viruses, at least 10 9 Viruses, at least 10 10 Viruses, at least 10 11 Viruses, at least 10 12 Viruses, at least 10 13 Viruses, at least 10 14 Viruses, at least 10 15 Viruses, at least 10 16 Viruses or at least 10 17 A population of virions can be heterogeneous or can be homogeneous (e.g., substantially homogeneous or completely homogeneous).
[0364] As used herein, the term "substantially homogeneous population" refers to a population of mostly identical virions with little or no contaminating virions (non-identical virions). A substantially homogeneous population is at least 90% identical virions (e.g., desired virions), and may be at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% identical virions.
[0365] A population of completely homogeneous virions contains only identical virions.
[0366] As used herein, "isolating" or "purifying" (or grammatical equivalents) a viral vector or viral particle or viral particle population means that the viral vector or viral particle or viral particle population is at least partially separated from at least some other components in the starting material. In representative embodiments, the "isolated" or "purified" viral vector or viral particle or viral particle population is enriched at least about 10-fold, 100-fold, 1000-fold, 10,000-fold, or more compared to the starting material.
[0367] Unless otherwise indicated, "efficient transduction" or "efficient tropism" or similar terms can be determined by reference to an appropriate control (e.g., at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350%, 400%, 500% or more of the transduction or tropism, respectively, of the control). In a specific embodiment, the viral vector efficiently transduces or has an effective tropism for neuronal cells and cardiomyocytes. Appropriate controls will depend on a variety of factors, including the desired tropism and / or transduction profile.
[0368] "Therapeutic polypeptide" refers to a polypeptide that can alleviate, reduce, prevent, delay and / or stabilize symptoms caused by protein deficiency or deficiency in a cell or subject, and / or a polypeptide that otherwise confers a benefit to a subject, such as enzyme replacement to reduce or eliminate disease symptoms, or improvement in transplant survival or induction of an immune response.
[0369] The terms "heterologous nucleotide sequence" and "heterologous nucleic acid molecule" are used interchangeably herein and refer to a nucleic acid sequence that is not naturally present in a virus. Typically, a heterologous nucleic acid molecule or heterologous nucleotide sequence comprises an open reading frame encoding a polypeptide of interest and / or non-translated RNA (e.g., for delivery to a cell and / or a subject), such as a GAA polypeptide.
[0370] As used herein, the term "viral vector," "vector," or "gene delivery vector" refers to a virus (e.g., AAV) particle that functions as a nucleic acid delivery vehicle and contains a vector genome (e.g., viral DNA [vDNA]) packaged in a virion. Alternatively, in some cases, the term "vector" may be used to refer to a vector genome / vDNA alone.
[0371] "rAAV vector genome" or "rAAV genome" is an AAV genome (i.e., vDNA) comprising one or more heterologous nucleic acid sequences. The rAAV vector generally only requires the inverted terminal repeat sequence (TR) to be in cis to produce the virus. All other viral sequences are non-essential and can be provided in trans (Muzyczka, (1992) Curr. Topics Microbial. Immunol. 158: 97). Typically, the rAAV vector genome will retain only one or more TR sequences to maximize the size of the transgene that can be effectively packaged by the vector. Structural protein and non-structural protein coding sequences can be provided in trans (e.g., from a vector, such as a plasmid; or by stably integrating the sequence into a packaging cell). In an embodiment of the present invention, the rAAV vector genome comprises at least one ITR sequence (e.g., an AAV TR sequence), optionally two ITRs (e.g., two AAV TRs), which will generally be located at the 5' and 3' ends of the vector genome and flanked by heterologous nucleic acids, but not necessarily adjacent to them. TRs may be identical or different from each other.
[0372] The term "terminal repeat sequence" or "TR" includes any viral terminal repeat sequence and a synthetic sequence that forms a hairpin structure and acts as an inverted terminal repeat sequence (i.e., an ITR that mediates a desired function (e.g., replication, viral packaging, integration, and / or provirus rescue, etc.). The TR can be an AAV TR or a non-AAV TR. For example, a non-AAV TR sequence (e.g., a non-AAV TR sequence of other parvoviruses (e.g., canine parvovirus (CPV), parvovirus of mice (MVM), human parvovirus B-19)) or any other suitable viral sequence that can be used as a TR (e.g., an SV40 hairpin that serves as the origin of SV40 replication), which can be further modified by truncation, substitution, deletion, insertion, and / or addition. In addition, the TR can be partially or completely synthetic, such as the "double D sequence" described in U.S. Pat. No. 5,478,745 to Samulski et al.
[0373] "AAV terminal repeats" or "AAV TRs" (including "AAV inverted terminal repeats" or "AAV ITRs") can be from any AAV, including but not limited to serotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 or any other AAV currently known or later discovered. The AAV terminal repeats do not have to have native terminal repeat sequences (e.g., the native AAV TR or AAV ITR sequence can be altered by insertions, deletions, truncations and / or missense mutations), as long as the terminal repeats mediate the desired function (e.g., replication, viral packaging, integration and / or proviral rescue, etc.).
[0374] AAV proteins VP1, VP2, and VP3 are capsid proteins that interact together to form the icosahedral symmetric AAV capsid. VP1.5 is an AAV capsid protein described in U.S. Publication No. 2014 / 0037585.
[0375] The viral vectors of the present invention may also be "targeted" viral vectors (e.g., having a targeted tropism) and / or "hybrid" parvoviruses (i.e., wherein the viral TR and viral capsid are from different parvoviruses) as described in International Patent Publication WO 00 / 28004 and Chao et al., (2000) Molecular Therapy 2:619.
[0376] The viral vector of the present invention may further be a duplexed parvoviral particle as described in International Patent Publication WO 01 / 92551 (the disclosure of which is incorporated herein by reference in its entirety). Thus, in some embodiments, a double-stranded (duplexed) genome may be packaged into a viral capsid of the present invention.
[0377] Recombinant AAV vectors expressing human GAA can be produced by a triple transfection method using closed-end linear duplex DNA molecules lacking bacterial backbone sequences, for example, as described in PCT / US2021 / 013689 (published as WO / 2021 / 146591), which is incorporated herein by reference in its entirety.
[0378] In several embodiments of the invention, plasmid DNA is used as a starting material to produce rAAV comprising SEQ ID NO: 606 encoding hGAA (as shown in SEQ ID NO: 600). In some embodiments of the invention, closed-end linear duplex DNA is used as a starting material to produce rAAV comprising SEQ ID NO: 606 encoding hGAA (as shown in SEQ ID NO: 600).
[0379] Additionally, the viral capsid or genomic elements may contain other modifications, including insertions, deletions, and / or substitutions.
[0380] As used herein, "chimeric" capsid protein means an AAV capsid protein (e.g., any one or more of VP1, VP2, or VP3) modified by substitution of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) amino acid residues in the amino acid sequence of the capsid protein relative to the wild type, and insertion and / or deletion of one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) amino acid residues in the amino acid sequence relative to the wild type. In some embodiments, the complete or partial domains, functional regions, epitopes, etc. from one AAV serotype can replace the corresponding wild-type domains, functional regions, epitopes, etc. of different AAV serotypes in any combination to produce the chimeric capsid protein of the present invention. The production of chimeric capsid proteins can be carried out according to protocols well known in the art, and a large number of chimeric capsid proteins that can be included in the capsid of the present invention have been described in the literature and herein.
[0381] As used herein, the term "haploid AAV" shall refer to the AAV described in International Application WO2018 / 170310 or U.S. Application US2018 / 037149, which are incorporated herein by reference in their entirety. In some embodiments, the population of virions is a haploid AAV population, in which virion particles can be constructed, wherein at least one viral protein from the group consisting of AAV capsid proteins VP1, VP2, and VP3 is different from at least one other viral protein required to form virion particles capable of encapsulating the AAV genome. For each viral protein (VP1, VP2, and / or VP3) present, the protein is of the same type (e.g., all AAV2 VP1). In one case, at least one viral protein is a chimeric viral protein, and at least one of the other two viral proteins is not chimeric. In one embodiment, VP1 and VP2 are chimeric, and only VP3 is non-chimeric. For example, only viral particles containing VP1 / VP2 from chimeric AAV2 / 8 (N-terminus of AAV2 and C-terminus of AAV8) are paired with only VP3 from AAV2; or only chimeric VP1 / VP2 28m-2P3 (N-terminus from AAV8 and C-terminus from AAV2, without mutation of VP3 start codon) are paired with only VP3 from AAV2. In another embodiment, only VP3 is chimeric, while VP1 and VP2 are non-chimeric. In another embodiment, at least one viral protein is from a completely different serotype. For example, only chimeric VP1 / VP2 28m-2P3 is paired with only VP3 from AAV3. In another example, there is no chimerism.
[0382] The term "hybrid" AAV vector or parvovirus refers to an rAAV vector in which the viral TR or ITR and the viral capsid are from different parvoviruses. Hybrid vectors are described in International Patent Publication WO 00 / 28004 and Chao et al., (2000) Molecular Therapy 2: 619. For example, hybrid AAV vectors typically contain adenoviral 5' and 3' cis ITR sequences (i.e., adenoviral terminal repeats and PAC sequences) sufficient for adenoviral replication and packaging.
[0383] The term "polyploid AAV" refers to an AAV vector composed of capsids from two or more AAV serotypes, for example, and can utilize each serotype for more robust transduction without eliminating the tropism from the parental serotype in certain embodiments.
[0384] As used herein, the term "GAA" or "GAA polypeptide" encompasses mature (-76 or -67 kDa) GAA and precursor (e.g., -110 kDa) GAA, as well as modified (e.g., mutated or truncated by insertion, deletion and / or substitution) GAA proteins or fragments thereof that retain biological function (i.e., having at least one biological activity of a native GAA protein, e.g., being able to hydrolyze glycogen as defined above) and GAA variants (e.g., GAA II described by Kunita et al., (1997) Biochemica et Biophysica Acta 1362:269; GAA polymorphs and SNPs are described in Hirschhorn, R. and Reuser, AJ (2001) The Metabolic and Molecular Basis for Inherited Disease (Scriver, CR, Beaudet. AL, Sly, WS & Valle, D., eds.), pp. 3389-3419, McGraw-Hill, New York, see pages 3403-3405; each of which is incorporated herein by reference in its entirety). Any GAA coding sequence known in the art may be used, for example, see Figure 8 and Fig. 9The coding sequence of GAA is as follows; GenBank Accession No. NM_00152 and Hoefsloot et al., (1988) EMBO J. 7:1697 and Van Hove et al., (1996) Proc. Natl. Acad. Sci. USA 93:65 (human), GenBank Accession No. NM_008064 (mouse), and Kunita et al., (1997) Biochemica et Biophysics Acta 1362:269 (quail); the disclosures of which are incorporated herein by reference for their teachings of GAA coding and non-coding sequences. The terms "GAA" or "hGAA" or "rhGAA" are used interchangeably to refer to nucleic acids encoding human GAA or to human GAA polypeptides.
[0385] As used herein, the term "targeting peptide" is also referred to as a "targeting sequence" and is intended to refer to a peptide that targets a specific subcellular compartment (e.g., a mammalian lysosome). The targeting peptides contemplated for use herein are lysosomal targeting peptides that are independent of mannose-6-phosphate. An exemplary targeting sequence is an IGF2 targeting peptide disclosed herein.
[0386] The term "signal sequence" is used interchangeably herein with the term "secretion signal sequence" or "leader sequence" or "signal peptide" or variants thereof, and is intended to refer to an amino acid sequence that functions to enhance (as defined above) the secretion of an operably linked polypeptide (e.g., a GAA polypeptide) from a cell, as compared to the secretion level seen with the native polypeptide. As defined above, "enhanced" secretion means that the relative proportion of lysosomal polypeptides synthesized by the cell that are secreted by the cell is increased; the absolute amount of secreted protein need not also be increased. In a particular embodiment of the invention, substantially all (i.e., at least 95%, 97%, 98%, 99% or more) of the GAA polypeptide is secreted. However, it is not necessary that substantially all or even most of the GAA polypeptide is secreted, as long as the secretion level is increased compared to the native GAA polypeptide. Exemplary leader sequences include, but are not limited to, the intrinsic GAA signal sequence (also referred to as the homologous GAA leader sequence or the endogenous GAA signal sequence), the AAT sequence, IL2(1-3), the IL2 leader sequence (IL2wt), the modified IL2 leader sequence (IL2mut), fibronectin (FN1, also referred to as FBN), or the IgG leader sequence or a functional variant thereof, as disclosed herein.
[0387] As used herein, the term "amino acid" encompasses any naturally occurring amino acid, its modified form and synthetic amino acid. Naturally occurring left-handed (L-) amino acids are disclosed in Table 2 of U.S. Publication 2018 / 0371496, which is incorporated herein in its entirety. Alternatively, amino acids may be modified amino acid residues (non-limiting examples are shown in Table 4 of U.S. Publication 2018 / 0371496) and / or may be amino acids modified by post-translational modifications (e.g., acetylation, amidation, formylation, hydroxylation, methylation, phosphorylation or sulfation). In addition, non-naturally occurring amino acids may be "non-natural" amino acids, such as Wang et al., Annu Rev Biophys Biomol Struct. 35: 225-49 (2006). These non-natural amino acids can be advantageously used to chemically connect molecules of interest to AAV capsid proteins.
[0388] To further illustrate, for example, if the specification indicates that a particular amino acid can be selected from A, G, I, L, and / or V, the language also indicates that the amino acid can be selected from any subset of these amino acids: e.g., A, G, I, or L; A, G, I, or V; A or G; only L; etc., as if each such subcombination is expressly set forth herein. In addition, such language also indicates that one or more of the specified amino acids can be disclaimed (e.g., by a negative proviso). For example, in a specific embodiment, the amino acid is not A, G, or I; is not A; is not G or V; etc., as if each such possible disclaimer is expressly set forth herein.
[0389] As used herein, the phrase "promoter" refers to a DNA region generally located upstream of a nucleic acid sequence to be transcribed, which region is required for transcription to occur, i.e., initiates transcription. A promoter allows for proper activation or inhibition of transcription of a coding sequence under its control. A promoter generally comprises a specific sequence recognized and bound by a plurality of TFs. TF binds to the promoter sequence and causes the recruitment of RNA polymerase, which is an enzyme that synthesizes RNA from a gene coding region. Many promoters are known in the art.
[0390] As used herein, the term "synthetic promoter" relates to a promoter that does not occur in nature. Portions of a synthetic promoter may occur in nature (eg a minimal promoter), but a synthetic promoter as a complete entity does not occur in nature.
[0391] As used herein, a "minimal promoter" (also referred to as a "core promoter") refers to a short DNA fragment that is inactive or substantially inactive by itself, but can mediate transcription when combined with other transcriptional regulatory elements. Minimal promoter sequences can be derived from a variety of different sources, including prokaryotic and eukaryotic genes. Examples of minimal promoters are discussed above, and include the dopamine β-hydroxylase gene minimal promoter, the cytomegalovirus (CMV) immediate early gene minimal promoter (CMV-MP), and the herpes thymidine kinase minimal promoter (MinTK). Minimal promoters typically include a transcription start site (TSS) and elements directly upstream, a binding site for RNA polymerase II, and a general transcription factor binding site (usually a TATA box).
[0392] As used herein, "proximal promoter" refers to the minimal promoter plus the proximal sequence upstream of the gene, which often contains major regulatory elements. It usually extends about 250 base pairs upstream of the TSS and includes a specific TFBS. The proximal promoter can be a naturally occurring liver-specific proximal promoter. However, the proximal promoter can be a synthetic one.
[0393] A "functional variant" of a promoter or other nucleic acid sequence in the context of the present invention is a variant of a reference sequence that retains the ability to function in the same manner as the reference sequence (e.g., as a liver-specific promoter). Alternative terms for such functional variants include "bioequivalents" or "equivalents."
[0394] When referring to a promoter, the term "liver-specific" or "liver-specific expression" refers to the ability of a promoter to enhance or drive gene expression in the liver (or in liver-derived cells) in a preferential or dominant manner relative to other tissues (e.g., spleen, muscle, heart, lung, and brain). The expression of the gene can be in the form of mRNA or protein. In some embodiments, liver-specific expression makes expression in other (i.e., non-liver) tissues or cells negligible, i.e., expression is highly liver-specific. In some embodiments, although a liver-specific promoter preferentially drives expression in the liver, it can also drive gene expression in another tissue of interest (e.g., muscle) at a lower level.
[0395] Therefore, the technician can easily determine whether any variant of the above-mentioned liver-specific promoter remains functional (i.e., it is a functional variant as defined above). For example, any given promoter to be evaluated can be operably connected to a minimal promoter (e.g., located upstream of CMV-MP), and the ability of the promoter-driven gene (usually a reporter gene) to express liver-specific expression can be measured. Similarly, the technician can easily assess the ability of the promoter-driven liver-specific expression (e.g., as described in the following examples). The gene expression level driven by the variant of the reference promoter can be compared with the expression level driven by the reference sequence. In some embodiments, when the liver-specific expression level driven by the variant promoter is at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 100% of the expression level driven by the reference promoter, it can be said that the variant remains functional. Suitable nucleic acid constructs and reporter assays for assessing liver-specific expression enhancement can be easily constructed, and the embodiments listed below provide suitable methods.
[0396] Liver specificity can be identified, wherein the expression of a gene (e.g., a therapeutic gene or a reporter gene) occurs preferentially or predominantly in a cell of liver origin. Preferential or predominant expression can be defined, for example, wherein the expression level in a cell of liver origin is significantly higher than in other types of cells (i.e., cells of non-liver origin). For example, the expression in a cell of liver origin is suitably at least 5 times higher than a non-liver cell, preferably at least 10 times higher than a non-liver cell, and in some cases may be more than 50 times higher. For convenience, liver-specific expression can be suitably demonstrated by comparing the expression level in a hepatocyte line (e.g., a cell line of liver origin, such as Huh7 and / or HepG2 cells) or a primary liver cell with a cell line of kidney origin (e.g., HEK-293), a cell line of cervical tissue origin (e.g., HeLa) and / or a cell line of lung origin (e.g., A549) compared to the expression level.
[0397] The synthetic liver-specific promoter of the present invention is preferably suitable for promoting expression in the liver of a subject, for example, driving liver-specific expression of a transgene, preferably a therapeutic transgene.
[0398] Preferred synthetic liver-specific promoters of the present invention are suitable for promoting liver-specific transgene expression, and the activity in hepatocytes is at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350% or 400% of the activity of the TBG promoter (see, for example, SEQ ID NO: 435 disclosed in International Application WO2021102107).
[0399] The synthetic liver-specific promoter of the present invention is preferably suitable for promoting liver-specific expression at a level that is at least 1.5 times higher than the CMV-IE promoter (see, for example, SEQ ID NO: 433 disclosed in International Application WO2021102107) in liver-derived cells, and preferably at least 2 times higher than the CMV promoter in liver-derived cells (e.g., HEK-293, HeLa and / or A549 cells).
[0400] The terms "identity" and "same" etc. refer to the sequence similarity between two polymer molecules, for example between two nucleic acid molecules, such as between two DNA molecules. Sequence alignment and determination of sequence identity can be performed, for example, using the Basic Local Alignment Search Tool (BLAST) originally described by Altschul et al., 1990 (J Mol Biol 215: 403-10), for example, the "Blast 2 Sequence" algorithm described by Tatusova and Madden 1999 (FEMS Microbiol Lett 174: 247-250).
[0401] As used herein, the term "synthetic / synthetic" means a nucleic acid molecule that does not exist in nature. The synthetic nucleic acid expression constructs of the present invention are artificially produced, usually by recombinant technology. Such synthetic nucleic acids may contain naturally occurring sequences (e.g., promoters, enhancers, introns, and other such regulatory sequences), but these sequences are present in a non-naturally occurring environment. For example, a synthetic gene (or a portion of a gene) typically contains one or more nucleic acid sequences that are discontinuous in nature (chimeric sequences), and / or may contain substitutions, insertions, and deletions and combinations thereof.
[0402] As used herein, a "spacer sequence" or "spacer" is a nucleic acid sequence that separates two functional nucleic acid sequences. It can have essentially any sequence, as long as it does not prevent the functional nucleic acid sequence (e.g., cis-regulatory element) from functioning as intended (e.g., this may occur if it includes a silencing sequence, prevents the binding of a desired transcription factor, etc.). Typically, it is non-functional because it exists only to separate adjacent functional nucleic acid sequences from each other.
[0403] The term "pharmaceutically acceptable" as used herein is consistent with the art and means compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.
[0404] The terms "treat", "treating" or "treatment of" (and grammatical variations thereof) mean that the severity of the subject's condition is reduced, at least partially improved or stabilized; and / or some relief, alleviation, reduction or stabilization of at least one clinical symptom is achieved; and / or the progression of the disease or disorder is delayed.
[0405] The terms "prevent / preventing / prevention" (and grammatical variations thereof) refer to preventing and / or delaying the onset of a disease, disorder, and / or clinical symptom in a subject relative to what would occur in the absence of the methods of the invention; and / or reducing the severity of the onset of a disease, disorder, and / or clinical symptom. Prevention can be complete, e.g., the complete absence of a disease, disorder, and / or clinical symptom. Prevention can also be partial, such that the onset and / or severity of the onset of a disease, disorder, and / or clinical symptom in a subject is substantially less than what would occur in the absence of the invention.
[0406] As used herein, a "therapeutically effective" amount is an amount sufficient to provide some improvement or benefit to a subject. Alternatively, a "therapeutically effective" amount is an amount that will provide some relief, alleviation, reduction, or stabilization of at least one clinical symptom in a subject. One skilled in the art will appreciate that the therapeutic effect need not be complete or curative, as long as some benefit is provided to the subject.
[0407] As used herein, a "prophylactically effective" amount is an amount sufficient to prevent and / or delay the onset of a disease, disorder, and / or clinical symptom in a subject relative to what would occur in the absence of the methods of the present invention; and / or an amount sufficient to reduce and / or delay the severity of the onset of a disease, disorder, and / or clinical symptom in a subject. Those skilled in the art will appreciate that the level of prevention need not be complete as long as some preventive benefit is provided to the subject.
[0408] The phrase "therapeutically effective amount" and similar phrases mean a dose or plasma concentration in a subject that provides a desired specific pharmacological effect (e.g., expression of a therapeutic gene in the liver and secretion into the plasma). It should be emphasized that a therapeutically effective amount may not always be effective for treating the conditions described herein, even if such a dose is considered by those skilled in the art to be a therapeutically effective amount. A therapeutically effective amount may vary depending on the route of administration and dosage form, the age and weight of the subject, and / or the disease or condition being treated.
[0409] The terms "individual", "subject" and "patient" are used interchangeably and refer to any individual subject suffering from a disease or condition that requires treatment. For the purposes of this disclosure, the subject may be a primate (preferably a human), or other mammals (e.g., dogs, cats, horses, pigs, goats or cows), etc.
[0410] Additional patents that are incorporated herein by reference and relate to, disclose, or describe AAV or aspects of AAV, including DNA vectors containing genes of interest to be expressed, are: U.S. Pat. Nos. 6,491,907; 7,229,823; 7,790,154; 7,201898; 7,071,172; 7,892,809; 7,867,484; 8,889,641; 9,169,494; 9,169,492; 9,441,206; 9,409,953; and 9,447,433; 9,592,247; and 9,737,618.
[0411] The invention may be defined as in any of the following numbered paragraphs. 1. A method for treating Pompe disease in a subject, the method comprising administering to a subject who is being treated for Pompe disease with long-term GAA enzyme replacement therapy (ERT) a pharmaceutical composition comprising no more than 4.0 E 12 vg / kg dose of a recombinant adeno-associated virus (AAV) vector, the vector comprising in its genome a heterologous nucleic acid sequence encoding a polypeptide, the polypeptide comprising an alpha-glucosidase (GAA) polypeptide in an expressible form, wherein the heterologous nucleic acid is operably linked to a liver-specific promoter, and wherein administration of long-term GAA enzyme replacement therapy (ERT) is withdrawn at least 26 weeks after administration of the recombinant AAV, and wherein, for at least two weeks of administration, the subject obtains a serum level of pharmacologically active GAA expressed by the AAV of at least 165 nmol / mL / hr. 2. The method of paragraph 1, wherein the Pompe disease is late-onset Pompe disease (LOPD) or infantile-onset Pompe disease (IOPD). 3. The method of paragraph 1 or 2, wherein the subject has previously undergone chronic administration of ERT for Pompe disease. 4. The method of paragraph 3, wherein the administration of ERT in the subject is withdrawn simultaneously with or prior to the administration of the AAV vector. 5. The method of paragraph 4, wherein the administration of the ERT is withdrawn on the same day (d1) as the administration of the AAV vector or at least one day before. 6. The method of paragraph 3, wherein the administration of the ERT is withdrawn after the administration of the AAV vector. 7. The method of paragraph 6, wherein administration of the ERT is withdrawn during a period of about day 0 to about 26 weeks after administration of the AAV vector. 8. The method of paragraph 6, wherein the administration of the ERT is discontinued at about 24 weeks or about 26 weeks after administration of the AAV vector. 9. The method of any of paragraphs 1-8, further comprising administering supplemental ERT after an extended period of time following administration of the AAV vector and further following cessation of administration of the long-term ERT. 10. The method of paragraph 9, wherein the extended period of time is about 25 weeks, about 97 weeks, or about 107 weeks after administration of the AAV vector. 11. The method of paragraph 9, wherein the extended period of time is at least 1 year after administration of the AAV vector. 12. The method of paragraph 9, wherein the extended period of time is between 12 months and 18 months after administration of the AAV vector. 13. The method of paragraph 9, wherein the extended period of time is at least 6 months after administration of the AAV vector. 14. The method of any of paragraphs 9-13, wherein the supplemental ERT is administered at a lower frequency and / or dose than the long-term ERT. 15. The method of paragraph 14, wherein the supplemental ERT is administered at regular intervals. 16. The method of paragraph 15, wherein the supplemental ERT is suspended for an extended period of at least 10 weeks. 17. The method of paragraph 14, wherein the supplemental ERT administration is irregular. 18. The method of any of the preceding paragraphs, wherein the pharmaceutical composition comprises rAAV at a dose between 1.6E12 vg / kg and 3.2E12 vg / kg. 19. The method of paragraph 17, wherein the dose of rAAV is sufficient to express GAA to achieve clinical stabilization of one or more symptoms of Pompe disease in the subject, wherein clinical stability is selected from the group consisting of: a) a ...
Claims
1. A method for treating Pompe disease in a subject, the method comprising administering to a subject who is being treated for Pompe disease with long-term GAA enzyme replacement therapy (ERT) a pharmaceutical composition comprising no more than 4.0 E 12 vg / kg dose of a recombinant adeno-associated virus (AAV) vector, the vector comprising in its genome a heterologous nucleic acid sequence encoding a polypeptide, the polypeptide comprising an alpha-glucosidase (GAA) polypeptide in an expressible form, wherein, The heterologous nucleic acid is operably linked to a liver-specific promoter, and wherein administration of long-term GAA enzyme replacement therapy (ERT) is discontinued at least 26 weeks after administration of the recombinant AAV, and wherein, for at least two weeks of administration, the subject achieves a serum level of pharmacologically active GAA expressed by the AAV of at least 165 nmol / mL / hr.
2. The method of claim 1, wherein: The Pompe disease is late-onset Pompe disease (LOPD) or infantile-onset Pompe disease (IOPD).
3. The method according to claim 1 or 2, wherein: The subject had previously undergone chronic administration of ERT for Pompe disease.
4. The method of claim 3, wherein: Administration of ERT in the subject is withdrawn concurrently with or prior to administration of the AAV vector.
5. The method of claim 4, wherein: The administration of the ERT is withdrawn on the same day (d1) as the administration of the AAV vector or at least one day before.
6. The method of claim 3, wherein: Administration of the ERT is withdrawn after administration of the AAV vector.
7. The method of claim 6, wherein: Administration of the ERT is withheld during a period of about day 0 of administration of the AAV vector to about 26 weeks after administration.
8. The method of claim 6, wherein: Administration of the ERT is discontinued at about 24 weeks or about 26 weeks after administration of the AAV vector.
9. The method of any one of claims 1-8, further comprising administering supplemental ERT after administration of the AAV vector and further after an extended period of time following cessation of administration of the long-term ERT.
10. The method of claim 9, wherein: The extended period of time is about 25 weeks, about 97 weeks, about 107 weeks after administration of the AAV vector.
11. The method of claim 9, wherein: The extended period of time is at least 1 year after administration of the AAV vector.
12. The method of claim 9, wherein: The extended period of time is between 12 months and 18 months after administration of the AAV vector.
13. The method of claim 9, wherein: The extended period of time is at least 6 months after administration of the AAV vector.
14. The method according to any one of claims 9 to 13, wherein: The supplemental ERT is administered at a lower frequency and / or dosage than the long-term ERT.
15. The method of claim 14, wherein: The supplemental ERT was administered at regular intervals.
16. The method of claim 15, wherein: The supplemental ERT was suspended for an extended period of at least 10 weeks.
17. The method of claim 14, wherein: The supplemental ERT was administered irregularly.
18. A method according to any one of the preceding claims, wherein: The pharmaceutical composition comprises rAAV at a dose between 1.6E12 vg / kg and 3.2E12 vg / kg.
19. The method of claim 17, wherein: The dose of the rAAV is sufficient to express GAA to achieve clinical stabilization of one or more symptoms of Pompe disease in the subject, wherein clinical stability is selected from the group consisting of: a) a decrease in forced vital capacity (FVC) of no more than 15% in two consecutive assessments measured no less than 3 months apart, b) a decrease in 6MWT of no more than 12% in two consecutive assessments measured no less than 3 months apart, and c) a decrease in 6MWT of no more than 43 meters in two consecutive assessments measured no less than 3 months apart.
20. A method according to any one of the preceding claims, wherein: The pharmaceutical composition comprises a dose of rAAV sufficient to achieve a serum level of hGAA expressed by the rAAV in a pharmacologically active range of at least about 165 nmol / mL / hr to ≤ 2,260 nmol / mL / hr.
21. A method according to any one of the preceding claims, wherein: The heterologous nucleic acid sequence encoding the GAA polypeptide further comprises a nucleic acid encoding a secretion signal peptide located 5' to the nucleic acid encoding the GAA polypeptide.
22. The method of claim 21, wherein: The signal sequence is the endogenous GAA signal sequence fused to the 5' end of the nucleic acid encoding the GAA polypeptide.
23. The method of claim 21, wherein: The signal sequence is a heterologous signal sequence fused to the 5' end of the nucleic acid encoding the GAA polypeptide.
24. The method of claim 23, wherein: The heterologous signal sequence is selected from any one of the following: fibronectin (FN1), IL2WT, 201IgG, IL2mut, AAT, pro-cathepsinogen L, and pro-α2 collagen.
25. The method of any one of claims 1 to 24, wherein: The nucleic acid sequence encodes a wild-type GAA polypeptide or a modified GAA polypeptide.
26. The method of any one of claims 1 to 25, wherein: The nucleic acid sequence encoding the GAA polypeptide is a human GAA gene or a human codon-optimized GAA gene (coGAA) or a modified GAA nucleic acid sequence.
27. The method of any one of claims 1 to 26, wherein: The nucleic acid sequence encoding the GAA polypeptide encodes a GAA polypeptide comprising at least one, at least two or at least all three amino acid modifications selected from the group consisting of H201L, H199R, R233H, V780I or V780R of SEQ ID NO:
10.
28. The method of any one of claims 1 to 22, wherein: The heterologous nucleic acid sequence encodes a GAA polypeptide having the amino acid sequence of SEQ ID NO: 600 or a functional variant or functional fragment thereof having at least 90%, 95% or 99% of the activity of SEQ ID NO:
600.
29. The method of any one of claims 1 to 28, wherein: The heterologous nucleic acid sequence encoding the GAA polypeptide is located between the 5' ITR and 3' ITR sequences.
30. The method of any one of claims 1 to 29, wherein: The AAV vector further comprises in its genome at least one polyA sequence located between the 3' end of the nucleic acid encoding the GAA gene and the 5' end of the 3' ITR sequence.
31. The method of any one of claims 29-30, wherein: The ITRs include insertions, deletions or substitutions.
32. The method of claim 31, wherein: One or more CpG islands in the ITR are removed.
33. The method of any one of claims 1 to 32, wherein: The recombinant AAV vector is a chimeric AAV vector, a haploid AAV vector, a hybrid AAV vector or a polyploid AAV vector.
34. The method of any one of claims 1 to 33, wherein: The recombinant AAV vector is a rationalized haploid vector, a mosaic AAV vector, a chemically modified AAV vector, or an AAV vector from any AAV serotype.
35. The method of any one of claims 1 to 34, wherein: The recombinant AAV vector is selected from the group consisting of: AAV3b, AAVXL32 vector, AAVXL32.1 vector, AAV8 vector or a haploid AAV8 vector comprising at least one AAV8 capsid protein.
36. The method of claim 35, wherein: The AAV3b serotype comprises one or more mutations in the capsid protein, the mutations being selected from any one of the following: 265D, 549A, Q263Y.
37. The method of claim 36, wherein: The AAV3b serotype is selected from any one of the following: AAV3b265D, AAV3b265D549A, AAV3b549A or AAV3bQ263Y or AAV3bSASTG.
38. The method of any one of claims 1 to 35, wherein: The recombinant AAV vector is of serotype AAV8, or comprises at least one AAV8 capsid protein.
39. The method of any one of claims 1-36, further comprising administering an immunosuppressant to the subject for a defined period of time.
40. The method of claim 39, wherein: The subject is administered an immunosuppressant at a first dose for a first time period, the first time period beginning on the day before or on the day of administration of the AAV vector.
41. The method of claim 39, wherein: The immunosuppressant is administered to the subject in decreasing doses, each decreasing dose being administered a defined period of time after a first period of time during which the immunosuppressant is administered at a first dose.
42. The method of claim 41, wherein: The subject is administered the immunosuppressant at the first dose for 4 weeks and at each tapering dose for 1 week thereafter.
43. The method of any one of claims 1 to 38, wherein: No immunosuppressants were administered to the subject.
44. The method of any one of claims 1 to 43, wherein: The pharmaceutical composition further comprises a pharmaceutically acceptable carrier, but lacks GAA ERT.
45. The method of any one of claims 1 to 44, wherein: The GAA polypeptide is secreted from the liver of the subject, such that the secreted GAA is taken up by skeletal muscle tissue, cardiac muscle tissue, diaphragm muscle tissue, or a combination thereof, and the uptake causes a reduction in lysosomal glycogen storage in the tissue.
46. The method of claim 45, wherein: The reduction in lysosomal glycogen storage in the tissue results in a reduction in symptoms of Pompe disease and / or clinical stabilization of lysosomal glycogen storage in the subject.
47. The method of any one of claims 1 to 46, wherein: The administration is selected from the group consisting of intramuscular, subcutaneous, intraspinal, intracisternal, intrathecal, intravenous, and combinations thereof.
48. The method of any one of claims 1 to 47, wherein: T cell reactivity to the vector capsid was substantially low.
49. The method of claim 48, wherein: T cell reactivity was below the threshold range of >40 / sfu / million to <129 / sfu / million.
50. A method of reducing or eliminating the clinical need for GAA enzyme replacement therapy (ERT) in a subject with Pompe disease, the method comprising or consisting essentially of: The subject is administered a pharmaceutical composition comprising no more than 4.0 E 12 vg / kg of a recombinant adeno-associated virus (AAV) vector comprising in its genome a heterologous nucleic acid sequence encoding a polypeptide comprising an alpha-glucosidase (GAA) polypeptide in an expressible form, wherein the heterologous nucleic acid is operably linked to a liver-specific promoter, and wherein, for at least two weeks of administration, the subject achieves a pharmacologically active serum level of GAA expressed by the AAV of 165 nmol / mL / hr to ≤2,260 nmol / mL / hr.
51. The method of claim 50, wherein: The frequency of administration of the GAA ERT and / or the dose of the GAA ERT administered is reduced by at least 20% in the first year after administration of the AAV vector compared to the year before the administration.
52. The method of claim 50 or 51, wherein: Following cessation of ERT, the subject has at least a 50% reduction in the level and / or rate of clinical decline over time.
53. The method of any one of claims 50-52, wherein: ERT can be withdrawn for extended periods of time without substantial clinical decline.
54. The method of claim 53, wherein: The extended period of time is selected from the group consisting of 2 weeks to 3 weeks, 1 month to 3 months, 3 months to 6 months, 6 months to 12 months, 12 months to 1.5 years, and 1 year to 2 years.
55. A method according to any one of the preceding claims, wherein: GAA activity in muscle is increased at least 2-fold compared to the level before administration of the AAV vector.
56. A method according to any one of the preceding claims, wherein: GAA activity in muscle is increased at least 2-fold above levels following withdrawal of long-term ERT for at least about 24 weeks.
57. A method according to any one of the preceding claims, wherein: There was no substantial increase in serum levels of hepatic alanine aminotransferase (ALT) following administration of the AAV vector.
58. A method of treating Pompe disease in a subject, the method comprising administering to a subject who is being treated for Pompe disease with long-term GAA enzyme replacement therapy (ERT) a pharmaceutical composition comprising about 1.6 e 12 vg / kg to about 1.6e 13 vg / kg dose of a recombinant adeno-associated virus (AAV) vector, the vector comprising in its genome a heterologous nucleic acid sequence encoding a polypeptide, the polypeptide comprising an alpha-glucosidase (GAA) polypeptide in an expressible form, wherein, The heterologous nucleic acid is operably linked to a liver-specific promoter, and wherein administration of long-term GAA enzyme replacement therapy (ERT) is withdrawn on the same day (d1), one day after, or at least one day before administration of the recombinant AAV, and wherein, for at least two weeks of administration, the subject obtains a serum level of pharmacologically active GAA expressed by the AAV of at least 165 nmol / mL / hr.
59. The method of claim 58, wherein: The subject was administered methotrexate and prednisone for immunomodulation.
60. The method of claim 59, wherein: Methotrexate was given at an initial dose of less than 30 mg / week.
61. The method of claim 60, wherein: Methotrexate is given at an initial dose of between about 5 mg / week to 30 mg / week.
62. The method of claim 61, wherein: Methotrexate was given at an initial dose of between 5 mg / week and 7.5 mg / week.
